Solara Active Pharma Sciences Ltd — Aamara Capital Research

Snapshot

Solara Active Pharma Sciences Ltd · NSE: SOLARA · BSE: 541540 · Pure-play API manufacturer (Strides / Arun Kumar Pillai promoter group) · Basis: consolidated, ₹ crore, FY = April–March

Data freshness: market data as of close 13-Oct-2026 (CMP ₹650.55, NSE, Investing.com; Screener ₹650). Latest reported quarter Q1 FY27 (Jun-2026). FY26 Annual Report (Board-approved 15-May-2026) read and verified against primary text. Labels: [Fact] sourced · [Est.] derived/calculated · [Analyst View] our judgement.

Refresh required after 16-Oct-2026

This report is written three days before a binary event. The Q2 FY27 results and board meeting on 16-Oct-2026 are where management has promised the ibuprofen strategic decision (sale / closure / partnering / conversion), the Vizag and Puducherry roadmap, the CRAMS demerger status and the size of any "cutoff or shaving" (impairment) on ~₹700 Cr of ibuprofen capital. The Sep-2026 shareholding pattern (pledge, TPG residual, forfeiture) is due ~21-Oct-2026. Coverage, holder, valuation and verdict sections must be refreshed after both.

₹1,369.0 Cr

FY26 Revenue from ops

+6.6% YoY · total income ₹1,375.1 Cr

–₹7.41 Cr

FY26 PAT (consol.)

Q1 FY27 PAT +₹16.3 Cr (18-qtr high)

13.9%

FY26 EBITDA margin

₹191.5 Cr on total income · base biz 23.5%

4.7%

FY26 RoCE (company)

RoE –0.6% · FY25 RoCE 7.6%

₹650.55

CMP (13-Oct-26)

52W ₹422 – ₹774

₹3,156 Cr

Market cap

EV ~₹3,657 Cr [Est.]

~18.5x

EV/EBITDA TTM

vs ~15.5x FY25–26 avg

~2.2x

P/B (Jun-26 book)

3-yr avg ~1.8x · P/TBV ~3.0x

₹479.5 Cr

Net debt (Jun-26)

gross ₹532.3 Cr · Mar-24 ₹999.4 Cr

BBB+

CRISIL (22-Jun-26)

Stable / A2 · upgraded from BBB/A3+

41.93%

Promoter (Jun-26)

30.49% Dec-23

37.1%

Promoter pledge

of promoter shares · 26.0% Dec-25

~24%

Revenue from Strides

₹329 Cr related-party sales FY26

~178 d

Strides receivable days

₹160.45 Cr vs ~97–98 d others

–₹53.0 Cr

Ibuprofen EBITDA FY26

on ₹333.7 Cr revenue (~–15.9%)

~₹700 Cr

Capital in ibuprofen

CFO: full recovery "farfetched"

EBITDA margin of 13.9% is the company-reported figure on total income (₹191.5 / ₹1,375.1 Cr, includes other income). On Screener's ex-other-income basis FY26 EBITDA is ₹187 Cr (OPM 13.7%); CRISIL quotes 13.64%. Revenue headline uses revenue from operations (₹1,369.0 Cr); segment data (base ₹1,041.4 + ibuprofen ₹333.7 = ₹1,375.1 Cr) is on the total-income basis.

Company overview

Registered office

Cyber One, Unit 902, Sector 30A, Vashi, Navi Mumbai

Corporate office

TICEL Bio Park, Chennai · sales office Bangalore

Incorporated

23-Feb-2017 · NCLT scheme approved 9-Mar-2018 (effective 1-Oct-2017)

Listed

2018, post-demerger (exact listing date not in inputs)

Index membership

Not Available — not stated in any input

Sector / industry

Pharmaceuticals — merchant API (+ small CRAMS, specialty polymers)

Employees

1,669 permanent (AR) · ~3,108 incl. 1,434 contract workers (BRSR)

Promoter group

Arun Kumar Pillai, K R Ravishankar, Pronomz Ventures LLP + entities (41.93%)

MD & CEO / CFO

Sandeep S. Rao (21-Feb-2025) / Sarat Kumar Asuri

Chairman

R. Ramakrishnan (Independent, since 11-Apr-2018)

Statutory auditor

Deloitte Haskins & Sells LLP — FY26 opinion unmodified

Footprint

6 plants (Ambernath, Cuddalore, Mangaluru, Mysuru, Puducherry, Vizag) + Chennai R&D

Portfolio

60+ commercial APIs (78 website SKUs) · 10 in development

Filings

96 US DMFs · 34 CEPs · 5 of 6 sites USFDA-approved

Reach

64 countries (AR/BRSR); website/other sources cite 60+ / 75+ · exports 52% of turnover

What it is, in plain English

Solara makes active pharmaceutical ingredients (APIs) — the chemical "active" inside tablets, injections and powders — and sells them to generic and innovator drug companies who turn them into finished medicines. It was carved out in 2017–18 from Strides Shasun (commodity API business: Puducherry and Cuddalore, ibuprofen, gabapentin, ranitidine) and SeQuent Scientific (human API business). Inside one P&L sit two very different businesses: a "base" specialty catalogue of ~60 APIs (anthelmintics, anti-malarials, CNS, anaesthesia, and a niche phosphate-binder/bile-acid polymer franchise at Cuddalore) that did ₹1,041.4 Cr of FY26 revenue at ~55% gross margin and 23.5% EBITDA margin; and commodity ibuprofen (Puducherry, plus a ~₹500 Cr-gross-block Vizag plant that is mothballed), which did ₹333.7 Cr at an EBITDA loss of ₹53.0 Cr. After a catastrophic FY24 (Puducherry fire, ₹567 Cr loss, rating downgrade to BBB/Negative), a ₹449.95 Cr rights issue halved gross debt from ₹999 Cr to ₹532 Cr, and CRISIL upgraded the company to BBB+ in June 2026. Q1 FY27 delivered the best PAT in 18 quarters (₹16.3 Cr). The investment question is almost entirely what happens to ibuprofen on 16-Oct-2026 — and whether the governance issues around the promoter's flagship Strides Pharma (24% of revenue, ~178-day receivable) are benign.

Quick verdict scorecard

Business

Medium

Good base API franchise; structurally broken ibuprofen arm

Management & Governance

Weak

Strides RPT/receivable, 37% pledge, poor guidance record

Financial

Weak · improving

5-yr PAT –₹654 Cr; EBIT ≈ interest; deleveraging real

Valuation

Fair-to-Expensive

18.5x TTM vs 15.5x history; ~12.6–15x on base-only

Overall

Neutral

Event-driven; wait for 16-Oct ibuprofen decision

Market data

Metric	Value	Basis / source
Last price (13-Oct-2026)	₹650.55 (–1.83%)	NSE via Investing.com [Fact]; Screener ₹650; stockanalysis close 12-Oct ₹662.65
Market capitalisation	₹3,156 Cr	Screener, ~4.86 Cr shares (fully-paid equivalent ~4.82 Cr) [Fact]
Enterprise value	~₹3,657 Cr	Mcap + net debt ₹479.5 Cr (Jun-26) + leases ₹22 Cr [Est.]. Alternatives: ₹3,635 Cr (heard.md, no leases); ₹3,843 Cr (market.md, gross debt incl. leases ₹687 Cr)
52-week range	₹422 – ₹774	Intraday high ₹774 on 15-Sep-2026; highest close ₹753.25 on 21-Sep-2026 [Fact]
Drawdown from high	~–16% / ~–14%	From intraday high / from highest close [Est.]
From 52-week low	+54%	Trendlyne [Fact]
Price CAGR 1y / 3y / 5y	+11% / +28% / –13%	Screener [Fact]; ~–53% over five years in absolute terms
P/E (TTM)	n.m.	TTM PAT ~–₹1.6 Cr [Est.]; Screener's "739x" cannot be reproduced
P/E on Q1 FY27 annualised PAT (₹65 Cr)	~48x	[Est.]
P/B	~2.2x	Jun-26 net worth ₹1,406.8 Cr / ~4.82 Cr shares = BVPS ~₹292 [Est.]. Screener shows BV ₹346 / ~1.9x — not reconcilable; stockanalysis 2.55x on Mar-26 book
Dividend yield	0%	Last dividend Aug-2021 (₹3.00); none since; no buybacks ever
Partly-paid line	SOLARAPP1	Rights 1:3 at ₹375 (Jun-2024); final call Apr–May 2026; forfeiture notice 9-Oct-2026
Shareholders	~70,490	Jun-26 (83,148 in Dec-24) [Fact]
Trendlyne momentum	63.8/100	"Technically Moderately Bullish"; labelled "Expensive Rocket" [Fact]

The two businesses at a glance (FY26)

₹ Cr	Base business	Ibuprofen (commodity)	Total
Revenue (total-income basis)	1,041.4 (76%)	333.7 (24%)	1,375.1
Gross profit after S&D / margin	573.2 / 55.0%	92.7 / 27.8%	665.9 / 48.4%
EBITDA / margin	244.5 / 23.5%	(53.0) / ~–15.9%	191.5 / 13.9%
Q1 FY27 revenue / EBITDA	307.7 / 72.2 (23.5%)	76.5 / (8.7) (–11.4%)	384.3 / 63.5 (16.6%)
Plants	Cuddalore, Mangaluru, Ambernath (+ Mysuru intermediates)	Puducherry (~6,000 TPA) + Vizag (mothballed)	6 + R&D
Utilisation	"a little over 70%"	~25–30% (≈3,000 of 10,000–12,000 TPA) [Est.]	—
Management guidance	≥10% growth; EBITDA 25% ±1%; GM 52–55%	EBITDA loss ₹10–15 Cr/qtr until resolved	Net-debt-free FY29

CRISIL's alternative ibuprofen figures: FY26 revenue ₹327 Cr at ~–18% EBITDA margin. Ind AS 108 reports a single "API" segment; the split is a management disclosure (AR FY26 MD message; Q1 FY27 deck).

Event calendar

Date	Event	Why it matters
16-Oct-2026	Q2 FY27 results + board meeting (trading window closed)	Ibuprofen decision; impairment size; Vizag/Puducherry/CRAMS roadmap; third consecutive strong quarter test
~21-Oct-2026	Sep-2026 shareholding pattern	Pledge trend; TPG residual (0.87% vs 1.98%); forfeiture outcome
H2 FY27	Forfeiture of unpaid partly-paid shares	~1,65,807 first-call defaulters (0.34%); small
FY27	OneSource-linked API launch; debottlenecking payback	Base-business growth ≥10%
Mar-2027	Net debt target ~₹440 Cr	Mechanical (₹479.5 Cr less ₹38.9 Cr scheduled repayments)
FY29	Net-debt-free target; 4–5 DMFs/yr revenue from FY29–30	Re-dated from "close to net cash by FY27"

Analyst Notes

The editorial read — what happened, what the market is pricing, and what should temper the enthusiasm. [Analyst View] throughout unless a figure is tagged.

Timing caveat. Written 13-Oct-2026, three days before the Q2 FY27 print and the promised ibuprofen decision (16-Oct-2026). Every conclusion below is conditional on that outcome; refresh this tab after it.

Solara is a good business wrapped around a bad one, owned by a promoter group whose flagship company has quietly become the good business's biggest — and slowest-paying — customer. The stock has priced the first half of that sentence and is ignoring the second.

What just happened. After five years in which cumulative PAT was –₹654 Cr (FY22–FY26) [Est.], the operating picture has genuinely turned. The base business stepped up from ~₹240–250 Cr a quarter to a ₹307 Cr plateau in Q4 FY26 and Q1 FY27, at a 23.5–25.9% EBITDA margin. Gross debt fell from ₹999.4 Cr (Mar-24) to ₹532.3 Cr (Jun-26), net debt to ₹479.5 Cr, and CRISIL upgraded the long-term rating to BBB+/Stable on 22-Jun-2026 [Fact]. Q1 FY27 PAT of ₹16.3 Cr was the best in 18 quarters. These are real numbers, not narrative.

But be precise about where the deleveraging came from. It was funded by equity, not earnings. About ₹448 Cr of rights money came in over three tranches [Est.]; the share count rose 33% (3.60 Cr → ~4.82 Cr). FY26 free cash flow after interest was only ~₹8 Cr; net debt barely moved across FY26 (₹633 Cr → ₹614 Cr) and only stepped down in Q1 FY27 because the ~₹135 Cr final call landed. EBIT (₹91.9 Cr) still did not cover finance cost (₹94.8 Cr) in FY26. The balance sheet is out of the danger zone, but the business has not yet proven it can de-lever itself.

The Strides problem is the one the market is not discussing. In FY26 Solara sold ₹329 Cr of API to Strides Pharma Science — an "enterprise owned by common promoters" — equal to ~24% of revenue and up 53% YoY. Strip Strides out and revenue from every other customer fell ~2.5% [Est.]. The Strides receivable rose from ₹62.83 Cr to ₹160.45 Cr, ~178 days of Strides sales versus ~97–98 days for everyone else, and ~37% of all trade receivables. In the same year the promoter group put in ~₹90 Cr of first-call money — so net cash from the promoter group to Solara in FY26 was roughly nil [Est.; a juxtaposition, not an allegation of intent]. Shareholders have now approved a cap of ₹480 Cr for FY27 (~35% of FY26 revenue), and one independent director on Solara's audit committee is also an independent director of Strides. This is the top governance flag in the report.

The ibuprofen decision is binary in timing, not in direction. Management itself puts the capital deployed in ibuprofen at ~₹700 Cr and says full recovery is "slightly farfetched". The CFO has flagged a "cutoff or shaving" to be clarified with Q2. My base case is an exit or partial exit with a non-cash impairment; a third-party estimate is that every ₹100 Cr of write-down is ~8% of equity. That would not hurt cash flow — it would likely improve reported EBITDA by removing a ₹40–60 Cr annual drag and the ₹12–15 Cr idle cost at Vizag — but it will crystallise how much shareholder capital the 2020–22 Vizag expansion destroyed. Note that goodwill (₹364.9 Cr) sits in the Human API CGU, not in ibuprofen, and that title deeds of ₹191 Cr of assets are still in the names of pre-demerger entities, which complicates any asset sale.

What the market is pricing. At ₹650.55 the stock trades at ~18.5x TTM EV/EBITDA versus ~15.5x its FY25–26 average, and ~2.2x book versus a ~1.8x three-year average. On the bull framing — base-business EBITDA only, Q1 annualised — the multiple is ~12.6x, which is cheap against specialty API peers. In other words, the market is already paying for most of the "remove the drag" outcome. The stock ran from ₹422 to ₹774 with a cluster of Substack bull pieces and an 80% "Buy" retail poll, while TPG, CDPQ, FSSA and mutual funds sold. There is no live sell-side coverage. This is a crowded retail turnaround idea going into an event.

What tempers the enthusiasm. (1) Management credibility: of 22 tracked promises since 2024, 13 were missed or re-dated and one more only partly met — FY25 revenue, FY26 EBITDA, Vizag restart (four times), CRAMS demerger, "net cash by FY27", the ibuprofen deadline (three slips). (2) The promoter pledge has gone back up from 26.0% to 37.1% in six months, and promoter equity is debt-funded. (3) The base business's reported gross margin has drifted from 58.1% to 51.3% YoY (54.5% adjusted for pass-through), and West Asia solvent shortages are shutting lines intermittently. (4) The going-concern basis note in the FY26 accounts is a management disclosure, not an auditor qualification — Deloitte's opinion is unmodified with no emphasis of matter — but net current liabilities of ₹35.81 Cr and bank-limit utilisation of 93–95% show how little liquidity headroom there is.

What amplifies it. The base franchise is real: 96 US DMFs, 34 CEPs, a clean USFDA record (Mangaluru and Puducherry VAI; Ambernath zero 483s), a polymer niche management describes as "fully sold for capacity", and ~₹156 Cr of unrecognised deferred tax assets that would shield profits for years. If Solara can exit ibuprofen without new cash outflow, hold base EBITDA at 25% on ≥10% growth, and show the Strides receivable unwinding, the business is worth materially more than today's price — the independent SOTP of ₹825–930/share is not absurd. Interest cover crossing 3x (Q1 FY27 run-rate ~3.1x) would also open the door to a CRISIL A-.

How to read the rest of this report. Read Tab 4 (segment economics) and Tab 7 (Strides, pledge, Spiracca, Synthix) together; the bull case lives in the first and the risk lives in the second. Tab 11's 22-row guidance ledger is the right discount rate for anything management says on 16-Oct. My stance is Neutral: I would not chase the stock into the print, and would revisit on (a) the size and cash cost of the ibuprofen exit, (b) the H1 FY27 Strides receivable, and (c) the Sep-26 pledge number.

The thesis in one table

Question	What the data says	Read
Is the base business good?	₹1,041.4 Cr, GM 55%, EBITDA 23.5% (FY26); Q1 FY27 ₹307.7 Cr, +24% YoY	Yes
Is growth organic and diversified?	All FY26 growth came from Strides (+₹114 Cr); ex-Strides revenue –2.5%	Not yet
Is ibuprofen fixable?	~25–30% utilisation; China ~US$9.9/kg vs India US$14.9/kg; IOL adding 6,000 MT	No — exit
Is the balance sheet safe?	Net debt ₹479.5 Cr (~1.9x annualised EBITDA); BBB+; going-concern basis note; 93–95% limit utilisation	Improving, thin
Is management credible?	13 of 22 tracked promises missed or re-dated, plus 1 partial	Low
Is governance clean?	Strides 24% / ~178 days; pledge 37.1%; Spiracca round-trip; Synthix pre-funding	Flags
Is it cheap?	18.5x TTM vs 15.5x history; 12.6x on base-only run-rate	Depends on basis

Business Deep-Dive

Product by product, plant by plant. Sources: FY26 Annual Report (AR) incl. BRSR, Q1 FY27 press release/deck, company website product pages (Oct-2026), CRISIL rationales, earnings-call transcripts (AlphaStreet auto-transcripts — indicative).

Corporate snapshot

Item	Detail
What it is	Pure-play API maker with a small CRAMS/CDMO business and a specialty polymer franchise. 60+ commercial APIs, 10 more under development. Sells to "leading generic and innovator pharma companies" in 64 countries and 21 Indian states [Fact, AR/BRSR]
Origin	Incorporated 23-Feb-2017. Formed by a Composite Scheme of Arrangement among Strides Shasun, SeQuent Scientific and Solara, approved by NCLT on 9-Mar-2018 (effective 1-Oct-2017). Combined the commodity API business of Strides Shasun (Puducherry and Cuddalore; ibuprofen, gabapentin, ranitidine) with the human API business of SeQuent (then Mangalore, Mahad and Mysore plants) [Fact]
Promoter link	Arun Kumar Pillai, founder of Strides (1990), is a Non-Executive Director and chairs the Management Committee. Promoter group 41.93% (Jun-26), 37.1% of it pledged. Related promoter-group entities: Strides Pharma Science, OneSource Specialty Pharma (ex-Stelis), Steriscience, Tenshi, Aurore Life Sciences, Instapill, Chayadeep Properties (AR Note 39)
Management	MD & CEO Sandeep S. Rao since 21-Feb-2025 (succeeded Poorvank Purohit); CFO Sarat Kumar Asuri; WTD & CHRO Mohanraj Sanjeevi since 1-Jan-2026; Mohan Muthunarayanan (WTD & COO) left 31-Dec-2025 to become COO of Synthix
Footprint	6 manufacturing sites — Ambernath, Cuddalore, Mangaluru, Mysuru, Puducherry, Vizag — and 1 R&D centre in Chennai [Fact, AR/BRSR]
People	BRSR: 1,032 employees (1,027 permanent) and 2,076 workers (642 permanent, 1,434 contract), ~3,108 total. AR's 1,669 = permanent employees + permanent workers. Avg raise 6.46%; median pay +1.74%
FY26 (consolidated)	Total income ₹1,375.1 Cr (+6.4%); revenue from ops ₹1,369.0 Cr (+6.6%); gross profit after S&D ₹665.9 Cr; EBITDA ₹191.5 Cr (13.9%); PAT –₹7.41 Cr
Q1 FY27	Revenue ₹384.3 Cr (+20% YoY); EBITDA ₹63.5 Cr (16.6%); PAT ₹16.3 Cr — highest EBITDA and PAT in 18 quarters; net debt ₹479.5 Cr, 1.9x annualised EBITDA
Pending	Strategic review of ibuprofen with appointed bankers; next steps to be finalised "by end of Q2'27" (Sep-2026). Board meeting intimated 9-Oct-2026 for 16-Oct-2026. No outcome announced as of 13-Oct-2026

Therapy areas and concentration

Therapy areas (AR)

Pain management, anti-infectives, anti-malarials, anthelmintics, anaesthetics, anticonvulsants, antipsychotics and anti-hyperkalaemia agents, plus "polymer-based and iron-based products" [Fact]. CRISIL cites an "established position" in anthelmintic, anti-malaria, anti-infective and NSAID segments.

Molecule concentration

15–16 of ~50 products = >75% of base sales; ~40 of 50–60 products made in a typical quarter (Q1 FY27) [Mgmt]
Top 5 molecules ≈ 55–60% of revenue (Q1 FY26 call)
Top 10 = 84% in an older profile cited on Screener
AR itself flags "dependence on a limited set of molecules". Revenue by molecule is not disclosed; management declines to name products.

Molecule-by-molecule catalogue

Website lists 78 SKUs (incl. 13 ibuprofen grades/salts). Site and filing columns from individual product pages [Fact, website, Oct-2026]; "—" = page not checked.

A. NSAIDs and analgesics — the ibuprofen franchise

Product	What it does	Site(s)	Filings
Ibuprofen S250, S380, S500, SHD, SN (commodity)	NSAID for pain, fever, inflammation; largest OTC analgesic molecule globally	Puducherry + Vizag (S250)	USDMF, CEP, JDMF (S250)
Ibuprofen DC66 / DC85 / DC90	Direct-compression granulated grades (customer skips wet granulation)	Puducherry (DC85)	USDMF, CEP, EDMF (DC85)
Ibuprofen Sodium / Sodium Dihydrate	Fast-onset salts	Puducherry + Cuddalore	USDMF, EDMF
Ibuprofen Lysine	Injectable salt for IV ibuprofen (incl. neonatal PDA)	Puducherry	USDMF, EDMF
Ibuprofen Arginine	Fast-onset salt	—	—
S-Ibuprofen (dexibuprofen)	Active enantiomer; chiral chemistry	Puducherry	USDMF, EDMF, Korea
Naproxen base / sodium	NSAID	Vizag (sodium)	USDMF
Mefenamic acid	NSAID	—	—

Ibuprofen in context: historically 50–60% of turnover; ~30% in FY25 (~21% plain + ~9% derivatives, Q1 FY26 call); "less than 45% including derivatives" (Q4 FY25 call). Solara (as Shasun) was once the world's largest ibuprofen maker (~16% of global production per Beroe 2019) and "marquee brands" use its API. The AR calls Puducherry "one of the world's largest Ibuprofen manufacturing facilities". Note: derivatives (salts, DC grades, S-ibuprofen) are counted in the base business; only plain commodity ibuprofen is in the ibuprofen segment.

B. Anthelmintics, anti-malarials and anti-infectives

Product	What it does	Site	Filings
Praziquantel (named by CRISIL as a key API)	Schistosomiasis and tapeworm; WHO Essential Medicines list	Mangaluru	USDMF, WHO, Canada
Albendazole	Broad-spectrum anthelmintic	Mangaluru	USDMF
Mebendazole	Anthelmintic	Mangaluru	USDMF
Artesunate	Severe malaria	Mangaluru	USDMF, WHO
Cycloserine	MDR-TB	Cuddalore	USDMF, WHO
Rifaximin	Gut-selective antibiotic	Mangaluru	USDMF
Dolutegravir	HIV integrase inhibitor	Ambernath	WHO
Posaconazole	Systemic antifungal	Puducherry	USDMF
Flucytosine, Efinaconazole, Tioconazole, Imiquimod	Antifungals; topical immune modulator	—	—

C. Polymers and inorganics — the high-margin specialty franchise (Cuddalore)

Product	What it does (originator brand)	Site	Filings
Sevelamer carbonate	Phosphate binder for CKD on dialysis (Renvela)	Cuddalore	USDMF, EDMF
Sevelamer HCl	Phosphate binder (Renagel)	Cuddalore	USDMF, EDMF, Health Canada
Colesevelam HCl	Bile-acid sequestrant for LDL and T2D (Welchol)	Cuddalore	USDMF, EDMF
Colestipol	Bile-acid sequestrant (Colestid)	Cuddalore	USDMF, EDMF
Patiromer sorbitex calcium	Potassium binder for hyperkalaemia (Veltassa); DMF filed 2019 — competes with Formosa, Alkem, Vifor	Cuddalore	USDMF
Lanthanum carbonate (octahydrate, tetrahydrate)	Phosphate binder (Fosrenol)	Cuddalore	USDMF, Japan
Sucroferric oxyhydroxide	Iron-based phosphate binder (Velphoro)	Cuddalore	USDMF, EDMF

Polymers [Mgmt]: "fully sold for capacity"; Solara is "one of few Indian producers" and supplies "almost all US ANDA players for this product" (Q2 FY25); claims "close to 50%+ global market share" in complex polymer APIs (Q3/Q4 FY26, not independently verified); short of polymer capacity — Vizag could help (Q3 FY26). CRAMS + polymers gross margin ~65% vs 53–55% for the catalogue (Q4 FY25).

D. CNS

Product	What it does	Site	Filings
Gabapentin (legacy Strides product)	Anticonvulsant; neuropathic pain	Cuddalore	USDMF, CEP, Canada, Korea
Levetiracetam	Anticonvulsant (incl. injectable grade)	Cuddalore + Ambernath	USDMF, EDMF, Korea
Brivaracetam	Anticonvulsant	Cuddalore	USDMF, EDMF
Lurasidone HCl	Antipsychotic	Puducherry	USDMF
Felbamate, Olanzapine, Chlorpromazine, Buspirone, Safinamide, Rotigotine, Edaravone, Citicoline, Disulfiram	Epilepsy, psychosis, anxiety, Parkinson's, ALS, neuroprotection, alcohol dependence	—	—

E. Cardio-renal, metabolic and other specialty

Product	What it does	Site	Filings
Mycophenolate mofetil / sodium	Transplant immunosuppressant	Ambernath	USDMF
Mesalamine	Ulcerative colitis	Cuddalore	USDMF, CEP
Obeticholic acid	Primary biliary cholangitis	Cuddalore	USDMF, EDMF
Mirabegron	Overactive bladder	Cuddalore	USDMF
Tranexamic acid	Antifibrinolytic	Vizag	none listed
Ranitidine HCl	H2 blocker — FDA withdrew it from the US market in Apr-2020 (NDMA)	Cuddalore	USDMF, CEP, Health Canada
SNAC (salcaprozate sodium)	Absorption enhancer used in oral semaglutide; US DMF #43784 filed 3-Apr-2026 — first new US DMF in ~4 years; earlier filers AMI Lifesciences (Nov-24), Micro Labs (Apr-25), Alembic (Feb-26)	—	USDMF
Cinacalcet, Pitavastatin, Hydralazine, Indapamide, Bumetanide (inj), Ethacrynic acid, Flecainide, Dipyridamole, Pentoxifylline, Sapropterin, Colchicine, Zileuton, Rebamipide, Nizatidine, Cetirizine, Methoxsalen, Aprepitant, Mesna	Various	—	—

F. Anaesthesia and hospital injectables

Product	What it does	Site	Filings
Sugammadex	Reverses neuromuscular blockade (generic Bridion)	Ambernath	USDMF, EDMF
Succinylcholine chloride	Depolarising muscle relaxant	Mangaluru	USDMF, EDMF, Health Canada
Etomidate, Methohexital	IV induction agents	—	—

Services and new businesses

Business	Detail	Status
CRAMS / CDMO	Hit-to-lead, impurity and reference-standard synthesis, route scouting, salt/polymorph screening, process safety, kilo-lab, cGMP Phase 1–3 supply, process validation, commercial supply. Analytical lab USFDA-audited, 21 CFR Part 11 compliant. Client IP stays with client; customers in North America, Europe, Japan. Sale of services ₹4.0 Cr in FY26 vs ₹13.5 Cr in FY25 (AR Note 26); management calls CRAMS "subscale", ~₹10–12 Cr/yr (Q4 FY26)	Subscale
CRAMS size reconciliation	The "CRAMS + polymers ~₹100–120 Cr" (FY25 calls; Q3 FY25: ~₹120 Cr at 25–27% adj. EBITDA) was mostly polymer product sales [Est.]. Q4 FY25 deck: business to be demerged ~₹108 Cr revenue in FY25	[Est.]
Synthix Global Pharma Solutions Ltd	Wholly-owned subsidiary incorporated 29-Apr-2025 (CIN U21001MH2025PLC447046), the vehicle to demerge polymers + CRAMS; plan to push down ~₹200 Cr of debt and Vizag and build a ₹400–500 Cr business in 3–4 years at 35–40% EBITDA. Holds ~₹49.5 Cr debt under a ₹50 Cr Solara guarantee, parked in deposits [Est.]	On hold pending ibuprofen review
Chemsynth Laboratories Pvt Ltd	49% held, consolidated as subsidiary via board control (BRSR calls it associate/JV; CRISIL says 100%). Acquired 1-Sep-2018; activity not described; non-operational	Dormant
Peptides	Entered the peptide value chain as a supplier to larger players; "early days"; "does not make peptides for any group companies" (Q2 FY25)	Early
OneSource-linked API	One API co-developed with OneSource Specialty Pharma (promoter-group CDMO), approval/launch targeted FY27 (Q3 FY26). Related-party sales to OneSource <₹1 Cr in FY26	FY27

How they make it — process, technology, inputs

Manufacturing process

Multi-step batch organic synthesis in SS, glass-lined and Hastelloy reactors. Finishing: crystallisation, drying, milling, compaction (DC grades), spray drying, lyophilisation, polymer cross-linking for sequestrants.

Chemistry platforms (AR)

Hydrogenation at commercial scale (Cuddalore, Mysuru)
Halogenation, Grignard
Polymer and inorganic chemistry (iron/lanthanum binders)
Lyophilisation
Reduction, oxidation, mesylation, esterification

R&D platforms (AR)

Flow, enzymatic, chiral and photochemistry; HPAPI capability
Analytics: NMR, HRMS, LC, GC, XRD
Nitrosamine detection/mitigation upgraded FY26
No technology imported in 3 years; no foreign collaborations; process optimisation "doubled some capacities within the same footprint"

R&D / technology metric	FY25	FY26	Comment
R&D recurring spend (₹ Cr)	41.5	31.1	+₹4.2 Cr capital in FY26; ~2.6% of revenue. Guidance ~₹25 Cr/yr
Cumulative R&D, 4–5 years	~₹200 Cr		With essentially no new US filing until SNAC (Apr-2026) — a recurring critique
New DMFs	4–5 / yr from FY27		Revenue impact ~FY29–30 [Mgmt]
Chennai R&D scale	4 labs, 20 hoods, 50+ scientists		Website still shows older 7 labs, 60 hoods, 130+ staff; R&D centre USFDA approval 2024
Ibuprofen process	~20-year-old route		New route in development, not filed; no enzymatic route (management denial, Q1 FY27); customers resist route changes (re-filing burden). Boots route (as IOL) vs BHC (BASF)
Physical output [Est.]	~4,850–4,900 MT	~5,000 MT	From BRSR intensities: GHG 37,336 tCO2e ÷ 7.47 ≈ 4,998 MT; waste 27,208 MT ÷ 5.45 ≈ 4,992 MT. If plain ibuprofen ≈ 3,000 MT, it is ~60% of tonnage but 24% of revenue
Renewable electricity	—	81%	PPA + captive solar; Scope 1+2 = 37,336 tCO2e; energy capex nil in FY26 "due to financial constraints"

Facilities

Site	AR description / scale	Key products	Approvals	Regulatory / status
Ambernath, Maharashtra	"Multi-purpose API and intermediate facility"; 250 L–8 KL; –20 to +130 °C	Sugammadex, mycophenolate, dolutegravir, levetiracetam	USFDA, EDQM, PMDA, WHO, CDSCO, Korea	USFDA May-2025: zero 483s (classification undisclosed). Base business. How acquired: unverified
Cuddalore, Tamil Nadu	"Multi-purpose API and intermediate facility"; "25 KL"; –90 to +200 °C; spray drying, hydrogenation	All 7 polymer/inorganic APIs; gabapentin, levetiracetam, brivaracetam, mesalamine, mirabegron, obeticholic acid, cycloserine, ranitidine, ibuprofen sodium	USFDA, EDQM, SUKL, Danish EU-GMP, MHRA, KFDA, WHO, COFEPRIS, TGA, PMDA — widest set	Was OAI (2022 calls; OAI Jun-2020 unverified). Re-inspection 31-Jul to 4-Aug-2023: zero 483s; company said NAI reinstatement. 11 pending product approvals at Q4 FY23
Mangaluru, Karnataka	"Niche as well as large-volume APIs and advanced drug intermediates"; 250 L–6.3 KL; glass 20–250 L	Praziquantel, albendazole, mebendazole, artesunate, rifaximin, succinylcholine	USFDA, EDQM, AEMPS, HPRA, KFDA, WHO, TGA, PMDA, CDSCO; EU GMP 2025	~4-week unscheduled shutdown Q2 FY26 "for upgradation" (Q2 EBITDA –43% YoY). USFDA 25–29 Aug-2025: 2 procedural 483s; EIR 18-Nov-2025 VAI
Puducherry	"One of the world's largest Ibuprofen manufacturing facilities. Highly flexible pilot plant"; 1.2–12.5 KL	Plain ibuprofen (single-product block ~6,000 TPA); DC grades, salts, S-ibuprofen, lysine, lurasidone, posaconazole	USFDA, EDQM, HPRA, AGES, Danish EU-GMP, MHRA, KFDA, COFEPRIS, PMDA	Fire Nov-2023 (Q3 FY24), ~43% of capacity, insured; two fatalities reported [as cited]. Unannounced USFDA 2–6 Feb-2026: 4 procedural 483s; EIR (filed 28-Apr-2026) VAI. Pledged to term lenders; main subject of the review
Mysuru, Karnataka	"Key intermediate manufacturing site"; 1.2–5 KL; hydrogenators 50 L–4 KL	Captive intermediates (backward integration) [Est.]	Local GMP only	Only non-USFDA site
Vizag, Andhra Pradesh	"State-of-the-art greenfield facility"; 100 L–25 KL; –40 to +250 °C; ~700 KL installed ("can roughly double"); Phase 1 = 17 acres, 4 blocks (3 operational); Phase 2 = 23 acres more	Ibuprofen S250 (second source), naproxen sodium, tranexamic acid	USFDA, EDQM, CDSCO; two consecutive USFDA inspections with zero 483s	Mothballed. ~33–35% of group capacity; gross block ~₹500 Cr, net ~₹250 Cr; CWIP ₹182.5 Cr; big-pharma customer part-funded it; idle cost ₹12–15 Cr/yr. Plans: polymers (Oct-24) → CRAMS (Jan–Jul 25) → multipurpose+HPAPI (Feb-26) → "on hold" (Jul-26)
Chennai R&D	"Research and innovation centre"	Process R&D, analytical	Analytical lab USFDA-audited	—
Other	Corporate office TICEL Bio Park, Chennai; sales office Bangalore; registered office Vashi, Navi Mumbai	—	—	Mahad (SeQuent plant at 2018 demerger) not in current list — status unverified

Capacity, utilisation and capex

Item	Value	Source
Network utilisation	~60% (Q4 FY25); 60–65% (Q1 FY26)	[Mgmt]
Base-business plants (Cuddalore, Mangaluru, Ambernath)	"a little over 70%" Q3 FY26 – Q1 FY27	[Mgmt]; transcript renders Mangalore as "Bangalore"
Ibuprofen capacity / output	10,000–12,000 TPA (Puducherry ~6,000 + Vizag) vs ~3,000 TPA produced → ~25–30% utilisation	[Mgmt Q3 FY26; Est.]
Global ibuprofen supply	~50,000 MT; >20,000 TPA new capacity added in last two years	[Mgmt]
FY27 capex	₹55–60 Cr: ₹40–45 Cr debottlenecking (+20–30% on high-margin lines; payback 2–3 quarters), ₹10–15 Cr maintenance	[Mgmt Q1 FY27]
FY28–29 capex	₹40–50 Cr / yr; no greenfield ("once bitten, twice shy")	[Mgmt]
Capital commitments	₹44.1 Cr (Mar-26)	[Fact, AR]

Certifications, filings, IP and exports

Agency	Product filings
USFDA (DMFs)	96
EDQM (CEPs)	34
MFDS (Korea)	22
Health Canada	20
EMA	16
PMDA (Japan)	9
ANVISA (Brazil)	8
TGA (Australia)	8
NMPA (China)	8
WHO	7
Medsafe (NZ)	4

Source: AR FY26 R&D page [Fact].

DMF utilisation: ~30 products sold against ~95 US DMFs (Q3 FY25); dormant DMFs being revived.
Plant approvals: 5 of 6 sites USFDA-approved; EDQM; EU-GMP via DKMA, HPRA, AGES, AEMPS, SUKL; MHRA, PMDA, MFDS, TGA, COFEPRIS; WHO-Geneva; CDSCO. Website: 33 successful USFDA audits; AR: 3 successful USFDA audits in FY26 (likely Ambernath, Mangaluru, Puducherry) [Est.].
No warning letter or import alert found (FDA databases not queried directly).
ISO: no management-system certifications disclosed.
IP: no product patents disclosed; moat = process know-how + DMF/CEP library; AR lists "patent compliance risk" in custom synthesis.
Exports: 52% of turnover (BRSR). AR "FX earned" ₹1,094.3 Cr (FY25 ₹1,170.6 Cr) and FX outgo ₹664.3 Cr (FY25 ₹656.2 Cr) — FX inflows likely include loan/packing-credit inflows, so not an export proxy [Est.].
Quality: 14 complaints FY26 (4 open), 0 recalls, 0 data breaches (BRSR).
ESG: CRISIL ESG score 56 → 63 "Strong" (10-Oct-2026).

USP and moat

Why customers stick: customers reference Solara's DMFs/CEPs in their ANDAs and marketing authorisations, so switching supplier means 12–24 months of re-filing [Est.]. Relationships run 25+ years with claimed 100% retention of big-pharma customers; Solara is "primary supplier in most of its DMFs"; >half of regulated revenue is big pharma [Mgmt]. Niche chemistry (polymers, lyophilisation, hydrogenation, Grignard) and a multi-agency compliance record are real barriers.
Where the moat is gone: plain ibuprofen — non-integrated (buys IBB/key input from third parties), sub-scale versus IOL and Shandong Xinhua, priced above China, loss-making for two years. Its only edge is that incumbent big-pharma customers already qualified it, earning a 15–17% price premium. [Analyst View]

Segment Analysis

Ind AS 108 reports one "API" segment; management discloses a Base vs Ibuprofen split (first shown Feb-2026, Q3 FY26). Revenue here is on the total-income basis so the two segments sum to ₹1,375.1 Cr.

What each segment is

Base business ("Growth API")

Every API except plain commodity ibuprofen — includes ibuprofen derivatives (salts, DC grades, S-ibuprofen), polymers, CRAMS and the specialty catalogue. Customers: generic and innovator formulators, US ANDA filers (polymers), Strides. Sites: Cuddalore, Mangaluru, Ambernath (+ Mysuru intermediates). Gross margin ~55%; EBITDA 23.5% (FY26).

Ibuprofen business

Plain commodity ibuprofen only. Sold only to "big pharma / marquee brands" at a reported 15–17% premium. Sites: Puducherry (~6,000 TPA block) + mothballed Vizag. Gross margin 21–29%; EBITDA negative for two years; ~₹700 Cr capital deployed (debt + equity).

Segment split — annual and quarterly

₹ Cr	FY25	FY26	YoY	Q1 FY26	Q4 FY26	Q1 FY27	Q1 YoY
Base revenue	985	1,041.4	+6%	248.7	307.0	307.7	+24% (~+18–19% ex ~₹30 Cr pass-through)
Base gross profit after S&D	541	573.2 (55.0%)	+6%	144.6 (58.1%)	164.8 (53.7%)	158.0 (51.3%)	+9%
Base EBITDA	~244	244.5 (23.5%)	~0%	67.0 (26.9%)	79.6 (25.9%)	72.2 (23.5%)	+8%
Ibuprofen revenue	307	333.7	+9%	71.4	84.9	76.5	+7%
Ibuprofen gross profit	103 (~33.5%)	92.7 (27.8%)	–12%	22.8 (31.9%)	19.2 (22.7%)	22.2 (29.0%)	–3%
Ibuprofen EBITDA	~(30)–(36) [Est.]	(53.0) (–15.9%)	–76%	(9.5) (–13.3%)	(17.9) (–21.1%)	(8.7) (–11.4%)	improved
Total revenue	1,292.1	1,375.1	+6.4%	320.1	391.9	384.3	+20%
Total EBITDA	213.8	191.5	–10.4%	57.5	61.7	63.5	+10%

FY25 base/ibuprofen revenue: AR ₹985 / ₹307 Cr; CRISIL ₹984 / ₹301 Cr (AR used). FY25 ibuprofen EBITDA is not disclosed: ~–₹30 Cr backed out of the AR's "76% deterioration" (business.md) vs ~–₹36 Cr (financials.md; CRISIL ~–12%) — hedged as a range. CRISIL FY26 ibuprofen: ₹327 Cr at ~–18%. FY24 and earlier segment splits are not disclosed.

Quarterly series, FY26–Q1 FY27

₹ Cr	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Base revenue	248.7	239.1	246.6	307.0	307.7
Base gross margin %	58.1%	53%	55% (call: 56.3%)	53.7%	51.3% (54.5% ex pass-through)
Base EBITDA (margin)	67.0 (26.9%)	45.9 (19%)	52.0 (21%; call 24.7%)	79.6 (25.9%)	72.2 (23.5%)
Ibuprofen revenue	71.4	~177 combined Q2+Q3 [Est.]; Q3 alone 102.4 (call)		84.9	76.5
Ibuprofen gross margin	31.9%	—	23% (call)	22.7%	29.0%
Ibuprofen EBITDA (margin)	(9.5) (–13.3%)	~(25.6) combined [Est.]; Q3 call –22.9% (~–23); 9M FY26 ~–23% (CRISIL)		(17.9) (–21.1%)	(8.7) (–11.4%)
Net debt	632.7	623.3	630.0	614.1	479.5

Q3 FY26 growth-API EBITDA was 24.7% as stated on the call vs 21% in the restated Q1 FY27 deck — definitions differ (gross margin after S&D). Q4 FY25 ibuprofen revenue ~₹53 Cr [Est., from Q4 FY26 +61%]. Q2/Q3 split of ibuprofen is internally inconsistent across sources and is shown combined.

Base vs ibuprofen EBITDA by quarter (₹ Cr)

Base EBITDAIbuprofen EBITDAQ2 FY26 ibuprofen not separately disclosed; Q3 from call (–22.9% on ₹102.4 Cr)

Consolidated five-year KPIs (AR basis)

₹ Cr	FY22	FY23	FY24	FY25	FY26
Revenue (total-income basis)	1,288.4	1,466.4	1,294.3	1,292.1	1,375.1
YoY growth	—	+13.8%	–11.7%	–0.2%	+6.4%
Regulated-market revenue	798.8	1,026.5	854.2	982.0	1,052.6
Regulated share (total-company basis)	62%	70%	66%	76%	76.5%
EBITDA	92.2	150.7	(92.0)	213.8	191.5
EBITDA margin	7.2%	10.3%	(7.1%)	16.5%	13.9%
PAT	(58.3)	(22.3)	(567.0)	0.54	(7.41)
RoCE	(5.3%)	(2.1%)	(12.6%)	7.6%	4.7%
Fixed-asset turnover	1.4x	1.5x	1.2x	1.2x	1.3x

Conflict inside the AR: the CEO letter says regulated markets were "~75% of base business revenues", but regulated revenue (₹1,052.6 Cr) exceeds total base revenue (₹1,041.4 Cr). The KPI must therefore be on a total-company basis including ibuprofen. Direct US billing is only ~7% of revenue; much "regulated" revenue is API sold to Indian/Asian formulators (incl. Strides) whose finished doses go to regulated markets [Est.].

FY26 revenue composition (standalone, AR Note 26)

Line	FY25 (₹ Cr)	FY26 (₹ Cr)
Sale of products	—	1,326.2
Sale of services (CRAMS)	13.5	4.0
Other operating revenue	42.3 (incl. export incentives 14.6)	38.8 (scrap/by-products 29.7; export incentives 8.65)
Sales returns and reversals (deducted)	92.0	46.8
Contract revenue (standalone)	1,241.5	1,330.2
Revenue from operations	1,283.8	1,369.0

Fastest grower and the segment under pressure

Base business — growing, margin compressing

Revenue +24% YoY in Q1 FY27; above ₹300 Cr/qtr since Q4 FY26 — "we've hit a new plateau … crossed that magical INR300 crores" (Rao).
Drivers: new geographies (LatAm, Korea, Middle East), new business wins, revived DMFs, polymers, and higher sales to Strides (all FY26 growth; ex-Strides –2.5%) [Est.].
Margins compressing: EBITDA 26.9% → 23.5% and GM 58.1% → 51.3% YoY on West Asia input costs, ~₹17–18 Cr base pass-through and mix.
Guidance: ≥10% growth; EBITDA 25% ±1%; GM 52–55% (Rao: "comfortable with the 50% to 55% range").
Adjusted Q1 FY27 base EBITDA margin ~24.9% (72.2 / (307.7 – 17.5)) [Est.] — in band adjusted, below band reported.

Ibuprofen — structurally loss-making

EBITDA negative for two years; guided loss ₹10–15 Cr/qtr. Q1 FY27 –₹8.7 Cr was "a tactical play" on solvent-constrained supply (prices up, volumes down).
Gross margin 21–29% vs >50% in base; generic pricing "does not even cover a cost of manufacturing" (Q4 FY25).
Utilisation ~25–30%; ~₹700 Cr deployed; recovery "slightly farfetched" (CFO).
Options: sale, technology change, sale of the Puducherry plant, or reset [Mgmt/CRISIL]. Rao: "ibuprofen is a commodity business … I don't think the dynamics … will change."
Vizag idle cost ₹12–15 Cr/yr.

Management focus and guidance record by segment

Item	Guided	Actual	Read
FY25 revenue	~₹1,500 Cr (Oct-24) → ₹1,300–1,400 Cr (Jan-25)	₹1,292 Cr total income / ₹1,284 Cr ops	Miss
FY26 EBITDA	₹240–250 Cr (+15–20%)	₹191.5 Cr (–10%)	Big miss
Growth-API GM "55–56% for next few years" (Feb-26)	55–56%	53.7% (Q4), 51.3% (Q1 FY27)	Slipping
Base EBITDA margin (May/Jul-26)	25% ±1%	25.9% Q4; 23.5% Q1 FY27	In band adj.
FY27 growth (May/Jul-26)	~10%, "mostly base business"	Q1 base +24% (18–19% adj.)	On track
Ibuprofen loss	₹10–15 Cr / qtr	₹8.7 Cr Q1 FY27	Beat (non-repeatable)
CRAMS	₹500 Cr in 3–4 yrs (Jan-25)	₹4.0 Cr services FY26; carve-out on hold	Abandoned/deferred

Financials: P&L

Consolidated, ₹ Cr, FY ending 31 March. Sources: FY26 AR (notes, KPIs), Q4 FY26 results, Q1 FY27 press release/deck/transcript, Q4 FY25 deck, CRISIL rationales, Screener, stockanalysis, Arihant (FY22–24 material cost).

Five-year earnings hole, only now closing. Cumulative PAT FY22–FY26 = –₹654 Cr [Est., sum]. FY24 alone lost ₹567 Cr (Puducherry fire, ₹190 Cr exceptional items, ₹79 Cr deferred-tax write-off, negative EBITDA). FY25 PAT +₹0.54 Cr; FY26 –₹7.41 Cr. Q1 FY27 PAT ₹16.3 Cr is the best in 18 quarters [Fact, company].

Five-year annual P&L

₹ Cr	FY22	FY23	FY24	FY25	FY26	TTM Jun-26
Revenue from operations [Fact]	1,268.3	1,443.8	1,288.9	1,283.8	1,369.0	~1,431
YoY growth	–21.6%	+13.8%	–10.7%	–0.4%	+6.6%	+15.5%
Other income [Fact]	18.8	22.1	5.4	8.3	6.2	small
Total income [Fact, AR KPI]	1,288.4	1,466.4	1,294.3	1,292.1	1,375.1	—
Gross profit (rev – materials – traded goods – inventory change)	614.5	655.0	483.9	657.4	684.5	—
Gross margin %	48.4%	45.4%	37.5%	51.2%	50.0%	—
Company "gross margin" (after S&D) [Fact]	—	—	489.1 (37.8%)	664.9 (51.5%)	~666 (48.4%)	—
EBITDA, company, incl. other income [Fact]	92.2	150.7	(92.0)	213.8	191.5	~197.5 [Est.]
EBITDA margin (on total income)	7.2%	10.3%	(7.1%)	16.5%	13.9%	~13.8%
EBITDA excl. other income (Screener)	81	134	(95)	206	187	192
OPM % (Screener)	6%	9%	–7%	16%	14% (13.7%)	13%
Depreciation & amortisation [Fact]	112.0	110.9	103.3	99.3	99.7	~103
EBIT (company EBITDA – D&A) [Est.]	(19.8)	39.8	(195.3)	114.6	91.9	~94
EBIT margin	–1.5%	2.7%	–15.1%	8.9%	6.7%	~6.6%
Finance cost [Fact]	75.3	90.1	105.0	114.8	94.8	~92
Exceptional items [Fact]	(4.3)	(0.5)	(190.2)	—	(5.9)	—
PBT [Fact]	(91.7)	(44.8)	(488.3)	0.54	(7.41)	~(1.6)
PBT margin	–7.2%	–3.1%	–37.9%	0.0%	–0.5%	–0.1%
Tax credit / (charge) [Fact]	33.4 credit	22.5 credit	78.6 charge	0	0	0
PAT [Fact]	(58.3)	(22.3)	(567.0)	0.54	(7.41)	~(1.6) [Est.]
PAT margin	–4.6%	–1.5%	–44.0%	0.04%	–0.5%	–0.1%
Basic EPS, ₹ [Fact, AR KPI]	(16.18)	(6.16)	(157.62)	0.14	(1.68)	~(0.35)
Dividend declared	Nil	Nil	Nil	Nil	Nil	—

Earlier context (CRISIL Oct-2021): FY20 revenue ₹1,329 Cr, PAT ₹115 Cr, interest cover 3.7x; FY21 revenue ₹1,618 Cr (Screener 1,617; EBITDA 386, OPM 23.9%), PAT ₹221 Cr, interest cover 4.9x — the Covid-era API peak. FY22–FY26 is post-peak normalisation then reset; FY21–26 sales CAGR –3.3% [Est.].

Revenue from operations (bars, ₹ Cr) and company EBITDA margin (line, %)

Revenue from ops (left axis)EBITDA margin on total income (right axis)

Notes, reconciliations and one-time items

Item	Detail	Tag
Gross profit FY25–FY26	AR notes 28–30: materials + stock-in-trade + change in FG/WIP — FY26 672.77 + 3.49 + 8.25 = 684.51 (consumption basis); FY25 581.66 + 5.75 + 39.00 = 626.41. Standalone notes; standalone revenue ≈ consolidated (1,368.98 / 1,283.76), subsidiaries immaterial. Caution: "materials only" figures (696.2 / 54.7%) omit inventory change and overstate GM	Fact-derived
Gross profit FY22–FY24	Same method using standalone raw-material plus stock-adjustment data (Arihant/ACE)	Est.
FY25 PAT conflict	Consolidated +0.54; standalone –1.08; CRISIL adjusted –2.35. Report uses +0.54	Fact
FY24 collapse	EBITDA –₹91.7 Cr; GM 37.8%; exceptional ₹190.2 Cr (₹122.1 Cr Q4 FY24, ~₹68 Cr mostly Q3 FY24); ₹78.5 Cr tax charge reversed the DTA (net DTA nil at Mar-24 from ₹78.6 Cr). Fire at Puducherry (~43% of capacity) put rating on Watch Negative 9-Nov-2023; insured. Includes Covid-drug (favipiravir/molnupiravir) inventory write-offs and Vizag impairment [as cited]. Company split of the ₹190 Cr: not retrieved [Open]; Screener books it inside "Other income" (FY24 –185)	Fact
Insurance claims in other income	₹1.07 Cr FY26, ₹1.02 Cr FY25 (AR note 27; alignment approximate). Insurance claim receivable ~₹6.18 Cr at Mar-26 vs ₹12.23 Cr	Fact
FY26 exceptional item	–₹5.89 Cr labour-code impact on gratuity/leave (Q3 –6.75, Q4 +0.86)	Fact
Revenue quality FY26	Sales returns/reversals ₹46.8 Cr (FY25 ₹92.0 Cr). Other operating revenue ₹38.8 Cr (scrap 29.7; export incentives 8.65) vs ₹42.3 Cr (incentives 14.6)	Fact
Q3 FY22 channel event	~₹120–130 Cr distributor sales returns when shifting from distributor-led to direct sales; quarterly turnover ₹401 Cr → ₹100 Cr; quarter loss ~₹140 Cr; CRISIL Watch Developing	Fact/as cited
Inventory provisions	Cumulative write-down to NRV ₹127.6 Cr at Mar-26, of which ₹122.8 Cr relates to Covid/anti-viral drugs (₹130.2 Cr at Mar-25) — explains part of FY22–24 build and losses	Fact
Off-balance-sheet tax shield	Unrecognised DTA on c/f losses ₹156.4 Cr; potential claims on goodwill/portfolio depreciation ₹607.2 Cr; not opted for s.115BAA (34.94% rate); losses and MAT credit expire FY32–FY37 → near-zero tax on profits for several years	Fact
ESOP expense	₹4.67 Cr FY26 vs ₹2.68 Cr FY25 (incl. MD & CEO ESOP perquisite ₹2.08 Cr)	Fact

Last eight quarters

Quarter	Revenue	Rev YoY	Rev QoQ	EBITDA (ex OI)	EBITDA %	EBITDA YoY	EBITDA QoQ	PAT	PAT YoY	PAT QoQ
Q2 FY25 (Sep-24)	347	–18.4%	–4.4%	61	17.6%	+61%	+45%	8.0	n.m. (vs –17)	n.m. (vs –13)
Q3 FY25 (Dec-24)	300	+41.5%	–13.5%	58	19.3%	n.m. (vs –162)	–5%	8.1	n.m. (vs –275)	flat
Q4 FY25 (Mar-25)	273.0	–8.8%	–9.0%	45	16.5%	+350%	–22%	(2.1)	n.m. (vs –255)	n.m.
Q1 FY26 (Jun-25)	319	–12.1%	+16.8%	57	17.9%	+36%	+27%	10.5	n.m. (vs –13)	n.m.
Q2 FY26 (Sep-25)	314	–9.5%	–1.6%	35	11.1%	–43%	–39%	(10.1)	n.m.	n.m.
Q3 FY26 (Dec-25)	349.0	+16.3%	+11.1%	37	10.6%	–36%	+6%	(17.4)	n.m.	n.m.
Q4 FY26 (Mar-26)	387.3	+41.9%	+11.0%	58	15.0%	+29%	+57%	9.6	n.m. (vs –2.1)	n.m.
Q1 FY27 (Jun-26)	382 (co. 384.3)	+19.7% (co. +20%)	–1.3%	62 (co. 63.5)	16.2% (co. 16.6%)	+9% (co. +10%)	+7%	16.3	+55%	+70%

Screener figures unless "co." (company). Business Standard shows Q1 FY27 revenue from ops ₹381.6 Cr. Base quarters for YoY: Q1 FY25 rev 363 / EBITDA 42 / PAT –13; Q2 FY24 425 / 38 / –17; Q3 FY24 (fire) 212 / –162 / –275; Q4 FY24 299 / 10 / –255.

Quarterly revenue and EBITDA (₹ Cr, Screener ex-other-income), with PAT

RevenueEBITDABottom row: PAT (₹ Cr)

Q1 FY27 — company-reported P&L (press release / deck)

₹ Cr	Q1 FY27	Q4 FY26	Q1 FY26	YoY
Revenue	384.3	391.9	320.1	+20%
Gross margin (after S&D)	180.2 (47.0%)	184.0 (47.0%)	167.4 (52.3%)	+8%; –530 bps
EBITDA (incl. OI)	63.5 (16.6%)	61.7 (15.8%)	57.5 (18.0%)	+10%
Finance cost (net)	20.5	26.9	23.5	—
Depreciation	26.7	26.0	23.5	—
PAT	16.3	9.6	10.5	+55%
EPS (₹, diluted)	3.52	2.20	2.46	Screener 3.38 (partly-paid weighting)

Company EBITDA incl. other income: Q3 FY25 59.1; Q4 FY25 51.0 (net finance cost 28.8); Q1 FY26 57.5; Q4 FY26 61.7; Q1 FY27 63.5. Consolidated gross margin after S&D fell to 47% on ibuprofen mix and ~₹30 Cr cost pass-through; CFO: adjusted "close to like 53%". Q1 FY27 revenue "almost look[s] like flat Q-on-Q" adjusting for pass-through (CFO).

Revenue growth decomposition and earnings quality

Organic vs inorganic; price vs volume

All growth is organic; no acquisitions since Strides Chemicals (2018, ₹131 Cr) and Chemsynth (2018).
FY26 growth (+₹89 Cr standalone contract revenue) was entirely Strides (+₹114 Cr); other customers –₹25 Cr (–2.5%) [Est.].
Q1 FY27 +20% includes ~₹30 Cr cost pass-through (price), underlying 18–19% YoY; QoQ flat.
Ibuprofen Q1 FY27: price increases accepted, volumes down — "Adjusted for the price increase, that numbers are slightly down" (CFO).
Volume/price split not otherwise disclosed.

Are profits backed by cash?

OCF positive FY23–FY26 despite accounting losses (D&A ~₹100 Cr/yr and write-downs are non-cash).
FY22: PAT –58 but OCF –242 (₹281 Cr inventory build) — cash-negative red flag.
FY24: PAT –567 but OCF +109 — held up by a ₹178 Cr receivables release, not earnings.
FY26: OCF 152.9 vs EBITDA 191.5 (80%); receivables +₹112 Cr, of which ~₹98 Cr Strides.
After capex and interest: FY26 ~₹8 Cr; FY22–26 cumulative ~–₹533 Cr. Detail in Tab 6.

Financials: Balance Sheet, Cash Flow & Ratios

Consolidated, ₹ Cr, 31 March unless stated. Debt figures per financials.md (authoritative): gross ₹532.3 Cr and net ₹479.5 Cr at Jun-26; ₹999.4 Cr gross at Mar-24.

Five-year balance sheet

₹ Cr	Mar-22	Mar-23	Mar-24	Mar-25	Mar-26	Jun-26
Net tangible fixed assets (PPE + CWIP + ROU)	1,137.4	1,159.1	1,114.2	1,076.5	1,055.2	1,044.1
of which CWIP	238.7	238.5	256.4	280.1	204.8	n.a.
of which owned PPE	—	—	—	738.7	793.2	n.a.
Goodwill	365.1	365.1	365.1	364.9	364.9	364.9
Other intangibles	67.9	54.4	42.6	29.8	22.2	n.a.
Inventory	575.6	558.1	359.7	317.9	317.9	n.a.
Trade receivables	489.7	537.0	348.5	326.6	438.7	n.a.
Cash, bank, ST investments	46.4	8.7	8.4	4.1	50.3	52.8
Trade payables	276.0	305.9	313.0	247.6	273.9	n.a.
Term debt (incl. current maturities)	~414.6	~352.4	239.1	203.2	163.8	149.4
Working-capital / short-term debt	609.9	648.8	760.3	572.9	500.8	382.9
Gross debt (excl. leases)	~1,024.5	~1,001.2	999.4	776.1	664.5	532.3
Lease liabilities	12.8	11.7	12.1	20.0	22.0	~22
Gross debt incl. leases (≈ Screener "Borrowings")	1,037	1,013	1,012	796	687	~554
Net debt (company definition)	~978	~992.5	~991	772	614.1	479.5
Net worth (total equity)	1,527.2	1,502.5	936.6	1,096.9	1,255.6	1,406.8
Tangible net worth (less goodwill)	~1,162	~1,137	571.5	732.0	890.7	1,041.9
Total assets	2,945	2,899	2,351	2,232	2,333	n.a.

Sources: Mar-25/Mar-26 AR and Q4 FY26 results [Fact]; Mar-24/Mar-25 debt split Q4 FY25 deck [Fact]; Mar-26/Jun-26 debt, net worth, fixed assets Q1 FY27 PR [Fact]; Mar-22–Mar-24 asset lines stockanalysis [Fact-secondary]; Mar-22/Mar-23 debt split [Est.]. Debt reconciliation: market.md's "₹687 Cr (Mar-26) / ₹796 Cr / ₹1,012 Cr" are Screener borrowings = gross debt including lease liabilities (664.5+22.0; 776.1+20.0; 999.4+12.1). heard.md's "net debt ~₹1,012 Cr at peak" is that same gross-incl.-leases figure, not net debt; peak net debt was ~₹991–992 Cr. Screener "Fixed assets" (1,238 at Mar-26) includes goodwill.

Gross debt (excl. leases) vs net debt, ₹ Cr

Gross debt excl. leasesNet debt (company)Mar-22/23 split [Est.]; target ~₹440 Cr net Mar-27; net-debt-free FY29

Balance-sheet notes

Item	Detail (Mar-26 unless stated)
Fixed assets	Freehold land 71.7; buildings (net) 262.9; plant & machinery (net) 437.1; gross block ₹1,453 Cr vs accumulated depreciation ₹667 Cr; ROU 57.2
CWIP	Vizag ₹182.5 Cr; Puducherry ₹6.9 Cr; ₹141.2 Cr of Vizag CWIP capitalised in FY26
Title deeds pending	₹191.3 Cr gross / ₹151.1 Cr net still in names of Shasun Chemicals & Drugs, Shasun Pharmaceuticals, Strides Shasun and SeQuent Scientific since 1-Oct-2017 (FY25: ₹180.71 Cr) — complicates any asset sale
Goodwill ₹364.9 Cr (AR note 7)	Human API CGU 357.95; R&D 0.43; Strides Chemicals 6.52. Pre-tax discount rate 21.35%, terminal growth 3%; headroom ≈ 9.15-pt rise in discount rate. KAM in FY25 and FY26. ~29% of Mar-26 equity / ~26% of Jun-26 equity. Not allocated to ibuprofen
Ibuprofen write-down risk	~₹700 Cr ibuprofen/Vizag capital "far-fetched" to recover fully [Mgmt]. Third-party estimate: each ₹100 Cr impairment ≈ 8% of equity; ₹100–300 Cr = 8–24%
Inventory mix	RM 81.7; goods in transit 4.3; WIP 150.7 (47%); FG 71.4; stores 9.8
Receivables ageing	Not due 357.8; <6 months 74.0; >6 months ~11; credit-impaired 6.1. Loss allowance fell to 10.2 from 26.6 (old dues written off). Strides receivable 160.45 (from 62.83)
Net current assets	Negative ₹35.8 Cr at Mar-26 vs –₹215.4 Cr at Mar-25; consolidated current ratio <1 since FY24. Q2/Q3 FY26 interim: –₹72.69 Cr / –₹92.44 Cr
Supplier finance	9.13% of trade payables (₹24.4 Cr; 60–90-day terms vs 90–120 days; supplier discount up to 11%) presented within payables — slightly flatters OCF (AR note 25)

Going concern — what it is and what it is not [Fact, verified from AR]

The FY26 accounts carry a going-concern basis disclosure by management in the accounting-policy note (Note 2). It is not an auditor qualification. Deloitte Haskins & Sells LLP's FY26 opinion (15-May-2026) is unmodified, with no "Material Uncertainty Related to Going Concern" paragraph and no emphasis of matter; KAMs are revenue cut-off and goodwill impairment; CARO (xix) reports no material uncertainty on meeting liabilities.
Consolidated: FY26 loss ₹7.41 Cr; accumulated losses ₹319.33 Cr; net current liabilities ₹35.81 Cr. Standalone: loss ₹7.24 Cr; accumulated losses ₹319.53 Cr; net current liabilities ₹78.84 Cr. Mitigants cited: the ₹134.99 Cr second and final rights call; expected renewal of working-capital facilities; improving revenue and margins. The Board approved the going-concern basis.

Five-year cash flow and PAT-to-OCF reconciliation

₹ Cr	FY22	FY23	FY24	FY25	FY26	5-yr total
PAT	(58.3)	(22.2)	(567.4)	0.5	(7.4)	(654.8)
D&A (incl. other amortisation)	112.3	111.2	103.3	99.3	99.7	525.8
Other non-cash items (residual) [Est.]	17.8	66.6	382.3	110.0	98.8	675.5
Change in working capital	(313.8)	0.7	190.7	3.0	(38.2)	(157.6)
OCF (before interest) [Fact]	(242.0)	156.3	108.9	212.8	152.9	388.9
Capex (incl. capital advances) [Fact]	(208.6)	(111.3)	(41.1)	(39.9)	(52.8)	(453.7)
FCF (OCF – capex)	(450.7)	44.9	67.8	172.9	100.1	(64.8)
Interest paid (FY25–26 Fact; earlier ≈ P&L)	~(73)	~(87)	~(103)	(113.1)	(92.2)	~(468)
FCF after interest [Est.]	~(524)	~(42)	~(35)	59.8	7.9	~(533)
Equity raised [Fact]	2.9	—	—	159.0	158.5	320.4
Dividends paid [Fact]	(10.8)	—	—	—	—	(10.8)
Net debt issued / (repaid)	+414.9	(25.3)	(3.0)	(223.5)	(119.8)	—
OCF / company EBITDA	n.m.	104%	n.m.	100%	80%	—
FCF yield on FY-end mcap [Est.]	–18.8% (2,398)	3.8% (1,179)	5.1% (1,335)	7.0% (2,466)	4.9% (2,050)	—

FY25–26 company; FY22–24 stockanalysis (Rs Mn converted). FY21 per Screener: CFO 155, FCF –16. Current FCF yield [Est.]: FY26 FCF ₹100 Cr on ₹3,156 Cr mcap = 3.2% before interest, ~0.25% after interest. Q1 FY27: ~₹35 Cr of operating cash to net-debt reduction (CFO), annualising ~₹140 Cr.

Working-capital cash flow lines (₹ Cr)	FY22	FY23	FY24	FY25	FY26
Inventory	–280.6	+17.3	+13.1	+41.8	0
Receivables	–14.6	–52.8	+178.2	+19.8	–111.3
Payables	–23.9	+38.9	+7.3	–59.4	+25.9

Divergence flags: PAT vs OCF

FY22 — cash-negative. PAT –58, OCF –242. ~₹281 Cr inventory build (inventory days 321), largely Covid/anti-viral stock later written down ~₹123 Cr. ₹209 Cr capex on Vizag ibuprofen expansion (CRISIL Oct-21: ₹200 Cr phase 2, full backward integration by Q3 FY22). FCF –451 funded by ~₹415 Cr new debt.

FY24 — accounting loss ≫ cash loss. PAT –567, OCF +109. ~₹676 Cr gap: exceptional 190 (fire/impairments), DTA reversal 79, write-downs within EBITDA ~110, D&A 103, and a ₹178 Cr receivables release. Working-capital release, not earnings, held OCF up. Auditor: FY24 cash loss ₹184.96 Cr; none in FY25/FY26.

FY25–FY26 — OCF positive, quality moderate. OCF is before interest; ₹92–113 Cr interest a year absorbs most FCF. FY26 receivables +₹112 Cr, ~₹98 Cr of it Strides. Supplier finance slightly flatters OCF.

Cumulative FY22–FY26. OCF +389 vs PAT –655: reported losses overstate cash burn. But after capex and interest the business consumed ~₹530 Cr [Est.], filled by rights money (₹320 Cr to Mar-26 + ~₹135 Cr in Q1 FY27) and working-capital release.

Working capital (days)

Days	FY22	FY23	FY24	FY25	FY26
Debtor days (on revenue)	141	136	99	93	117
Inventory days (on COGS)	321	258	163	185	170
Creditor days (on COGS)	154	142	142	144	146
Cash conversion cycle	308	252	120	134	140
Inventory turnover (stockanalysis)	1.63x	1.48x	1.88x	1.95x	2.31x
Receivables turnover (standalone, AR)	—	—	—	3.66x	3.48x

Screener [Fact-secondary], reproduced [Est.]: FY26 debtor days = 438.7/1,369.0×365 = 117; inventory days = 317.9/684.5×365 = 170. CRISIL (Mar-23): receivables ~142 days, inventory ~156 days. Strides receivable ~178 days vs ~97–98 days for other customers. CRISIL lists a "significant stretch in working capital cycle" as a downgrade trigger. S&OP measures target lower inventory norms; no days guidance.

Bank-limit utilisation — 12 months to	Aug-21	Dec-23	Jun-24	Dec-25	May-26
Average utilisation (CRISIL)	88%	95.7%	94.9%	94.9%	93%

Ratios

Ratio	FY22	FY23	FY24	FY25	FY26	Source
RoE (PAT / avg equity)	–3.7%	–1.5%	–46.5%	0.05%	–0.6%	[Est.]; company: (0.9), 1.9, (107), 0.01, (0.6)
RoCE (company-reported)	(5.3%)	(2.1%)	(12.6%)	7.6%	4.7%	[Fact, AR KPI]
RoCE (EBIT / equity + debt)	–0.8%	1.6%	–10.0% (ex-exc.)	6.1%	4.7%	[Est.]; standalone AR 7.54% / 6.10%
Gross D/E	0.68	0.67	1.08	0.73	0.55	[Est./stockanalysis]
Net D/E (company)	0.8	0.7	1.1	0.7	0.5 (0.51)	[Fact]
Net debt / tangible net worth	~0.84	~0.87	~1.73	~1.05	~0.69 (Jun-26 ~0.46)	[Est.]
CRISIL adj. debt / adj. net worth	0.94	0.92	1.89	1.11	<1	[Fact, CRISIL]
Interest cover (EBITDA / finance cost)	1.22x	1.67x	(0.88x)	1.86x	2.02x	[Est.]; CRISIL 1.04/1.49/(0.89)/1.81/~2
Interest cover (EBIT / finance cost)	(0.26x)	0.44x	n.m.	1.00x	0.97x	[Est.] — EBIT does not cover interest
Net debt / EBITDA	~10.6x	~6.6x	n.m.	3.6x	3.2x	[Est.]; company FY26 2.5x (= 614 / base 245)
DSCR (standalone)	—	—	—	0.95	1.06	[Fact, AR]
Current ratio	1.17	1.08	0.64	0.77	0.96 (SA 0.91)	[stockanalysis / AR]
Quick ratio	0.56	0.53	0.33	0.41	0.53	[stockanalysis]
Asset turnover	0.46	0.49	0.49	0.56	0.60	[stockanalysis]
Fixed-asset turnover	1.4	1.5	1.2	1.2	1.3	[Fact, AR]

Q1 FY27 net debt/EBITDA: 1.9x annualised (CFO) vs 1.6x (slide) — inconsistent. Q1 FY27 interest cover run-rate ~3.1x (63.5/20.5) [Est.]. Finance cost = ~51% of FY26 EBITDA. Rates (AR note 21): INR WC 9.00–12.00%; USD loans 6.32–8.42%; unsecured 14.05–18.00% (nil at Mar-26); bank term loans MCLR + 1.0–1.65% (9.3–10.45%); others lender reference + spread (~11%). All floating: 1% move = ₹6.6 Cr PBT.

Debt structure, lenders and maturity

₹ Cr	Mar-24	Mar-25	Mar-26	Jun-26
Term loans	239.1	203.2	163.8	149.4
Working-capital loans (CC/PCFC/WCDL)	760.3 (incl. unsecured)	572.9 (incl. 37.5 unsecured)	500.8	382.9
Gross debt	999.4	776.1	664.5	532.3
WC loans as % of gross debt	76%	74%	75%	72%

Term loan (Mar-26)	Lender [Est.]	Pricing	Repayment	Outstanding ₹ Cr
Loan 3	Bank	6M MCLR + 1.20%	₹1.72 Cr EMI, Nov-22 to Dec-26	14.4
Loan 4	Bank	6M MCLR + 1.50%	₹1.17 Cr/month, Feb-23 to Jan-28	27.4
Loan 5	NBFC, likely Aditya Birla Finance	Lender LTRR ± spread	₹0.99 Cr EMI, Jan-22 to Apr-27	10.6
Loan 6	NBFC, likely ABFL	Lender LTRR ± spread	₹1.66 Cr EMI, Mar-25 to Jan-30	61.8
Loan 7 (new FY26; secured on Vizag assets; sits in subsidiary — Synthix)	ABFL	LTRR + spread (~11%)	₹3.13 Cr/month, Apr-27 to Jan-31	49.5
Loans 1, 2	Banks	MCLR + spread	Fully repaid Sep-25, Mar-26	0

Loan 7 appears only in consolidated borrowings (standalone debt 615.0 vs consolidated 664.5; difference exactly 49.5). Security: first pari-passu charge on fixed assets (excl. leasehold land at Cuddalore, Vizag, Ambernath); second charge on current assets. Covenant breach: FY25 financial covenants breached on ₹203.16 Cr term loans "mainly due to temporary softness in demand for some of the key products"; waivers sought (AR FY26 note 21). FY26 compliance not stated [Open].

Maturity (Mar-26, undiscounted)	₹ Cr
Within 1 year (mostly WC rollovers + 53.3 current maturities)	554.5
1–2 years	39.4
2–3 years	29.3
3–4 years	29.9
4–5 years	12.5
Beyond 5 years	nil
Scheduled repayments Jul-26 to Mar-27	38.9

CRISIL-rated limits (Jun-26)	₹ Cr	Lenders
Cash credit	474.5	HDFC 170; IDFC First 146.5; YES 65; RBL 50; ICICI 43
Letters of credit	185.5	RBL 100; ICICI 57; HDFC 25; IDFC First 3.5
Long-term loans (to 31-Mar-2030)	131.2	Aditya Birla Finance 78.7; YES 31.2; HDFC 21.3
Total	791.2	—

Rated-limit history: Oct-21 ₹1,320 Cr (term loans ₹433 Cr: HDFC 110, IDFC First 50, ICICI 170, IndusInd 103, maturing Mar-27; unencumbered cash ~₹195 Cr at Mar-21) → Feb-24 ₹1,484 Cr (CC ₹619 Cr across six banks incl. IndusInd; TL ₹361 Cr across seven lenders, Mar-25 to Dec-27; HDFC BG ₹60 Cr) → Apr-25 ₹1,484 Cr (incl. ₹563 Cr proposed WC) → Apr-26 cut to ₹791.2 Cr after withdrawing ₹692.8 Cr proposed limits. CRISIL expects debt obligations ₹30–60 Cr/yr vs accruals ₹120–150 Cr; liquidity "Adequate". Promoter/related funding: unsecured loans nil at Mar-26 (₹37.5 Cr Mar-25); Chayadeep Properties lent and was repaid ₹9.5 Cr in FY26; Tenshi loans ₹18 Cr repaid in FY25; CRISIL expects need-based promoter support.

Credit rating history (CRISIL only — no ICRA/CARE/India Ratings found; AR discloses only CRISIL)

Date	Long term	Short term	Action / driver
7-Oct-2021	A-/Positive (from Stable)	A2+	Net worth up on TPG capital infusion; strong FY21; proposed Aurore merger
17-Feb-2022	Watch Developing	—	Q3 FY22 sales-return shock
Mar-2023	BBB+/Negative	A2	Downgraded between Oct-21 and Mar-23 (exact date [Open]) after FY22–23 losses
9-Nov-2023	BBB+ on Watch Negative	A2 on Watch Neg.	Puducherry fire (~43% of capacity)
22-Feb-2024	BBB/Negative	A3+	Weak 9M FY24 (PAT –311.5 on revenue 1,026); negative accruals vs ₹117 Cr term debt due
7-Jun-2024	BBB/Stable	A3+	Outlook to Stable — rights issue [Est.]
16-Apr-2025	BBB/Stable (reaffirmed)	A3+	Gearing ~1x at Dec-24; 9M FY25 margin 15.95%; ₹120 Cr equity infused in FY25
30-Apr-2026	BBB/Stable (reaffirmed)	A3+	Limits cut 1,484 → 791.2; debt ~630 at Dec-25
22-Jun-2026	BBB+/Stable (upgrade)	A2 (upgrade)	Debt ~₹500–530 Cr at May-26 vs ₹999 Cr Mar-24; ~₹445 Cr equity raised; interest cover ~2x; adj. net worth ~₹868 Cr; FY26 operating margin 13.64% vs 16.23% FY25 (news coverage dated 24-Jun-2026)

Current sensitivities (Jun-2026). Upgrade: revenue growth with sustained margins; interest cover >3x; better liquidity. Downgrade: sharp revenue fall or operating margin below 9%; large debt-funded capex; working-capital stretch. Key monitorable: ibuprofen losses. Still two notches below Oct-2021's A-.

Equity dilution and share-count history

Date / period	Event	Shares (Cr)	Paid-up (₹ Cr)
FY18	Demerger of Strides Shasun API business (effective Oct-2017); listed 2018	~2.5	25
Feb-2019	TPG Growth invests US$30 mn (~₹200 Cr) by preferential allotment [Fact, governance]	~2.6	26
~Sep-2020	Preferential convertible warrants: EGM notice up to 20 lakh to Arun Kumar Pillai + 10 lakh to Pronomz at ₹400, 18-month conversion (₹120 Cr). A blog cites ~₹384 Cr of warrants to promoters and TPG — does not reconcile [Open]	~2.7	27
FY21	TPG capital infusion cited by CRISIL; equity bridge 1,086 → 1,589 implies ~₹298 Cr raised and ~0.9 Cr new shares [Est.]; net worth ₹633 Cr (FY20) → ₹1,148 Cr (FY21) per governance source — basis differs	3.60	36
FY22–FY24	No meaningful change	3.60	36
19-Jun-2024	Rights 1:3 at ₹375 (FV 10 + 365 premium): 1,19,98,755 shares, ₹449.95 Cr, partly paid. Letter of offer 9-May-2024; record date 15-May-2024. Application ₹131.25/share = ₹157.48 Cr	4.80	40.25
Apr/May-2025	First call ₹131.25/share = ₹155.31 Cr; reminders 1-Jul-2025, 4-Feb-2026. ₹2.17 Cr unpaid — 1,65,807 shares still ₹3.5 paid at Mar-26 (market.md cites first-call money collected on 71,402 laggard shares in Mar-2026)	4.80	44.51
FY26	ESOP 2018 exercises: 1,18,540 shares (₹3.2 Cr)	4.817	44.51
Apr–May 2026	Final call ₹112.50/share = ₹134.99 Cr; notice 6-Apr; record date 2-Apr; window 23-Apr to 7-May. ₹129.94 Cr received on 1,15,50,478 shares, converted fully paid 15-May-2026; further 5,999 (Jul) and ~2.76–2.80 lakh (Aug/Sep)	~4.82	~48.2
Jun-2026	ESOP allotment 5.34 lakh shares (promoter dips 42.00% → 41.93%) [Figures conflict: exceeds the ~4.40 lakh options reported outstanding — verify against the allotment filing]	~4.82–4.86	—
9-Oct-2026	Rights Issue Committee approves final reminder-cum-forfeiture notice	—	—

Share count (Cr shares, fully-paid equivalent)

+33.4% from the 2024 rights issue; weighted paid-up share count +4.4% FY25, +10.4% FY26, +13.5% TTM (stockanalysis)

Rights collection and use of proceeds

Total collected ~₹448 Cr [Est.: 157.5 + 155.3 + ~135]; CRISIL "~₹445 Cr across three tranches"; narrative cites ₹442.7 Cr received by 30-Jun-2026; ₹309.79 Cr received to 31-Mar-2026.
Equity bridge: Jun-26 funds 1,406.8 – Mar-26 1,252.9 – Q1 PAT 16.3 ≈ ₹137.6 Cr inflow in Q1 FY27 [Est.].
~₹100 Cr of call money cut net debt in Q1 FY27 (~75% debt allocation).
Use: application money ₹118.6 Cr to debt; overall ₹233.61 Cr debt repayment + ₹74.97 Cr GCP; ₹8.32 Cr unutilised at Q1 FY27; monitoring-agency reports May-26 and Jul-26: no deviation.
Forfeiture exposure small: 1,65,807 first-call defaulters (0.34%; ~₹4–6 Cr) plus any final-call defaulters; at most ~0.17–0.18 mn shares (~1.5% of issue); narrative estimates ~₹7 Cr unpaid.

Who subscribed; ESOP overhang

Devicam Capital LLP: 64,24,262 partly-paid shares = 53.5% of the issue (AR note 19). Promoters took ~6.88–6.92 mn shares (~57.6%) vs ~30.5% entitlement [Est.].
Rights at ₹375 were above FY24-end price (~₹342) and below today's ₹650.
Largest fully-paid holders Mar-26: Pronomz 12.95%; Authum 5.02%; Spiracca 4.72% (from 10.29%) — percentages on fully-paid basis.
ESOP 2018: 64,810 options outstanding (WAEP ₹363). ESOP 2024 (pool 9,60,000): 3,75,000 outstanding at ₹375, incl. 25,000 granted FY26 to WTD Mohanraj Sanjeevi. Total ~4.40 lakh = ~0.9% of shares; reserved pool 11.9 lakh (2.5%).
No warrants, QIP or convertibles outstanding [Est.]. Possible future event: Synthix mirror-listing demerger (on hold); 2021 Aurore merger withdrawn Q4 FY22.

Key balance-sheet risks

Impairment of ibuprofen/Vizag assets at Q2 FY27 (₹700 Cr capital; Vizag CWIP ₹182.5 Cr; ~₹250 Cr Vizag net block).
Liquidity: net current liabilities; 93–95% limit utilisation; ₹554.5 Cr due within one year (rollovers).
Strides receivable ₹160.45 Cr (~37% of receivables) — collection risk sits with a related party.
Covenant compliance after the FY25 breach on ₹203 Cr; FY26 status undisclosed.
Goodwill ₹364.9 Cr (~26% of equity) — tested at 21.35% discount rate; tax authorities disallow its depreciation.
Tax disputes up to ~₹405 Cr in CARO (see Tab 7); ₹342 Cr loss restriction for AY2024-25.

Management, Promoters & Governance

Sources: FY26 AR (Board's Report, CG Report, AOC-1, AOC-2, MR-3, Deloitte audit reports and CARO, Notes 37/39), Q1 FY27 transcript, Trendlyne/Screener SHP transcriptions, NSE/BSE deal logs, MCA via aggregators, CRISIL. Some AR tables were extracted with misaligned columns — interpretive readings flagged.

Top governance flag: Strides Pharma Science (promoter flagship)

FY26 API sales to Strides ₹328.97 Cr (~24% of revenue, +53% YoY); receivable ₹160.45 Cr (from ₹62.83 Cr) ≈ 178 days of Strides sales vs ~97–98 days for all other customers [Est.: 160.45/328.97×365; (438.87–160.45)/(1,374.87–328.97)×365]; Strides ≈ 37% of trade receivables. Shareholder-approved cap ₹400 Cr (AGM 25-Sep-2025) → ₹480 Cr (9th AGM, 18-Sep-2026; 99.87% for, promoters excluded). Independent Director Dr Kausalya Santhanam sits on Solara's audit committee and on the Strides board. In FY26 promoters paid ~₹90 Cr of first-call money while the Strides receivable rose ~₹98 Cr → net promoter-group cash to Solara roughly nil [Est.; juxtaposition, not a finding of intent].

Governance verdict

Dimension	Assessment	Key evidence
Promoter commitment	Mixed	Holding 30.5% (Dec-23) → 41.9% (Jun-26). Took ~57.6% of the ₹450 Cr rights vs 30.5% entitlement (~6.88 mn shares via Devicam, Agraganya); bought 20 lakh shares (~₹99 Cr) in Jun-25 block. Offset by group working-capital take-out via Strides receivable
Promoter leverage	Red flag	37.1% of promoter shares pledged (Jun-26) from 26.0% (Dec-25); Devicam has ₹28 Cr of charges to a debenture trustee; ~2.4 mn shares moved from 95%-pledged vehicles to Spiracca in Q3 FY24 (pledge workout?)
Related parties	Red flag, rising	Strides 24% of revenue / ~178 days; cap to ₹480 Cr; Tenshi and Chayadeep lend to Solara; CEO ex-Tenshi CEO; Strides ID on audit committee
Management stability	Historic red; stabilising	6 MD/CEO and 6 CFO tenures (5 transitions each) 2020–25; chairman Aditya Puri + two IDs left Jul–Aug 2023; stable since Feb-2025
Board independence	Amber	4 of 8 independent; independent chair; all-ID audit committee with full attendance. Two IDs ~8.5 years; one re-designated independent within 15 days
Audit	Clean opinion recurring exceptions	Deloitte FY26 unmodified, no EoM, no material uncertainty. Audit-trail gap (FY25, FY26); ₹191.26 Cr title deeds untransferred; ₹8.89 Cr RP advances without terms; whistle-blower complaints in FY26 (undisclosed)
Subsidiary opacity	Amber	Synthix: pre-operational, ₹0.01 Cr equity, ~₹49.5 Cr debt under ₹50 Cr Solara guarantee, parked in deposits. Chemsynth 49%, non-operational 8 years
Tax and legal	Amber	CARO: disputed IT ₹105.08 Cr at ITAT + ₹300.36 Cr at CIT(A); ₹161.92 Cr AY2019-20 demand rectified to nil 28-Aug-2026; ₹342.08 Cr loss restriction AY2024-25; no SEBI/exchange penalties in 3 years
Capital allocation	Red flag	~₹700 Cr deployed in ibuprofen at –16% to –18% EBITDA margin FY26; "slightly far-fetched" to recover; write-down/loss on exit likely

Promoter group — who controls Solara

Arun Kumar Pillai (DIN 00084845)

Founded Strides in 1990; Non-Executive Chairman of Strides; NED & Chairperson of OneSource Specialty Pharma (ex-Stelis Biopharma).
On Solara board since 4-Aug-2021 as NED; holds 16,68,463 shares (3.46%), 80.5% pledged Jun-26 (was 100% Jun-24; swings 0–94% across quarters).
Attended 4/5 board meetings FY26; no sitting fee.
Chairs the Management Committee (with MD & CEO and CFO) since 17-Dec-2025 — operational control without an executive title.
Re-appointed NED at 9th AGM 18-Sep-2026 (99.96% for). Education: not in inputs (AGM notice not supplied).
Dominated earnings calls until Feb-2026; absent from Q1 FY27 call.

Identity and corrections

Information Memorandum (2018) names Arun Kumar, K R Ravishankar and Pronomz Ventures LLP as promoters; same group promotes Strides.
K R Ravishankar: Strides co-founder; 2.75%, unpledged.
AR Note 39 promoter-controlled/influenced enterprises: Strides Pharma Science; Tenshi Pharmaceuticals; Aurore Life Sciences and Aurore Pharmaceuticals (confirms the aborted 2021–22 merger counterparty was promoter-linked); Instapill (ex-Tenshi Kaizen); OneSource Specialty Pharma; Steriscience Specialties; Chayadeep Properties.
TPG is a public shareholder (Foreign Company), not a promoter. Invested US$30 mn Feb-2019; nominee Ankur Thadani resigned 22-Jul-2024; stake 11.47% → 1.49%.
Deepak Vaidya appears in no promoter, named-holder or related-party list.

Devicam Capital LLP — largest promoter vehicle (15.47%), promoter group in SHP. LLPIN AAB-9882, incorporated 7-Jan-2014, Bengaluru. Designated partners R. J. Sriraman and Chandrappa Seetharamaiah; partners Akila Chandrashekar Raju and Shridhara Kela. Shares partners with 44 entities incl. Pronomz Ventures/Holdings, Chayadeep Ventures, Agnus Capital, SRJR Enterprise, Karuna Business Solutions, the Tenshi companies (Ventures, Pharmaceuticals, KSM, Healthcare, Life Sciences), Hydra Active Pharma Sciences, Steriscience, Sequent Specialty Chemicals, Stellence Life Sciences. Beneficial ownership undisclosed. Two open charges ₹18.20 Cr + ₹9.80 Cr = ₹28 Cr in favour of Catalyst Trusteeship, created 17-Dec-2024 → structured, leveraged promoter funding [Est.]. Sold 20.1 lakh shares to Spiracca at ₹341.36 on 26-Dec-2023.

Promoter entities, Jun-2026 (41.93%; 20,218,140 shares; 7,507,436 pledged = 37.11%)

Entity	% of equity	Shares	Pledged (% of own)	Notes
Devicam Capital LLP	15.47	7,463,560	0.00	Stake built through 2024 rights issue (~1.04 mn → 7.46 mn)
Pronomz Ventures LLP	9.71	4,685,529	48.58	Core holding LLP; also ~19.6% of Strides; pledge 18–49% across quarters
SRJR Enterprise LLP	3.52	1,700,100	88.23	1.5 mn pledged since at least Jun-24
Arun Kumar Pillai	3.46	1,668,463	80.52	Was 100% pledged Jun-24
K R Ravishankar	2.75	1,325,260	0.00	—
Chayadeep Ventures LLP	2.10	1,012,400	100.00	Released to 0% by Mar-26, re-pledged by Jun-26
Agnus Capital LLP	1.76	849,635	100.00	77–100% across quarters
Chayadeep Properties Pvt Ltd	1.09	525,730	100.00	Also a lender to Solara
Agraganya Private Trust	1.08	523,384	0.00	Trustee: Barclay Wealth Trustees (India); ~61k → 523k in rights
Karuna Business Solutions LLP	0.14	69,526	0.00	—
Family individuals (9)	~0.84	~460k	0	Deepa, Aditya, Tarini Arun Kumar; Padmakumar K. Pillai; Sajitha, Hemalatha, Vineetha Pillai; K R Lakshmi; Rajitha Gopalakrishnan
Total promoter group	41.93	20,218,140	37.11	7,507,436 shares pledged; pledgee names not obtained (Reg 31 not accessed)

Promoter track record

Strides: sold Agila Specialities to Mylan for ~US$1.65 bn (2013–14) [Unverified]; acquired Shasun ~US$200 mn [Unverified]; carved out API into Solara and sold Strides Chemicals to Solara for ₹131 Cr cash (2018) [Fact]; spun out OneSource [Fact].
SeQuent: human-API business went to Solara; Carlyle agreed in 2020 to buy 74% of SeQuent [Unverified].
Solara dividends: 50% (FY19), 20% (FY20), interim 40% + final 30% (FY21); nothing since. Per-share by ex-date: ₹5.00 (Aug-19), ₹2.00 (Jul-20), ₹4.00 (Nov-20), ₹3.00 (Aug-21).
Pledge history: Strides promoter pledge cut 41.96% → 25.98% in 2021; Solara pledge ~51% Jun-2020 → 8.25% after 18-May-2021 release → rebuilt to 26–49% since Sep-2023 (peak 49.06% Dec-23).
2020 ValuePickr concerns: ICDs to SeQuent; deal-making style; pledge ~51%.

Capital raising and promoter participation

Date	Event	Promoter participation
Feb-2019	TPG Growth invests US$30 mn (~₹200 Cr) by preferential allotment	n.a.
~Sep-2020	Preferential warrants: up to 20 lakh to Arun Kumar Pillai, 10 lakh to Pronomz at ₹400, 18-month conversion (₹120 Cr); blog's ₹384 Cr unverified; allotment/conversion dates not obtained	Principal allottees
10-May-2021	TPG (1.34 mn) and Pronomz sell in block at ₹1,552–1,557 to ABSL MF schemes, First State/Scottish Oriental, CDPQ, Kotak Life, Shivanand Mankekar HUF (8.7 lakh)	Pronomz seller
19-Jun-2024	Rights 1:3 at ₹375, ₹449.95 Cr	Devicam +6.42 mn; Agraganya +0.46 mn; others renounced; ~6.88–6.92 mn (~57.6%) vs entitlement ~3.66 mn (30.5%); ~₹259 Cr commitment; stake 30.49% → 37.27%
Apr-2025 (FY26)	First call ₹131.25: ₹155.31 Cr received	~₹90 Cr [Est.]
Apr–May 2026	Final call ₹112.50: ₹129.94 Cr received on 1,15,50,478 shares (fully paid 15-May-2026)	~₹77 Cr [Est.]; pledged shares rose 6.39 mn → 7.51 mn Mar–Jun-26, consistent with pledging to fund the call [Est.]
9-Oct-2026	Final reminder-cum-forfeiture notice. One FY26 complaint: call money payable only by DD/cheque	Exposure bounded at ~0.18 mn shares
ESOPs	ESOP 2018 (12,28,778): FY26 1,18,540 exercised, 42,690 lapsed, 64,810 outstanding. ESOP 2024 (9,60,000): 3,50,000 granted FY25 (approved 21-Feb-2025); 25,000 to WTD Sanjeevi FY26 at ₹375. MD & CEO perquisite ₹2.08 Cr	—

Shareholding trend

Quarter	Promoter %	FII %	DII %	of which MF	Public %	Pledge (% of promoter)	Holders	Key movement
Sep-2023	37.19	17.86	1.79	—	43.16	43.47	—	Devicam 8.48% (95% pledged); SRJR 99.99% pledged
Dec-2023	30.49	16.62	1.75	—	51.14	49.06	—	~2.41 mn shares leave promoter vehicles (Devicam –5.59 pp, Agnus Holdings –0.76, Karuna Ventures –0.26, Karuna Business –0.10); Spiracca 3.74% → 10.44%
Mar-2024	30.49	15.80	2.97	—	50.73	47.99	—	—
Jun-2024	37.27	14.00	2.83	—	45.89	38.28	—	Rights allotment; Devicam 15.55%; TPG diluted to 8.60%
Sep-2024	37.27	14.25	3.37	—	45.11	38.00	71,882	—
Dec-2024	37.23	14.67	3.19	—	44.92	40.74	83,148	Devicam creates ₹28 Cr of charges
Mar-2025	37.94	14.63	2.61	—	44.82	34.64	75,791	Pronomz +3.42 lakh in market; TPG 8.60% → 2.61%; Authum enters 3.80%
Jun-2025	42.01	14.25	2.62	1.18	41.10	38.95	74,334	Pronomz buys 20 lakh from Spiracca (16-Jun-25, ~₹495)
Sep-2025	42.01	13.58	2.69	1.18	41.71	35.32	72,479	MUFG/First Sentier indirect 8.09% → 4.37%
Dec-2025	42.00	11.98	3.64	1.18	42.37	26.04	71,890	Pledge releases (Pronomz, Chayadeep Ventures); CDPQ off >1% list
Mar-2026	42.00	11.59	3.75	1.18	42.66	31.57	70,400	AR: promoters 2,02,31,281 shares; FPI 11.59%; bodies corporate 8.32%; 77,051 holders (AR basis)
Jun-2026	41.93	11.52	3.74	0.95	42.79	37.11	70,490	Chayadeep Ventures re-pledged 100%; TPG 2.61% → 1.49%; promoters pledged +5.54% (Trendlyne)

Sep-2026 SHP not yet filed (due ~21-Oct-2026). Mar-26: 55 holders with >1 lakh shares hold 68.31%; 99.95% demat incl. all promoter shares. Non-MF DII ~1.44% (Jun-25) → ~2.79% (Jun-26) [Est.]; Choice India's 2.79% "DII" matches non-MF DII. Total institutions ~16.9% → 15.3%.

Promoter holding, promoter pledge and FII holding (%), Sep-23 to Jun-26

Promoter holding % of equityPledge % of promoter holdingFII %

Interpretation [Est.]. (1) Promoter ownership is debt-funded: stake +11.4 pp since Dec-23, but ~37% pledged. (2) The Spiracca round-trip: the Dec-23 transfer of ~2.4 mn shares from heavily pledged vehicles to Spiracca came ~5 months after Kartheek Chintalapati Raju (iLabs, Hyderabad; DIN 02921819) joined the board (5-Jul-2023), in the fire/CRISIL-watch quarter. Spiracca built ~10.5% at ~₹350 average; Pronomz bought 2.0 mn back at ₹495 in Jun-25; Raju resigned 5-Nov-2025. Spiracca behaves like a financing or pledge-workout counterparty; its ownership and any iLabs link are unverified. A ValuePickr poster (Jan-2024) alleged links between Aurore, Hydra Active and Spiracca and to a former Strides director [Unverified]. (3) The original PE sponsor has nearly exited (TPG 11.5% → 1.5%; FII 17.9% → 11.5%). (4) No pledge invocation disclosure found; pledgees not obtained.

Notable non-promoter holders (Jun-2026)

Investor	% (Jun-26)	Change vs Jun-25	Known view / thesis
Authum Investment & Infrastructure	3.78	~0 (3.79)	Bought 20 lakh from TPG at ₹495 (28-Jun-2024); held through the turnaround; Dangi family, special-situations investor [Est.]
Spiracca Ventures LLP	3.54	Down (sold 4.16% to promoter Jun-25; 37.09 → 17.09 lakh)	Built ~10.5% at ~₹350 in 2023; promoter-alignment debated [Unverified]
Scottish Oriental Smaller Companies Trust (First Sentier/FSSA)	2.33	–0.05	Holder since Apr-2021 (~₹1,462); passive trimming
HBM Healthcare Investments (Cayman)	2.17	0	Bought 31-Oct-2018 at ₹302.90 from Satpal Khattar; patient specialist holder
FSSA Indian Subcontinent Fund	1.83	–0.04	Bulk sale 2,24,730 at ₹538.11 on 20-Jun-2025
TPG Growth IV SF Pte Ltd	1.49	Down ≥1.1 pp	Exiting. US$30 mn in 2019; sold 2021 (₹1,557), 2024 (₹495), 2026 (₹573). Post-10-Jul residual 0.87–1.98% unresolved until Sep-26 SHP
Route One Offshore Master Fund, L.P.	1.44	–0.01	Static foreign fund
Raptakos, Brett & Co.	1.38	0	Static corporate holder
Mauryan India Fund	1.35	New (1.11% Mar-26; 534,932 → 650,000 shares)	Only clearly visible fresh accumulator; AIF/FPI category unconfirmed
Turnaround Opportunities Fund	1.01	0 (485,227 shares)	Static; AIF/FPI category unconfirmed
Ritesh Kantilal Oswal	<1 (1.02–1.04 Sep-25 to Mar-26)	Possibly trimmed	HNI
CDPQ (via First Sentier)	<1 (was 1.63–1.73)	Exit/trim from Dec-25	Bought May-2021 at ₹1,552
Aditya Birla Sun Life MF (Manufacturing Equity Fund)	≤0.95 (total MF)	–0.23 pp (1.18% → 0.95%; ~107k+ shares trimmed)	Bought in May-2021 TPG block at ₹1,552; 3 MF schemes total 459,011 shares

Bulk / block deals and insider / SAST disclosures

Date	Party	Side / type	Qty	Price ₹	Read-through
20-Aug-2026	Junomoneta Finsol Pvt Ltd	Buy 283,420 / Sell 282,513 (NSE bulk)	~2.8 lakh	626.19 / 626.82	Intraday churn on +16% day
10-Jul-2026	TPG Growth IV SF	Sell (NSE bulk)	300,000 (0.62%)	573.20	Continuing PE exit, ~₹17.2 Cr (Univest dates 13-Jul)
Apr–Jun 2026	TPG Growth IV SF	Sale (sub-threshold)	1,255,149 → 720,000	—	If Trendlyne 1.49% correct
1-Sep-2025	MUFG (via First Sentier)	Indirect reduction	8.09% → 4.37%	—	—
20-Jun-2025	FSSA Indian Subcontinent Fund	Sell (NSE bulk)	224,730	538.11	Trimming into strength
16-Jun-2025	Pronomz Ventures LLP (promoter) from Spiracca	Buy (NSE bulk + block); disclosure 19-Jun-25	2,000,000 (4.16%)	~495 (ValueResearch 508.65)	Promoter consolidation, ~₹99 Cr
Jun-24 to Mar-25	Pronomz	Open-market buys (incl. ~₹4 Cr Feb-25)	+3.42 lakh	—	—
Jun-24 to Mar-25	TPG Growth IV SF	Sale	4,130,321 → 1,255,149	—	—
24-Feb-2025	Aarti Bhatia from Bhatia Suresh	BSE bulk + block	204,527	490.00	Apparent family transfer
28-Jun-2024	Authum from TPG Growth IV	NSE bulk + block; TPG SAST filed	2,000,000	495.00	Authum enters
18–22-Apr-2024	Graviton, QE Securities, HRTI, Microcurves	Matched buy/sell	2–4 lakh each	476–589	HFT/arbitrage around rights
26-Dec-2023	Spiracca from Devicam (promoter group)	NSE bulk	2,013,747	341.36	Promoter group transfers stock
Jun–Dec 2023	Spiracca from Karuna Business Solutions, Agnus Holdings	Buy	~7.4 / ~6 / ~2.7–3.1 lakh	336–374	~10.5% at ~₹350 average (ValuePickr)
2022	Devicam	Inter-se promoter transfer (Reg 10(1)(a)(ii))	n.a.	—	—
20-Dec-2021	IMCO Emerging Markets from Ontario Pension Board	Block	183,474	1,077.95	Pension-to-pension
10-May-2021	TPG + Pronomz sell to ABSL MF, First State/Scottish Oriental, CDPQ, Kotak Life, Mankekar HUF	Block / bulk	TPG 1.34 mn	1,552–1,557	Peak-cycle entry; buyers ~58% below cost
19–20-Apr-2021	Scottish Oriental, First State buy; BNP Paribas Arbitrage, Jitesh Devendra sell	Bulk / block	1.99 / 2.3 lakh	~1,462	—
31-Oct-2018	HBM Healthcare from Satpal Khattar	Bulk	530,894	302.90	HBM entry

Director holdings Mar-26: Arun Kumar Pillai 16,68,463; Sandeep Rao 5,000; Ramakrishnan ~5,000 and Santhanam ~1,000 (misaligned table). Reg 26(6): no third-party compensation agreements. Exchange volume queries answered "no undisclosed information" on 26-Sep-2025 and 4-Dec-2025 (the latter one day before the WTD/COO resignation). No promoter sale in the last four quarters. Unverified rumour: "PE firms consider majority stake in Solara" — untraceable headline.

Management — KMP history, pay and churn

Period	MD / CEO	Note
2017/18 – mid-2020	Jitesh Devendra	Change approved 3-Aug-2020
2020 – Q3 FY22	Bharat Sesha	[Unverified]
Q3 FY22 – ~May-22	Rajender Rao	Resigned ~1-May-2022; stock –15%
2022 – Jul-2023	Jitesh Devendra (re-appointed)	[Unverified]
5-Jul-2023 – 21-Feb-2025	Poorvank Purohit	Special resolution 6th AGM; resigned "personal reasons"
21-Feb-2025 –	Sandeep S. Rao (DIN 10838251)	3-yr term (postal ballot 22-Apr-2025). Ex-CEO Tenshi Pharma (promoter group) from Jul-2024; VP & Head BD Emerging Markets, Viatris; 16 yrs Biocon (SVP, Head of Insulins)

Period	CFO	Note
2017/18 – 2020	S. Hariharan (ED & CFO)	[Fact]
2020 – 2022	Subhash Anand	[Unverified]
2022 – 31-Jul-2023	S. Hariharan	Resigned
26-Oct-2023 – early 2024	P V Raghavendra Rao	[Fact]
8-Mar-2024 – 21-Feb-2025	Arun Kumar Baskaran	[Fact]
21-Feb-2025 –	Sarat Kumar Asuri	18+ yrs; ex-Strides, BioCina, Torrent Power, Shell; also Chief IR Officer from 5-Nov-2025

Other KMP / senior management	Role	Detail
Mohanraj Sanjeevi (DIN 08420411)	WTD & CHRO, 1-Jan-2026 to 31-Dec-2028	Postal ballot (closed 6-Mar-2026): 2,60,32,102 for, 7,752 against (99.97%). Fixed CTC ₹85 lakh (9.90x median; ~₹1 Cr/yr package per announcement); 25,000 ESOPs. Ex-Mylan, Manipal, Tata Advanced Materials
Mohan Muthunarayanan (DIN 03610282)	ED/WTD & COO from 14-Feb-2024	Resigned 31-Dec-2025 (announced 5-Dec-2025) to be COO of Synthix; FY26 pay ₹1.27 Cr; fixed CTC ₹1.45 Cr (17.08x median); 7% raise
Pooja Jaya Kumar (A57415)	Company Secretary	Since 15-May-2025 (S. Murali Krishna retired)
Vishal Mathur	Chief Commercial / Business Officer (from 21-Feb-2025)	Ex-Cohance, Emcure API, Glenmark Life Sciences
Dr Hero Velladurai	Chief Scientific Officer	—
V. Sundara Moorthy	Chief Quality Officer	—
Neeta Dani	VP Marketing (15-May-2025)	Replaced Ganesh Mukundan Sasikala (retired 15-May-2025)
Ajit Manocha	Chief Information Officer (appointed 23-Jul-2026; joined 17-Aug-2026)	Ex-Syngene per a call participant; management declined to comment on an "innovator pivot"
Abhishek Singhal	Investor Relations	Q1 FY27 call

FY26 remuneration	₹ Cr	Detail
Sandeep Rao (MD & CEO)	6.06	Salary 3.98 + ESOP perquisite 2.08; fixed CTC ₹3.25 Cr = 37.85x median (₹8.59 lakh); no increase; paid in a year with standalone loss ₹7.24 Cr
Mohan Muthunarayanan	1.27	Apr–Dec 2025
Mohanraj Sanjeevi	0.45	Jan–Mar 2026
Executive directors total	7.78	—
Non-executive sitting fees	0.45	₹1 lakh per board/audit meeting; Arun Kumar takes nil. CFO/CS pay not reliably parsed

Churn assessment [Est.]: very high CEO/CFO turnover in 2020–25. Since Feb-2025 the team is stable but drawn from the promoter ecosystem (CEO ex-Tenshi, CFO ex-Strides, NED Manish Gupta ex-SeQuent). ValuePickr posters suspected the Purohit-era team was pushed out. With the promoter chairing the Management Committee, effective control stays with the promoter.

Board of Directors (Oct-2026)

Name (DIN)	Role	Category	Since	Other boards	FY26 attend.
R. Ramakrishnan (Rajagopal) (00161542)	Chairman; chairs Audit Committee	Independent	11-Apr-2018	—	5/5
Dr Kausalya Santhanam (06999168)	ID; chairs CSR and SRC	Independent	11-Apr-2018	Strides Pharma Science: Independent Director	5/5
Prof. Rajendra Kumar Srivastava (07500741)	ID; chairs NRC	Independent	14-Nov-2023	Happiest Minds: ID	5/5
Rajiv Vijay Nabar (10383397)	ID; chairs Risk Management Committee	Independent (appointed non-independent 14-Nov-2023; re-designated ID 29-Nov-2023)	14-Nov-2023	TAC Infosec: ID	5/5
Arun Kumar Pillai (00084845)	Founder NED; chairs Management Committee	Promoter, non-executive	4-Aug-2021	Strides (Non-Exec Chairman); OneSource (NED & Chairperson)	4/5
Manish Gupta (06805265)	NED	Non-independent	22-Jul-2024	Jagsonpal Pharmaceuticals (MD); ex-CEO & MD SeQuent (8+ yrs)	5/5
Sandeep S. Rao (10838251)	MD & CEO	Executive	21-Feb-2025	—	5/5
Mohanraj Sanjeevi (08420411)	WTD & CHRO	Executive	1-Jan-2026	—	1/1

8 directors: 2 executive, 2 non-independent NEDs, 4 IDs (one woman); independent chair; no inter-director relationships. 5 board meetings FY26 (15-May, 25-Jul, 5-Nov, 17-Dec-2025; 6-Feb-2026); IDs met separately 6-Feb-2026. Audit: Ramakrishnan (chair), Srivastava, Nabar, Santhanam — all ID, 5 meetings, full attendance. NRC: Srivastava (chair), Ramakrishnan, Santhanam, Nabar (Kartheek Raju until Nov-25, 1 of 2) — 3 meetings. SRC: Santhanam (chair), Rao, Gupta. RMC: Nabar (chair), Santhanam, Ramakrishnan, Srivastava, Rao. Non-mandatory: Rights Issue Committee, Management Committee. PCS certifies no director debarred; CG certificate clean. Policies: RPT and materiality revised Feb-2026; RPT policy v4 Jun-2026; board-evaluation policy adopted and whistle-blower policy amended May-2026. Chairman's and Santhanam's second terms end ~Apr-2028.

Board exits since 2023	Director	Role	Stated reason
19-Jul-2023	Nirmal P. Bhogilal	ID	Pre-occupation
31-Jul-2023	S. Hariharan	ED & CFO	—
5-Aug-2023	Aditya Puri (ex-MD & CEO HDFC Bank)	Chairman & NED (since 2021)	Not stated in sources
5-Aug-2023	Vineeta Rai	ID	Not stated in sources
22-Jul-2024	Ankur Nand Thadani	TPG nominee	Coincides with TPG selldown
21-Feb-2025	Poorvank Purohit	MD & CEO	Personal reasons
5-Nov-2025	Kartheek Chintalapati Raju (iLabs)	NED (since 5-Jul-2023)	Preoccupation; "no other material reasons"
31-Dec-2025	Mohan Muthunarayanan	WTD & COO	Move to Synthix; "no other material reasons"

Red flag: the chairman and two IDs left within ~17 days in Jul–Aug 2023, right after the rights-issue approval and the new CEO's appointment (both 5-Jul-2023). Interlock: Santhanam (Strides ID) approves Strides RPTs on Solara's audit committee — permissible, but weakens independent oversight.

Related-party transactions (FY26, AR Note 39 and AOC-2)

Counterparty	Relationship	Nature	FY26 ₹ Cr	FY25 ₹ Cr
Strides Pharma Science Ltd	"Enterprise owned by common promoters"	Sale of goods (API), net of returns	328.97	214.97
Strides	as above	AOC-2 total material arm's-length contracts (API sales "for long-term API supplies", services, reimbursements, leasing of properties)	339.13	—
Strides	as above	Trade receivable at year-end	160.45	62.83
Strides	as above	Purchases (₹0.5 Cr), services, reimbursements, guarantee commission	small–~8.5/line	—
Tenshi Pharmaceuticals	Promoter-influenced	Interest on loans received by Solara	1.86	1.04
Tenshi Pharmaceuticals	as above	Corporate-guarantee-related line (direction unclear)	—	0.19
Chayadeep Properties	Promoter-influenced shareholder	Interest on loans received by Solara	0.28	1.31
Tenshi / Chayadeep	as above	Loans received and repaid	~9.5	~10.5–18
Aurore Life Sciences	Promoter-influenced	Sales, services, expense recovery; purchases ₹3.2 Cr	~0.3–3.2	—
OneSource / Instapill / Steriscience	Promoter-influenced	Services; security deposit; loan to Steriscience	small (OneSource <1)	—
Synthix Global Pharma Solutions	WOS	₹50 Cr corporate guarantee (granted FY26) — CARO: "not prejudicial"	50.00	—
Chemsynth Laboratories	Subsidiary (49%)	Loans 1.34 (gross, provided for) and 0.72	—	—
Unspecified related parties	—	Advances repayable on demand / no terms (100% of loans and advances)	8.89	8.89

Approvals: Strides material RPT approved by Audit Committee and Board 21-Feb-2025 and 15-May-2025; shareholders ₹400 Cr (AGM 25-Sep-2025) and ₹480 Cr (9th AGM 18-Sep-2026; heard.md's "Aug-2026" is incorrect). AOC-2 reports no contracts "not at arm's length". Historic: Strides Chemicals bought for ₹131 Cr (2018); Aurore all-stock merger (appointed date 1-Apr-2021; Aurore holders 27%) withdrawn Q4 FY22; FY24 ₹18 Cr loan and ₹50 Cr guarantee from Tenshi [Unverified, blog]. Growth decomposition: sales to Strides +₹114 Cr vs standalone contract revenue +₹89 Cr → ex-Strides ~–₹25 Cr (–2.5%) [Est.]. Strides' base/ibuprofen product mix undisclosed.

Subsidiaries, associates and acquisitions

Entity (CIN)	Holding	Since	FY26 (₹ Cr)	Status
Synthix Global Pharma Solutions Ltd (U21001MH2025PLC447046)	100%	29-Apr-2025	Equity 0.01; reserves –0.40; total assets ~49.4; investments 3.00; turnover nil; loss 0.40	Yet to commence operations; auditor Deloitte; COO = ex-WTD Muthunarayanan
Chemsynth Laboratories Pvt Ltd (U24297TG2009PTC064991)	49%; subsidiary via board control (Sec 2(87)(i)); CRISIL says 100%	1-Sep-2018	Capital 6.86; reserves –2.48; turnover nil; NCI ₹2.67 Cr	Non-operational ~8 years; auditor R. Sundararaman & Co.; 51% holder unnamed; consideration not found
Shasun USA Inc	100%	1-Oct-2017	Turnover nil; reserves –4.54	Dissolved 16-Sep-2025
Solara LTDA, Brazil	100%	—	Nil	Deregistered 30-Jul-2025 (closure approved Feb-2025)
Sequent Penems Pvt Ltd	100%	until 25-Apr-2024	—	Ceased to be a subsidiary
Associates / JVs	None	—	—	—

What Synthix holds [Est., consolidated minus standalone, Mar-26]: non-current borrowings 110.45 vs 60.94 → ~₹49.5 Cr debt in Synthix (ABFL loan 7, secured on Vizag assets); other bank balances 45.86 vs 0.16 → ~₹45.7 Cr deposits; current investments ₹3.00 Cr. A pre-operational shell has raised ~₹49.5 Cr backed by Solara's ₹50 Cr guarantee and parked it in deposits — negative carry and opaque intent; purpose (Vizag CDMO, polymers/CRAMS) put on hold Feb-2026. No material subsidiary; consolidated ≈ standalone (revenue 1,375.14 vs 1,374.87; PAT –7.41 vs –7.24). Acquisitions: Strides Chemicals (2018, ₹131 Cr, absorbed); Chemsynth (2018). "Hydra" = promoter-group Hydra Active Pharma Sciences Pvt Ltd, no Solara transaction found; "Aquatica" not found.

Auditor

Item	Detail
Statutory auditor	Deloitte Haskins & Sells LLP (FRN 117366W/W-100018); partner Sandeep Kukreja (M.No. 220411), Bengaluru
Tenure	Since inception (FY18); reappointed at 6th AGM (15-Sep-2023) for 4 years to the 10th AGM (FY27); 10-year rotation cap ~FY28
Fees FY26	Solara ₹83.20 lakh; Synthix ₹0.32 lakh (Deloitte); Chemsynth ₹0.52 lakh (R. Sundararaman); total ₹84.04 lakh
Changes	No resignation, no change of auditor (CARO xviii)
FY26 opinion (15-May-2026)	Unmodified (standalone and consolidated); no emphasis of matter; no material-uncertainty paragraph; CARO (xix) no material uncertainty on meeting liabilities; IFC opinion unmodified; no fraud, no ADT-4; whistle-blower complaints received in year considered (FY25: none; number undisclosed); Sec 197 complied; reliance on other auditors for 2 subsidiaries (total assets ₹6.75 Cr)
Key audit matters (FY25, FY26)	(1) Revenue cut-off near year-end; (2) goodwill impairment ₹364.90 Cr (Human API CGU), tested with valuation specialists
Exceptions (FY26)	(a) Audit trail not enabled for certain critical tables in one accounting software (Note 48) — repeated from FY25; (b) title deeds ₹191.26 Cr gross (₹151.06 Cr carrying) in transferor names; (c) ₹8.89 Cr RP advances with no terms; (d) ₹50 Cr subsidiary guarantee "not prejudicial"
Other	FY24 cash loss ₹184.96 Cr; none FY25/FY26. CSR not mandatory (3-yr avg profit –₹178.03 Cr); ₹0.76 Cr spent voluntarily
Interim reviews	Q2/Q3 FY26 results carried going-concern-basis notes (negative NCA ₹72.69 Cr / ₹92.44 Cr); Q1 FY27 limited review unmodified
Secretarial auditor	Parimala Natarajan (FCS 5597; CoP 5239), FY26–FY30; MR-3: no observations
Internal auditor	PwC (FY25) → Grant Thornton Bharat LLP (FY26)
Cost auditor	K. Suryanarayanan, FY26–27, ₹4.75 lakh

Litigation, tax and regulatory

Assessment year	Issue	Status
AY2018-19	Depreciation on goodwill and product portfolio disallowed	Upheld 18-Apr-2024; ITAT appeal 6-May-2024
AY2019-20	Same + Sec 35(2AB) R&D deduction disallowed; order 12-Feb-2026 (17-Mar-2026, ACIT Thane per news); demand ₹161.92 Cr	CIT(A) appeal 28-Mar-2026; rectified to nil 28-Aug-2026 ("incorrectly computed"; order received 8-Aug-2026 per news)
AY2020-21	35(2AB), goodwill/portfolio depreciation, Sec 41	Upheld 31-Mar-2024; at ITAT
AY2022-23 / 2023-24	Portfolio depreciation ₹30.05 Cr / ₹24.05 Cr disallowed	Nil demand
AY2024-25	Carried-forward loss restricted by ₹342.08 Cr	CIT(A) appeal and rectification filed
CARO FY26 disputed IT	₹105.08 Cr at ITAT + ₹300.36 Cr at CIT(A) (₹161.92 Cr unpaid); FY25 CARO ~₹124 Cr	Contingent: direct tax ₹161.92 Cr (nil Mar-25); indirect ₹5.63 Cr
Indirect / other	Excise 2.74; service tax 0.17; MEIS 2.77; customs 0.12; drawback 0.16; PF 0.66 (₹ Cr)	Open

Systemic disallowance of demerger goodwill/portfolio depreciation threatens tax shields [Est.]. SEBI/MCA/exchanges: no penalties or strictures in 3 years; no IBC, OTS or significant regulator/court orders; directors' report: no orders impacting going concern. One shareholder complaint FY26. An aggregator wrongly attached a "TV Vision Ltd" NCLT/NPA item to Solara — not a Solara event. Ibuprofen disclosure: losses began ~two quarters before first separate disclosure (Feb-2026) — Anupam Jain (Indira Securities) challenged this on the Q3 FY26 call.

Governance red-flag checklist

#	Flag	Severity	Status
1	Strides: ₹329 Cr sales (24%); ₹160 Cr receivable ~178 days vs ~97 others; cap rising to ₹480 Cr; Strides ID on audit committee	High	New in FY26; check H1 FY27 unwind
2	FY26 promoter equity (~₹90 Cr) offset by ~₹98 Cr rise in Strides receivable	High	[Est.]
3	Promoter pledge 37% and rising; Devicam ₹28 Cr trustee charges	High	Ongoing
4	~₹700 Cr in ibuprofen at negative EBITDA; likely write-down at Q2 FY27	High	Decision 16-Oct-2026
5	Synthix holds ~₹49.5 Cr guaranteed debt in deposits	Medium	Purpose on hold
6	~2.4 mn pledged-vehicle shares to Spiracca (Q3 FY24); 2.0 mn bought back Jun-25	Med-High	Mode/ownership unverified
7	CEO/CFO churn 2020–25; chairman + 2 IDs left Aug-2023	High (historic)	Stable since Feb-2025
8	Management from promoter ecosystem; promoter chairs Management Committee	Medium	Structural
9	Two-way inter-group funding (Tenshi, Chayadeep loans; ₹8.89 Cr advances with no terms)	Medium	Open
10	Income-tax disputes up to ~₹405 Cr (CARO); ₹342 Cr loss restriction	Medium	Partly resolved
11	Audit-trail gap 2 years; ₹191 Cr title deeds untransferred 8.5 years; whistle-blower complaints undisclosed	Low-Med	Open
12	Aborted promoter-linked Aurore merger; ₹130 Cr sales returns Q3 FY22	Medium (historic)	Closed
13	Chemsynth: 49%, board-controlled, non-operational since 2018, co-owner unnamed	Low	Open
14	Two IDs ~8.5 years' tenure; one re-designated within 15 days	Low	Query
15	Forfeiture of unpaid rights shares (~1.5% of issue max)	Low	Promoter exposure bounded

Open items: Strides receivable post-Mar-26 and ageing; Synthix lender/purpose; Spiracca partners (MCA) and pledgee names; 2020 warrant dates (₹120 Cr vs ₹384 Cr); Chemsynth consideration and co-owner; Arun Kumar's education; dates for Sesha, Rajender Rao, Anand, Devendra; Sep-2026 SHP.

Supply Chain

Upstream dependencies and downstream customers. Sources: AR FY26 Notes 26/28/39, BRSR, AOC-2, Q1 FY27 call, CRISIL, industry reports.

↑ Upstream — What Solara Depends On

Dimension	Finding
Spend	Standalone materials consumed ₹672.8 Cr in FY26 (49% of revenue), up from ₹581.7 Cr in FY25; purchases ₹679.4 Cr [Fact, AR Note 28]
Import dependence	71% of input value sourced within India in FY26 (67% FY25) → ~29% imported (33% FY25); direct sourcing from MSMEs 33% (20% FY25) [Fact, BRSR]
China	Not quantified. AR calls India and China "critical" in the global API supply chain; China-origin KSMs probably a large part of the ~29% imported [Est.]. Industry: ~73% of India's bulk-drug imports come from China
Key inputs	Ibuprofen: isobutylbenzene (IBB), acylation reagents, solvents, catalysts — standard industry chemistry; Solara's own route and suppliers undisclosed [Est.]. Polymers: monomers, cross-linkers [Est.]. Many KSMs are "dependent on the petroleum products" [Mgmt]; IBB/benzene set the ibuprofen cost floor
Backward integration	Solara buys the key ibuprofen input from third parties; new management declined IBAP/IBB backward integration (would need ~₹200–400 Cr and 3–4 years, per Loggical Investor) — the structural gap vs IOL, which is fully integrated into IBB
Named suppliers	None disclosed. CRISIL cites long-standing supplier ties. Related-party purchases FY26: Strides ₹0.5 Cr; Aurore ₹3.2 Cr
Mitigation	"Strategic vendor partnerships, backward integration for key intermediates, alternate-supplier development" (AR); Mysuru is the captive intermediate site
2026 shock	West Asia crisis: solvent shortages ("an overall shortage in terms of all the solvents"), higher KSM prices; "lines are shut intermittently until we can get hold of the raw materials"; ibuprofen volume constrained; base GM fell to 51.3%. Middle East petrochemical disruptions firmed costs in Q2-26 (EMR); Red Sea freight disruption cited
Cost pass-through	Partial and lagged: ~₹30 Cr passed through in Q1 FY27 (₹17–18 Cr in base), "largely accepted" — "A few customers, it's always a challenge". "Average duration of a customer's order is less than 12 months" (AR). Management "fairly confident of maintaining our absolute values of gross margin"; % may dip
Single-source / lock-in	Changing a KSM supplier named in a DMF requires regulatory change control → de facto lock-in [Est.]. Trade payables ₹267.6 Cr (standalone; ₹273.9 Cr consolidated), 9.13% under supplier-finance arrangements
Liquidity constraint	Rao: "we have limited working capital. So every rupee has to be used judiciously" — limits ability to stock raw materials through shocks

↓ Downstream — Who Depends On Solara

Customers: "leading generic and innovator pharmaceutical companies globally" that make finished formulations (BRSR). Ibuprofen is sold only to "big pharma / marquee brands" at a reported 15–17% premium (Q3 FY26). >Half of regulated revenue goes to big pharma; Solara is "primary supplier in most of its DMFs"; relationships 25+ years with claimed 100% big-pharma retention [Mgmt]. Polymers: supplies "almost all US ANDA players". Customer-level top-5/top-10 shares are not disclosed; product concentration: top 15–16 products >75%, top 5 ~55–60%.

Largest customer = Strides Pharma Science (related party)

Evidence	Detail
Size	One customer ₹329.5 Cr = 24% of FY26 standalone revenue, up from ₹216.1 Cr (16.8%) in FY25 (Note 26)
Identity	Related-party note: sales of goods to Strides ₹329.0 Cr FY26 (₹215.0 Cr FY25); AOC-2 ₹339.1 Cr under "specific arrangements … for long-term API supplies"; cap ₹400 Cr (Sep-25 AGM) → ₹480 Cr (Sep-26 AGM) → top customer is almost certainly Strides [Est., high confidence]
Contract form	Long-term API supply arrangements [Fact]; tenure and pricing terms not seen; arm's-length cannot be independently verified

Growth ex-Strides (₹ Cr)	FY25	FY26	Change
Sales to Strides	215.0	329.0	+114
Standalone contract revenue	1,241.5	1,330.2	+89
Ex-Strides [Est.]	~1,026.5	~1,001.2	~–25 (–2.5%)

Credit concentration	Receivable ₹ Cr	Sales ₹ Cr	Days
Strides	160.45 (from 62.83)	329	~178
All other customers	278.42	~1,040–1,046	~97–98
Company total	438.87	1,369	~117

Strides ≈ 37% of trade receivables and pays almost twice as slowly as other customers. "Other customers" sales base: ~1,040 (revenue from ops less Strides) or ~1,046 (total income less Strides) — hence 97–98 days.

Customer geography (FY26 standalone, by customer location, AR Note 26)

Region	FY26 ₹ Cr	Share	FY25 ₹ Cr	YoY
Asia-Pacific (incl. India)	894.6	67%	838.4	+7%
Europe	235.1	18%	259.8	–10%
South America	91.0	7%	59.8	+52%
North America	88.7	7%	75.1	+18%
Rest of World	20.8	2%	8.4	+148%
Total (contract revenue)	1,330.2	100%	1,241.5	+7%

Direct US billing only ~7%, yet "regulated-market" revenue ~76% → much regulated revenue is API sold to Indian/Asian formulators (incl. Strides) whose finished doses go to US/EU [Est.]. India-domestic revenue ≈ 48% (100% – 52% exports) [Est.].

Stickiness and contract tenor

DMF/CEP referencing → 12–24 months to re-file a new supplier [Est.].
Ibuprofen customers resisted even a route change [Mgmt].
A big-pharma customer co-funded Vizag [Mgmt].
Strides buys under long-term supply arrangements; individual orders <12 months [Fact].
No order book disclosed; book-to-bill not applicable (merchant API supplier on supply agreements/POs).

End products containing Solara's output [Est.]

OTC ibuprofen tablets and gels; fast-acting salts; IV ibuprofen (incl. neonatal PDA)
Dialysis phosphate binders; hyperkalaemia powders; lipid sequestrants
Anthelmintic tablets for mass drug administration; antimalarial injections; MDR-TB
Antiepileptics; antipsychotics; transplant immunosuppressants
Anaesthesia injectables (sugammadex, succinylcholine)
Quality: 14 complaints FY26 (4 open), 0 recalls

Value-chain map

Petrochemicals / solventsBenzene, IBB, basic chemicals — West Asia and China linked

→

KSM / intermediates~71% India by value; ~29% imported; Mysuru captive intermediates

→

SOLARA6 sites; ~5,000 MT/yr [Est.]; 96 US DMFs / 34 CEPs. Base (76% rev; GM ~55%; EBITDA 23–25%) | Ibuprofen (24%; GM ~28%; EBITDA –16%)

→

CustomersStrides (24%, RP); Indian/Asian formulators (APAC 67%); Europe 18%; LatAm 7%; N. America 7%; big-pharma OTC brands; US ANDA filers

→

Finished dosesUS/EU/Japan/RoW markets; WHO/public-health tenders

→

PatientsOTC retail, dialysis centres, hospitals/anaesthesia, mass drug administration

Where pricing power sits

Link	Who holds power	Why
Niche/complex APIs and polymers	Solara	Small volumes, few qualified sources, DMF lock-in, hard chemistry, "fully sold" polymer capacity; base GM 51–58% is the evidence
Commodity ibuprofen	Buyers and low-cost rivals	Big brand owners and new low-cost Indian capacity set price; ~50k MT supply ample; Solara a price-taker at ~25–30% utilisation; only edge = incumbent qualification (15–17% premium)
Upstream KSMs/solvents	Shifts with cycle	Moderate in normal times; high in shocks (West Asia 2026); <12-month orders allow only partial pass-through
Strides	Outlet and risk	Large, fast-growing, near-captive buyer — but a related party paying in ~178 days; arm's-length pricing unverifiable

Supply-chain gaps: customer names other than Strides; named KSM suppliers and China share of imports; revenue by molecule; reconciliation of 52% exports with FX earnings. [Analyst View] on power allocation.

Competitive Position

Solara competes on two fronts — commodity ibuprofen and niche specialty APIs — so peers are split. Peer data recomputed from Screener (FY26; market data 13-Oct-2026).

Market position [Est.]: mid-tier Indian merchant API maker by revenue (~₹1,370 Cr) — below Divi's, Granules, Aarti Drugs, IOL and Neuland; roughly at par with Shilpa; larger than Supriya. In ibuprofen it has fallen from global leader (~16% of production, Beroe 2019, as Shasun) to ~6–7% implied volume share today. In polymers it claims ~50%+ global share in complex polymer APIs (unverified).

Peer selection logic

Ibuprofen / commodity API: IOL Chemicals & Pharmaceuticals (world's largest ibuprofen producer; only fully backward-integrated via IBB); Granules India (large-volume paracetamol/metformin/ibuprofen/guaifenesin, API-PFI-FD); Aarti Drugs (similar-revenue commodity API). Unlisted/global: BASF (Bishop, Texas), Shandong Xinhua Pharmaceutical and Hubei Biocause (China).
Niche/specialty API (base business): Neuland Laboratories (complex API + CDMO), Supriya Lifescience (niche API, high margin), Shilpa Medicare (oncology/niche API + CDMO); Divi's Laboratories as quality benchmark. Hikal and Aarti Drugs named as competitors by one analyst (Nivezo). Ami Organics (Acutaas) excluded — data not retrievable.

Peer comparison (FY26)

Company	Revenue ₹ Cr	YoY	EBITDA %	PAT %	RoE	P/E TTM	EV/EBITDA FY26	Mcap ₹ Cr	Gross debt ₹ Cr	Moat
Solara Active	1,369	+6.6%	13.7%	–0.5%	n.m.	n.m.	20.6x*	3,156	687*	Regulated approvals across 5 sites; niche polymers; long relationships; ibuprofen not integrated
IOL Chemicals	2,319	+11.5%	11.6%	6.0%	8.4%	32.1x	21.5x	5,664	135	Only fully backward-integrated ibuprofen maker (IBB ~30% global share); 12,000 → 18,000 MT
Granules India	5,366	+19.7%	22.1%	11.1%	13.8%	33.7x	19.7x	21,904	1,512	Scale + API-PFI-FD integration; US FD front-end
Aarti Drugs	2,565	+7.5%	12.2%	7.6%	13.4%	19.4x	13.8x	3,732	577	Scale, partial backward integration, low-cost base
Neuland Labs	2,023	+37.0%	28.7%	18.0%	21.2%	51.8x	45.0x	25,815	301	Complex API + CMS with innovator relationships
Supriya Lifescience (SA)	828	+19.0%	35.6%	25.2%	19.1%	34.5x	23.3x	6,860	5	Niche API leadership; near debt-free
Shilpa Medicare	1,535	+19.8%	28.3%	15.8%	9.0%	67.2x	45.4x	19,098	660	Oncology/HPAPI + CDMO + differentiated formulations
Divi's Labs (benchmark)	10,560	+12.8%	32.6%	24.3%	16.5%	83.1x	~72x (gross)	2,47,762	7	Global custom-synthesis & generic API leader; process-chemistry cost moat

*Peer-consistent basis: EV = mcap + Screener gross borrowings incl. leases (Solara ₹687 Cr, Mar-26), cash not deducted; EBITDA = Screener ex-other-income (Solara ₹187 Cr). This 20.6x is not the report's headline multiple; headline EV/EBITDA is ~18.5x TTM on EV ~₹3,657 Cr (net debt + leases) and company EBITDA ~₹197.5 Cr (Tab 12). Base-only on this basis ~15.7x (₹3,843 / ₹244.5 Cr). RoE and P/E are Screener TTM. Raw inputs (Sales FY25→FY26 / EBITDA / PAT): Solara 1,284→1,369/187/–7; IOL 2,079→2,319/270/138; Granules 4,482→5,366/1,188/595; Aarti 2,387→2,565/312/195; Neuland 1,477→2,023/580/364; Supriya 696→828/295/209; Shilpa 1,281→1,535/435/243; Divi's 9,360→10,560/3,442/2,568.

Latest quarter (Jun-26)	Sales ₹ Cr	OPM	Note
IOL Chemicals	756 (+37% YoY)	14%	EBITDA ₹111 Cr (+60.7%) — ibuprofen-led rebound while Solara's ibuprofen loses money
Granules India	1,477	23%	—
Aarti Drugs	703	14%	—
Neuland Labs	642	35%	—
Solara	382	16%	Base 23.5%; ibuprofen –11.4%

Leverage (gross debt incl. leases / FY26 EBITDA): Solara 3.7x — highest in set (Aarti 1.8x, Shilpa 1.5x, Granules 1.3x, IOL 0.5x, Neuland 0.5x, Supriya ~0x). Solara is the only peer with negative PAT and the lowest RoE.

Ibuprofen market structure

Producer	Capacity (est.)	Route / position	Share (Verified Market Research, methodology unverified)
IOL Chemicals (India)	10,000–12,000 MT → 18,000 MT (~₹350 Cr Barnala unit, by ~Dec-2027) + ₹1,200–1,400 Cr greenfield programme	Boots route; fully integrated into IBB	~35%
BASF (Bishop, Texas)	Significant	BHC route	~18%
Shandong Xinhua (China)	~8,000–10,000 MT	Aryl rearrangement; #2 producer (HDIN)	~15%
Solara (India)	~5,000–6,000 MT Puducherry; 10,000–12,000 MT incl. mothballed Vizag	Boots route; non-integrated	~5% (implied ~6–7% by volume: 3,000/~45,000 MT)
Hubei Biocause (China)	~3,500 MT	Aryl rearrangement	—
Others	Generally ≤5,000 MT	SI Group exited ibuprofen in 2024	—

~81% of global production from six manufacturers; China ~48%, India ~30% of output (Intel Market Research). HDIN: "heavily consolidated at the top". All routes start from IBB. Implied Solara realisation ₹333.7 Cr / ~3,000 MT ≈ ₹1,110/kg (~US$12.6/kg) [Est.], consistent with the global index and the 15–17% premium claim. Global volume ~45,233 MT projected for 2022 (Beroe). In FY19 ibuprofen was ~25–30% of Solara revenue (Loggical Investor). Vizag capacity framed by one writer as ~9,000 MT vs ~3,000 MT demand — a cyclical-boom capex "trap".

Industry size and trends

Metric	Value	Source
Global API market	US$238.7 bn (2025) → US$252.2 bn (2026) → US$425.3 bn (2035); CAGR 5.95% 2026–35; North America 38.4% of 2025	Precedence Research
Generic vs innovative API	Generic US$83.3 bn (34.9%) vs innovative US$155.4 bn (65.1%); generics faster-growing	Precedence
Captive vs merchant	Captive 57.1% / merchant ~42.9%; merchant faster-growing	Precedence
India's share of global API	~8% (3rd largest); 500+ APIs; 57% of WHO-prequalified APIs	IBEF
India pharma	Domestic US$60 bn (FY26) → US$130 bn by 2030; exports ~US$31 bn FY26	IBEF
India bulk-drug import dependence on China	~73% of bulk-drug imports	docmadhu citing industry
Ibuprofen API market	US$180–280 mn (2025); CAGR 2.5–4.5% to 2030; ~45 kt	HDIN; Beroe
Global CDMO market	Not Available — not sourced (search budget exhausted)	—

Global ibuprofen API price index (US$/kg)

Expert Market Research index. Q2-26 regional: China 9.9, India 14.9, US 16.4, Germany 19.9 US$/kg; H2-26 forecast US$14.0–15.4/kg

Key industry trends

China cost advantage persists — Chinese ibuprofen ~33% below Indian (US$9.9 vs 14.9/kg, Q2-26) [Est.]; Chinese plants returning after Covid drove the post-FY21–22 price collapse.
Cost-leader capacity additions — IOL +6,000 MT (~13% of global volume) into a 2.5–4.5% growth market: structurally bearish for non-integrated producers.
Exit/consolidation — SI Group exited 2024; Solara evaluating sale/restructuring.
China+1 — Western buyers diversifying; favours clean USFDA/EDQM records. US BIOSECURE and tariff actions mainly help Indian CDMOs; not directly material given tiny CRAMS [unverified].
Shift to specialty — polymers, HPAPI, GLP-1 adjacencies (SNAC DMF; one Vizag block planned HPAPI, one multipurpose).
Feedstock/energy — IBB/benzene cost floor; Middle East disruptions; Red Sea freight.
Sustainability as buyer criterion — CRISIL ESG 63 "Strong"; 81% renewables.

Government policy, PLI and regulation

Policy	Detail	Relevance to Solara
PLI — Bulk Drugs (KSMs/DIs/APIs)	₹6,940 Cr outlay, 41 products, to FY29; 48 projects approved, 39 commissioned (28 APIs/KSMs); ₹5,210.74 Cr invested vs ₹4,330 Cr committed; cumulative sales ₹3,792.49 Cr incl. ₹560.16 Cr exports (Jun-2026). Named: Pen-G, clavulanic acid, rifampicin, atorvastatin, olmesartan, sulfadiazine, PAP	Not a named beneficiary; ibuprofen/IBB not among named products [Est.] — PLI-backed rivals gain cost advantage in specific molecules
PLI — Pharmaceuticals	₹15,000 Cr; 55 applicants (20 MSMEs); ₹46,744 Cr invested vs ₹17,275 Cr target; cumulative sales ₹4,02,869 Cr (Jun-2026)	Not a known beneficiary
Bulk Drug Parks	3 mega parks; ₹1,400 Cr in Budget 2025-26	Indirect — lowers cost for new entrants
Dec-2025 API push	~₹60,000 Cr programme to cut import dependence (detail unverified)	Potential tailwind via KSM localisation
USFDA / EDQM / PMDA / MHRA	Five sites USFDA/EDQM; Mysuru local GMP; Puducherry VAI (Apr-2026); 3 clean FY26 audits	Core asset; any OAI/WL would hit ~75% regulated revenue
State PCBs (environment)	CRISIL flags ETP upgrades and continuous effluent investment	ESG/compliance risk; recurring capex
Revised Schedule M (GMP)	Upgraded GMP norms phased in (status unverified)	Raises costs for smaller domestic rivals; neutral-to-positive
US tariffs	"The intent has been announced. There is no legal implementing framework … Is it only formulations? Is it APIs?" (Q1 FY27 call)	Scope unclear vs 75%+ regulated exposure
SEBI LODR / RPT	RPT/materiality policies revised Feb-2026; board-evaluation and whistle-blower policies May-2026	Governance hygiene

Barriers to entry and Porter's Five Forces

Force	Intensity	Rationale
Rivalry	High ibuprofen / Medium base	Ibuprofen: few large players but excess capacity → "price war" (CRISIL); base: a handful of qualified suppliers per niche molecule
Buyer power	High	Large generic/OTC buyers; top customer ~24%; dual-sourcing standard; commodity priced off China
Supplier power	Medium-High	Non-integrated in ibuprofen; ~73% China dependence for India bulk-drug inputs; Q1 FY27 RM supply hit GM
Substitutes	Low-Medium	OTC substitutes (paracetamol, naproxen) but stable demand; newer phosphate binders (Solara also makes sucroferric oxyhydroxide)
New entrants	Low regulated / Medium commodity	DMF/CEP filings, 2–4-year qualification, multi-agency audits (33 successful USFDA audits), environmental clearances vs PLI-subsidised entrants and Chinese scale; ibuprofen routes well known, incumbents add capacity fast

Moat durability [Est.]: base moat moderate and reasonably durable (approvals, niche polymers, long relationships, ~54–55% GM, ~23–25% EBITDA through FY25–Q1 FY27). Ibuprofen moat effectively gone. Pricing power: ibuprofen is consolidated-supply but capacity-surplus, price-taking (China sets floor); niche base APIs fragmented at portfolio level but each molecule has few qualified suppliers. The investment case depends on separating the two.

Strengths and weaknesses vs each peer

Peer	Solara stronger	Solara weaker
IOL Chemicals	Broader specialty portfolio (60+ APIs, polymers); base margin ~23–25% vs IOL 11.6%; 15–17% ibuprofen premium via big pharma; more regulated sites	IOL integrated into IBB (structural cost edge), ~3–4x Solara's ibuprofen volume and expanding; debt ₹135 Cr; profitable; Solara loses ₹10–15 Cr EBITDA/qtr in ibuprofen
Granules India	Higher-complexity niche molecules (polymers, anaesthesia, CNS)	~4x revenue, 22% OPM, 13.8% RoE, PFI/FD integration, US front-end, cost leadership
Aarti Drugs	Higher base margin; higher regulated exposure (~75%)	Profitable (7.6% PAT, 13.4% RoE); lower leverage (1.8x vs 3.7x); cheaper (13.8x)
Neuland Labs	Polymer depth; far lower P/B	29% OPM, 21% RoE, 37% growth, strong innovator CDMO pipeline vs Solara CRAMS ~₹10–12 Cr
Supriya Lifescience	~1.65x revenue, more sites/approvals, broader portfolio	35.6% OPM, 25% PAT margin, debt-free, 19% RoE — superior on every return metric
Shilpa Medicare	Similar scale; lower EV/EBITDA (20.6x vs 45.4x, peer basis)	28% OPM, CDMO/oncology positioning, profitable
Divi's (benchmark)	Far cheaper; phosphate-binder depth Divi's does not emphasise	33% OPM, cash-rich, custom-synthesis moat; Solara lacks a CDMO franchise

Risks & Red Flags

Comprehensive risk register synthesised from the business, financial, governance, market and street-sentiment modules. Severity is our assessment [Analyst View]; facts as tagged in source tabs.

Reconciliation note. The market module rated the going-concern item "Red (verify)" because it could not confirm the nature of the note. It has since been verified from the AR: it is a management going-concern basis disclosure (Note 2), and Deloitte's FY26 opinion is unmodified with no emphasis of matter and no material-uncertainty paragraph. It is treated below as a liquidity signal, not an audit red flag. Likewise, the market module's "no specific related-party abuse identified" is superseded by the AR related-party evidence on Strides (Tab 7), now the top governance risk.

Risk register

#	Risk	Category	Severity	Detailed explanation	Mitigant
1	Ibuprofen value destruction / unresolved exit	Business / Execution	High	FY26 EBITDA –₹53.0 Cr (~–15.9%; CRISIL ~–18%); guided –₹10–15 Cr/qtr; ~₹700 Cr deployed; recovery "slightly farfetched"; decision slipped three times (Q4 FY26 results → H1 FY27 → "with Q2 results"); no deal visible as of 13-Oct-2026. Expect impairment/exceptional charge; hit to tangible net worth (₹1,042 Cr); possible Puducherry/Vizag closure costs	Bankers appointed; goodwill not allocated to ibuprofen; big-pharma contracts make Puducherry saleable; removing drag adds ~₹40–60 Cr EBITDA
2	Ibuprofen price war — China + IOL capacity	Business	High	China ~US$9.9/kg vs India ~US$14.9/kg; integrated IOL adding 6,000 MT to 18,000 MT by ~Dec-2027 into a 2.5–4.5% growth market; >20,000 TPA new capacity in two years; fewer buyers for the unit	Exit/sale; 15–17% premium positioning; Vizag conversion
3	Strides related-party concentration and receivable	Governance / Financial	High	₹329 Cr sales (~24% of revenue; all FY26 growth); receivable ₹160.45 Cr ≈ 178 days vs ~97–98 others (~37% of receivables); cap ₹480 Cr FY27 (~35% of FY26 revenue); Strides ID on audit committee; FY26 promoter equity ≈ offset by receivable build	Audit Committee/Board/shareholder approvals (promoters excluded); AOC-2 arm's-length; monitor H1 FY27 RPT disclosure
4	Promoter pledge (37.1%)	Governance	High	Rose 26.0% → 31.6% → 37.1% (Dec-25 → Jun-26); Pillai 80.5%, Chayadeep/Agnus 100%, SRJR 88% pledged; Devicam ₹28 Cr trustee charges; a stock fall could trigger invocation and overhang; pledges plausibly funded rights calls	Promoter stake ~42%; Devicam (15.5%) unpledged; deleveraging and upgrade support equity value
5	USFDA / regulatory adverse action	Regulatory	High	~75% revenue from regulated markets; WL/OAI at Cuddalore (polymers) or Puducherry would halt US supply; Cuddalore was OAI previously; CRISIL flags increased inspections	33 successful USFDA audits; Mangaluru and Puducherry VAI; Ambernath zero 483s; multi-agency approvals
6	Management credibility / execution slippage	Execution	High	13 of 22 tracked promises missed or re-dated, plus 1 partial (Tab 11): FY25 revenue, FY26 EBITDA, Vizag restart (4x), CRAMS demerger, "net cash by FY27", ibuprofen deadline (3 slips)	New CEO/CFO give narrower, hedged outlooks; base step-up is in reported numbers
7	KSM / raw-material dependence; West Asia shock	Business / Macro	Med-High	~29% inputs imported (China likely large); non-integrated ibuprofen; solvent shortages shut lines intermittently; Q1 FY27 GM hit; partial pass-through	Supplier diversification; Mysuru intermediates; PLI KSM localisation
8	Base-margin compression	Business	Medium	Base GM 58.1% → 53.7% → 51.3% (–675 bps YoY); EBITDA 26.9% → 23.5%; Q2–Q3 FY26 base EBITDA 19–21%; if no recovery, 25% ±1% and 52–55% bands at risk	Adjusted GM 54.5%; debottlenecking on high-margin lines; opex base flat
9	Leverage, liquidity and refinancing	Financial	Medium (down from High)	Net debt ₹479.5 Cr (~1.9x annualised); finance cost ~51% of FY26 EBITDA; EBIT/interest 0.97x FY26; limit utilisation 93–95%; ₹554.5 Cr due within a year (mostly WC rollovers); FCF after interest ~₹8 Cr FY26	~₹445–448 Cr rights equity; BBB+ upgrade; repayments ₹30–60 Cr/yr vs accruals ₹120–150 Cr (CRISIL); Q1 FY27 interest cover ~3.1x
10	Going-concern basis note / negative working capital	Financial	Medium	Management Note 2: consolidated NCL ₹35.81 Cr, accumulated losses ₹319.33 Cr (standalone NCL ₹78.84 Cr). Not an auditor qualification — Deloitte unmodified, no EoM/MU	₹134.99 Cr final call received post year-end; WC line renewals; rating upgrade; need-based promoter support (CRISIL)
11	Covenant compliance	Financial	Medium	FY25 financial covenants breached on ₹203.16 Cr term loans; waivers sought; FY26 compliance not disclosed	Term debt down to ₹149.4 Cr; improved metrics
12	Goodwill / asset impairment	Financial	Medium	Goodwill ₹364.9 Cr (~26% of Jun-26 equity); Vizag CWIP ₹182.5 Cr; ₹100–300 Cr write-down = 8–24% of equity	Goodwill tested at 21.35% discount rate with 9.15-pt headroom; base business growing
13	Governance opacity — Spiracca, Synthix, two-way funding	Governance	Medium	Spiracca round-trip (2.4 mn shares out of pledged vehicles Dec-23; 2.0 mn bought back Jun-25); Synthix ₹49.5 Cr guaranteed debt in deposits; Tenshi/Chayadeep loans; ₹8.89 Cr RP advances with no terms; Aurore/Hydra web [Unverified]	Clean MR-3; CG certificate clean; RPT policy v4
14	Smart-money exit / crowded retail positioning	Market	Medium	TPG (11.5% → 1.5%), CDPQ, FSSA, Scottish Oriental, ABSL MF trimming/exiting; FII 17.9% → 11.5%; MF 1.18% → 0.95%; retail poll 80.5% Buy; Substack bull pieces clustered Aug–Oct 2026 (late-narrative signal); +8%/+16% days with no filing; no live sell-side coverage; stale consensus ₹566 Sell; holder count 83k → 70k	Promoter buying (₹99 Cr Jun-25); Mauryan accumulating; non-MF DII ~1.4% → ~2.8%; possible broker initiation post-resolution
15	Vizag conversion / new launches	Execution	Medium	Vizag mothballed despite Feb-26 "5–6 month" guidance; HPAPI needs re-qualification; ~₹200 Cr R&D with limited filings; SNAC DMF behind 3 earlier filers; idle cost ₹12–15 Cr/yr	Modest capex (₹55–60 Cr FY27; ₹40–50 Cr FY28–29); no greenfield; ESOP-aligned management
16	Customer and product concentration	Business	Medium	Largest customer ~24%; top 15–16 products >75%; top 5 ~55–60%	Long relationships; 60–75+ countries; DMF switching costs
17	Plant disruption / single-site concentration	Business / Execution	Medium	Q2 FY26 Mangaluru shutdown (EBITDA –43% YoY); Puducherry ~43% of capacity; polymers concentrated at Cuddalore	6 sites; insurance (fire claim)
18	Effluent / EHS / ESG	ESG	Medium	ETP upgrades needed (CRISIL); Nov-2023 Puducherry fire (two fatalities reported); PCB action could shut capacity; energy capex nil FY26	CRISIL ESG 63 "Strong"; 81% renewable electricity
19	Management transition / key-person	Governance / Execution	Medium	Entire top team new since Feb-2025 (CEO, CFO, CBO; WTD 2026; CIO Aug-2026); promoter chairs Management Committee	Promoter backing; board-evaluation policy; ESOPs at ₹375
20	Polymer niche competition	Business	Medium	~50% claimed share invites new DMF filers (patiromer: Formosa, Alkem, Vifor) and price erosion	Complex chemistry; capacity-constrained demand; qualification lag
21	Disclosure quality	Governance	Medium	Ibuprofen losses undisclosed until Feb-2026; refuses to name products/customers; audit-trail gap two years; whistle-blower complaints undisclosed; CRAMS size contradictions (₹100–120 Cr vs ₹4 Cr services)	Segment split now given quarterly
22	Tax / litigation	Regulatory	Low-Med	₹161.92 Cr AY2019-20 demand rectified to nil (28-Aug-2026), but CARO disputes ~₹405 Cr; ₹342.08 Cr loss restriction; systemic goodwill-depreciation disallowance threatens ₹156 Cr unrecognised DTA value	Appeals at ITAT/CIT(A); rectification precedent
23	Asset title / encumbrance	Legal	Low-Med	₹191.26 Cr gross title deeds still in pre-demerger names; Puducherry pledged to term lenders — complicates ibuprofen asset sale	Transfer in process
24	Rights forfeiture / partly-paid overhang	Governance / Financial	Low-Med	Forfeiture notice 9-Oct-2026; forfeited shares may be reissued	Small (≤~1.5% of issue; ~₹4–7 Cr)
25	FX volatility	Macro	Low-Med	Exports 52%; USD revenue; INR appreciation compresses margin	Natural hedge via ~29% imported inputs; USD loans; LC lines ₹185.5 Cr
26	Interest-rate risk	Macro / Financial	Low-Med	All borrowings floating; 1% = ₹6.6 Cr PBT; CC limits ₹474.5 Cr	Debt falling; upgrade lowers spreads
27	US trade policy on pharma	Macro / Regulatory	Low-Med	Tariff scope on APIs unclear (management unsure); MFN pricing "mainly for branded"	Direct US billing ~7%; diversified countries
28	Legacy portfolio obsolescence	Business	Low	Ranitidine (withdrawn from US 2020) still listed; ibuprofen route ~20 years old	Pipeline of 10 APIs; 4–5 DMFs/yr

Specific red-flag check

Red flag	Status	Evidence
Rising debt	Improving	Gross excl. leases ₹999.4 Cr (Mar-24) → ₹664.5 Cr (Mar-26) → ₹532.3 Cr (Jun-26); net ₹479.5 Cr; still highest leverage in peer set
Margin deterioration	Mixed	Consolidated OPM 16.0% → 13.7% FY26 (ibuprofen price war + Q2 shutdown); Q2–Q3 FY26 ~11%; base ~23–25%
Auditor concerns	Clean opinion	Deloitte unmodified; no EoM/MU; management going-concern basis note; recurring audit-trail and title-deed exceptions
Related-party abuse	Red	Strides 24% / ~178 days / ₹480 Cr cap; two-way inter-group loans; Synthix guarantee
Promoter pledge	Red	37.11% (Jun-26) from 26.04% (Dec-25)
Promoter selling	No	30.5% → 42.0% (Jun-25), flat since; Pronomz bought ₹99 Cr Jun-25; Dec-23 Devicam→Spiracca transfer is the exception
Dilution	Yes (largely done)	+33% shares via rights; ₹120 Cr infused FY25 (CRISIL); no further fund-raise guided; ESOP overhang ~0.9%
Customer loss / concentration	Watch	Ex-Strides revenue –2.5% FY26; Q3 FY22 ~₹120–130 Cr returns shock
Stranded capex	Red	~₹700 Cr ibuprofen incl. Vizag; Vizag assets impaired in FY24 [as cited]; idle cost ₹12–15 Cr/yr
Execution slippage	Red	Ibuprofen decision from end-Apr-2026 → H1 FY27; Vizag restart missed; carve-out deferred
Safety	History	Nov-2023 Puducherry fire; two fatalities reported; FY24 loss ₹567 Cr
Working capital	Watch	Receivables consumed ₹111.32 Cr cash FY26; utilisation ~93%
Institutional exit	Watch	FII 17.86% → 11.52%; TPG persistent seller (latest 10-Jul-2026 at ₹573.20)
Brazil / USA subsidiaries	Closed	Brazil deregistered 30-Jul-2025; Shasun USA dissolved 16-Sep-2025

The three risks that matter most: (1) the cost and terms of the ibuprofen exit on 16-Oct-2026; (2) whether the Strides receivable unwinds or keeps growing under the ₹480 Cr cap; (3) the pledge trajectory in the Sep-26 SHP. [Analyst View]

Concall Highlights & Guidance

Last six quarters plus two earlier calls for the credibility baseline. Q1 FY27 from the primary transcript (filed 29-Jul-2026); Q2 FY25–Q1 FY26 and Q3 FY26 from AlphaStreet auto-transcripts (names/figures partly garbled); Q2 FY26 and Q4 FY26 from secondary summaries (arthneeti — AI-generated, ScanX, CRISIL) plus back-references.

Speakers: Sandeep (Shashikantha) Rao, MD & CEO (from 21-Feb-2025); Sarat Kumar Asuri, CFO (and Chief IR Officer from Nov-2025); Arun Kumar Pillai, founder/NED (dominated calls until Feb-2026; absent Q1 FY27); Abhishek Singhal, IR; Poorvank Purohit, CEO on FY25 calls.

Quarter-by-quarter log

Call	Numbers	Key statements and guidance	Tone
Q2 FY25 21-Oct-2024	GM 50.5% (+620 bps YoY); EBITDA ₹61 Cr (+61%); regulated 76%	Q4 FY25 EBITDA ₹80–90 Cr at ~20% on implied FY25 revenue ~₹1,500 Cr — Arun Kumar: "we are very confident that our Q4 will be within the guided numbers." Vizag (~33–35% capacity) mothballed, retrofit as multipurpose + HPAPI, restart Q1 FY26 ("about three full quarters of contribution in FY'26"); "no need … to have a dedicated facility for ibuprofen"; Vizag gross block ~₹500 Cr, net ~₹250 Cr, ~₹100 Cr more capex planned. "0 under-recoveries in FY'26"; ibuprofen ~25% of revenue, "stable for over 20 years"; "close to net cash by FY'27". Investor: EBITDA guide slipped ₹260–290 Cr → ₹230–260 Cr; reply "Nothing has changed in our outlooks." China+1: "is it a flood? The answer is no." Peptides "early days"	Promotional
Q3 FY25 24-Jan-2025	—	"we have this time … revised the guidance downwards on the revenue standpoint": FY25 revenue ₹1,400–1,500 Cr → ₹1,300–1,400 Cr; EBITDA held ₹230–260 Cr (Q4 cut ~₹10 Cr). "Increased pricing competition on our … ibuprofen range"; chose not to match. CRAMS carve-out announced (9–12-month NCLT): FY25 CRAMS ~₹120 Cr at 25–27% adj. EBITDA; aspire ~₹500 Cr in 3–4 years at 35–40%; +100 scientists in 12 months; ₹100–150 Cr more on Vizag. 3-yr outlook: low-double-digit growth, EBITDA ~20% → 22–23%; ~95 US DMFs, ~30 commercial products; asset turns 1.2–1.3x; Vizag two USFDA inspections zero 483s	Defensive
Q4 FY25 15-May-2025	FY25 GM 51.5% (FY24 37.8%); EBITDA 16.5%; positive all 4 quarters	"A year of reset"; admitted revenue and EBITDA misses; henceforth "outlook" not guidance. FY26 outlook: revenue +10%, EBITDA +15–20%; net debt/EBITDA 1.7–1.8x by Q1 FY27, ~1.5x after ~₹200 Cr pushed to Synthix (inc. Apr-2025). Ibuprofen generic pricing "does not even cover a cost of manufacturing"; share "less than 45% including derivatives" (60% peak); new Indian capacity on efficient routes. CDMO "just about hundred crores"; utilisation ~60%; FY26 interest ~₹85 Cr, D&A ~₹99 Cr; catalogue GM 53–55% sustainable; Vizag "no capex yet"; opex –22% YoY. Ambernath USFDA zero 483s; Mangalore EU GMP; WHO for Mangalore, Ambernath, Pondicherry. CEO/CFO "here for the long term"; MFN "mainly for branded"; exchange halt of partly-paid "not our decision"	Humble reset
Q1 FY26 25-Jul-2025	Rev ~₹320 Cr (+15–17% QoQ); GM 54%; EBITDA ₹57 Cr (~18%); developed markets ~77%	Rao: "FY26 is going to be all about growth." FY26 outlook reiterated. Debt –₹143 Cr (₹113 Cr call money + ₹31 Cr OCF); ND/EBITDA ~2.6x; target debt <₹450 Cr by Q1 FY27 (~1.5x). Analyst implied FY26 EBITDA ₹240–250 Cr; "too early to revise". CRAMS FY26 "tepid", Vizag onboarding H2, 2–3 years to matter; ≥₹200 Cr capex + loss funding toward ₹400–500 Cr; equity likely needed at Synthix. Ibuprofen ~30% (21% plain + 9% derivatives), below cost; global supply ~50,000 MT; new route in development. Top-5 molecules 55–60%; utilisation 60–65%	Confident
Q2 FY26 5-Nov-2025	Rev ₹313.5 Cr (–10%); EBITDA ~₹35 Cr (11.1%, –43%); loss ₹10.1 Cr; stock –8.3% to ₹566. Base EBITDA 19% (restated)	Cause: "unscheduled operational shutdown at its Mangalore facility for upgradation" (3–4 weeks, CRISIL); ibuprofen price war. Rao: "our transformation journey remains intact … underlying fundamentals … remain strong." Lost orders to be fulfilled over two quarters. FY26 outlook held; needs 3–4 consecutive growth quarters to claim a turnaround; debt target ~₹446 Cr by Q1 FY27; CRAMS demerger still on	Defensive
Q3 FY26 6-Feb-2026	Rev ₹349 Cr (+15%); GM 47% (–386 bps QoQ); EBITDA ₹37.4 Cr (10.7%); loss ₹17.4 Cr incl. ₹6.75 Cr labour code	First segment split: growth API ₹246.6 Cr, GM 56.3%, EBITDA 24.7% (restated 21%); ibuprofen ₹102.4 Cr, GM 23%, EBITDA –22.9%. Arun Kumar: "we've been struggling significantly with the drag of our ibuprofen business"; capacity 10,000–12,000 t vs ~3,000 t used; "We are just delaying all our corporate actions"; advisors appointed; outcome promised with Q4 FY26 results; selling a plant "should be one of the solutions". CRAMS reversal: "more value to retain everything in one house"; Vizag multipurpose + HPAPI, restart "in the next five to six months". OneSource product awaiting approval, FY27 launch. Generic ibuprofen GM ~21% despite 15–17% premium; growth-API GM ~55–56% "for the next few years". Anupam Jain (Indira Securities) asked why ibuprofen was never disclosed separately: losses began ~2 quarters earlier; GM –800 bps YoY. Solara short of polymer capacity	Candid
Q4 FY26 15-May-2026	Rev ₹387.3 Cr (+40%); EBITDA ₹61–61.7 Cr; PAT ₹9.6 Cr. Base ₹307 Cr, GM 53.7%, EBITDA ₹79.6 Cr (25.9%); ibuprofen ₹84.9 Cr, EBITDA –₹17.9 Cr. FY26: rev ₹1,369 Cr, EBITDA ₹191.5 Cr, loss ₹7.4 Cr; stock +15–18%	Rao: "highest revenue, gross margin, and EBITDA in the last eight quarters." Going-concern basis note (NCL ₹35.81 Cr; accumulated losses ₹319 Cr), Deloitte unmodified. Ibuprofen review slipped to "H1 FY27"; bankers appointed; CRAMS/polymers carve-out on hold. FY27: ~10% growth "mostly towards the base business"; base EBITDA ~25%. No greenfield; R&D ~₹25 Cr/yr; 4–5 DMFs/yr from FY27 (revenue FY29–30); utilisation ~70%; no further fund-raise; net-debt-free by FY29; order book "very healthy" (unquantified); CRAMS "subscale … INR 10–12 Cr" (arthneeti)	Measured / confident
Q1 FY27 23-Jul-2026	Rev ₹384.3 Cr (+20%); GM 47.0%; EBITDA ₹63.5 Cr (16.6%); PAT ₹16.3 Cr (+55%); net debt ₹479.5 Cr	Rao: "another quarter of stellar execution … highest EBITDA and PAT … in the last 18 quarters"; base up "in spite of all the cost pressures … triggered by the ongoing geopolitical developments in West Asia"; ibuprofen "continues to face profitability challenges … marginal sequential improvement". CFO: GM "marginally lower … driven by the raw material pricing and supply challenges"; EBITDA margin +80 bps QoQ; net debt –₹135 Cr (~22%) to ~₹479 Cr (~1.9x); "line of sight to … close to INR440-odd crores by end of March '27, considering the scheduled repayments" (= 479.5 – 38.9 scheduled; no FCF sweep assumed)	Measured; founder absent

Q1 FY27 analyst Q&A (primary transcript) — what it reveals

Analyst	Question	Answer / reveal
Sajal Kapoor (Antifragile Thinking)	Priorities next 12–18 months; ibuprofen timing; profit driver; WC; capital allocation (Vizag "twice US FDA approved")	Rao: (1) "expanding our existing business and seeding new businesses" ("new pipeline will take time"); (2) debottlenecking, "not … green field"; (3) "working capital optimization and generating the free cash". Ibuprofen: "expecting something coming your way in H1 … I would like to address this question in the September time." Profit: when RM pricing reverts, growth "from … business expansion as well as gross margin expansion"; "opex base remains the same … all of it will flow into EBITDA". CFO: turnaround only after "back to back 3 to 4 quarters"; S&OP for inventory. "Once bitten, and twice shy" on greenfield; FY27 capex ₹55–60 Cr (₹40 Cr debottleneck, payback "2 or 3 quarters max"; ₹10–15 Cr maintenance); FY28–29 ₹40–50 Cr/yr
Akash Jain (Moneycurves)	Why base GM swings "52%, 58%"; utilisation; Vizag	~₹30 Cr consolidated pass-through; adjusted consolidated GM "close to like 53%"; base 51.3% reported, 54.5% adjusted (₹17–18 Cr pass-through). Rao: "comfortable with the 50% to 55% range … aspiration … close to 55%". "Most customers have been accepting … A few customers, it's always a challenge." Base plants ~70% (Cuddalore, "Bangalore"=Mangalore, Ambernath). Vizag "not yet used for CRAMS … kept on hold", "continues to be mothballed"; CRAMS demerger "not yet decided"
Anand Mundra (Soar Wealth)	Ibuprofen capital and run-rate	CFO: "deployed capital … close to INR700-odd crores" (debt + equity). Solvent shortages cut supply; price increases accepted but volumes down ("Adjusted for the price increase … slightly down"). Run-rate loss "INR10 crores to INR15 crores of EBITDA … each quarter"
Parth Mehta (Antique)	RM and tariffs	KSMs "dependent on the petroleum products"; "overall shortage … all the solvents"; "fairly confident of maintaining our absolute values of gross margin" (% may dip). US tariffs: "no legal implementing framework … Is it only formulations? Is it APIs?"
Aman Chakraborty (AK Investment)	Flat QoQ revenue	CFO: adjusted for cost price, revenue "almost look[s] like flat Q-on-Q"; Q1 seasonally soft; ~50 products, "15 to 16 products contribute to 75% plus"; underlying YoY 18–19%. Rao: "new plateau … crossed that magical INR300 crores". Polymer APIs previously "promised" — not addressed
Gautami Agarwal	Debt and base margin	"Net debt free by FY'29" with some gross debt retained; "25% plus/minus 1% should be the margin profile"
Zakir Naseer	Ibuprofen outlook	Rao: "ibuprofen is a commodity business … I don't think the dynamics … will change … a couple of other big manufacturers … in India." CFO: recovering "entire capital invested … slightly farfetched … what is the cutoff or shaving which we are taking off" — with Q2 results
Prince	New CIO from Syngene; enzymatic route	"we don't want to comment about individuals"; "We do not have an ibuprofen that is manufactured from enzymatic route"
Shashwat Singh (Bajaj)	Growth drivers; long-term outlook	"incremental business … at different geographies where we were not earlier present" + FY26 debottlenecking; "fairly confident of growing … at least 10%"; no 5-yr outlook — "The world has changed in the last 12 months"; GM 52–55%
Neeraj Shah	Ibuprofen timeline	"on track to be resolving this matter by H1 … please bear with us"; Q1 improvement "a tactical play" on reduced supply
Japreet Singh	Business comparison; progress	Customer relationships equivalent; base molecules more complex; 50–60 products, ≥40 made each quarter; base revenue ~₹245–250 → >₹300 Cr; base EBITDA ~₹55 → ₹70+ Cr/qtr; net debt –₹135 Cr
Achuth (Rockstar Equity)	Strategic decision?	"We haven't made any strategic decision on ibuprofen as yet."
Abhay Amrutiya (Credence Wealth)	Risks to turnaround	Rao: "first and foremost risk is … the West Asia crisis … we have limited working capital … every rupee has to be used judiciously … lines are shut intermittently … Some customers have not been so willing."
Hiten (Sequent)	FY27 outlook basis	10% outlook "mostly towards the base business"

Guidance vs outcome ledger (credibility check)

#	When	Promise	Outcome	Verdict
1	Oct-2024	FY25 revenue ~₹1,500 Cr; Q4 FY25 EBITDA ₹80–90 Cr at ~20%	FY25 ₹1,284 Cr; Q4 EBITDA ₹45.7 Cr at 16.6%	Big miss
2	Jan-2025	Revenue cut to ₹1,300–1,400 Cr; EBITDA ₹230–260 Cr held	₹1,284 Cr; EBITDA ~₹206–214 Cr	Miss after cut
3	Oct-2024	"0 under-recoveries in FY26"	Ibuprofen EBITDA –₹53 Cr FY26	Miss
4	Oct-2024	Vizag restart Q1 FY26	Still mothballed Jul-2026	Miss
5	Oct-2024	"Close to net cash by FY27"	Net debt ₹479.5 Cr; now FY29	Re-dated 2 yrs
6	Jan-2025	CRAMS carve-out in 9–12 months; ₹500 Cr CRAMS in 3–4 yrs	On hold; "not yet decided" (Jul-2026)	Deferred/abandoned
7	May-2025 (reiterated)	FY26 revenue ~+10%	+6.6%	Miss
8	May-2025 (reiterated)	FY26 EBITDA +15–20% (~₹240–250 Cr)	₹191.5 Cr, –10%	Big miss
9	May-2025	FY26 interest ~₹85 Cr; D&A ~₹99 Cr	₹94.75 Cr; ₹99.7 Cr	Partial
10	May-2025	QoQ growth "as early as" Q1 FY26	₹320 Cr vs ₹273 Cr	Met
11	May-2025	ND/EBITDA 1.7–1.8x by Q1 FY27	~1.9x	Narrow miss
12	Jul-2025	Debt <₹450 Cr by Q1 FY27	₹479.5 Cr	Miss
13	Nov-2025	~₹446 Cr by Q1 FY27	₹479.5 Cr	Miss (~7%)
14	Nov-2025	Mangalore volumes recovered within 2 quarters	Base ₹307 Cr Q4 FY26	Met
15	Jul-2025	GM 53–55% sustainable	Consolidated 47% Q3/Q4/Q1; base ok	Base only
16	Feb-2026	Debt <₹500 Cr by May-2026	CRISIL ₹500–530 Cr total (31-May); net ₹479.5 Cr (30-Jun)	Broadly met
17	Feb-2026	Ibuprofen outcome with Q4 FY26	→ H1 FY27 (May) → "with Q2 results"/"September time" (Jul)	Slipped; deadline 16-Oct
18	Feb-2026	Vizag multipurpose/HPAPI restart in 5–6 months	"kept on hold", "mothballed"	Miss
19	Feb-2026	Growth-API GM ~55–56% "for next few years"	53.7% / 51.3% reported; 54.5% adj.	Slipping
20	May/Jul-2026	Base EBITDA ~25% ±1%	25.9% Q4; 23.5% Q1 (~24.9% adj.) [Est.]	In band adj.
21	May/Jul-2026	FY27 ~10% growth, mostly base	Q1 base +24% (18–19% adj.); flat QoQ	On track
22	Jul-2026	Ibuprofen loss ₹10–15 Cr/qtr	Q1 –₹8.7 Cr ("tactical")	Beat (non-repeatable)

Credibility conclusion [Est.]: 13 of 22 promises missed or re-dated plus 1 partial (#9); 5 met/on track; 3 amber. Haircut multi-quarter targets: shift leverage targets by 1–2 quarters and assume strategic actions (Vizag, CRAMS, ibuprofen) slip until filed. The base-business step-up since Q4 FY26 is the most credible element — it is in reported numbers and explained mechanically (debottlenecking + new geographies). The new CEO/CFO make narrower, hedged statements ("slightly hesitant in giving an outlook"), a positive for future credibility. Net debt barely moved across FY26 (₹633 → ₹614 Cr) despite rights calls and rose in Q3; the Q1 FY27 step-down came from the final call (~₹100 Cr) plus only ₹35 Cr operating cash.

Tone arc and recurring themes

Period	Tone
H1 FY25 (founder-led)	Promotional — "very confident" on Q4
Q3 FY25	Defensive — revenue guidance cut
May-2025	Humble "reset" — outlook, not guidance
Jul-2025	Confident — "all about growth"
Nov-2025	Defensive — Mangalore shutdown
Feb-2026	Candid — "struggling significantly"
May/Jul-2026	Measured, confident on base; cautious on capital ("once bitten, twice shy"; "slightly farfetched")

Recurring themes and contradictions

Annual "reset" language.
Vizag "restart soon" — four times (polymers → CRAMS → multipurpose/HPAPI → on hold).
CRAMS as next leg, then dropped; CRAMS size ₹100–120 Cr (2025) vs ₹10–12 Cr (2026) vs ₹4 Cr services in AR.
75–77% regulated-market mix as an anchor (but direct US billing ~7%).
Deleveraging funded mainly by rights.
Refusal to name products or customers.
"3 to 4 quarters" turnaround test — two strong quarters so far (Q4 FY26, Q1 FY27); Q2 FY27 is the third.
Q3 FY26 growth-API EBITDA 24.7% (call) vs 21% (restated deck); entity name Syntex vs Synthix.

Growth, Outlook & Valuation

Order book, visibility, catalysts, guidance, street coverage, sentiment and valuation. Valuation basis per the financial module (authoritative): CMP ₹650.55 (13-Oct-2026), EV ~₹3,657 Cr, EV/EBITDA ~18.5x TTM vs ~15.5x historical, P/B ~2.2x. Alternative bases shown and labelled.

Refresh after 16-Oct-2026. Q2 FY27 results and the ibuprofen decision will reset the EBITDA base (removal of a ~₹40–60 Cr annual drag), the book value (any impairment) and possibly the share count (forfeiture). Every multiple, coverage and sentiment item below is pre-event; the Sep-26 SHP (~21-Oct) will also date the holder data.

Order book and revenue visibility

Item	Detail
Order book	Not disclosed. Merchant API supplier on supply agreements and POs; book-to-bill not applicable. "Very healthy" (Q4 FY26); "order book visibility is something we are working on" (Q1 FY27) [Fact]
% contracted	Not Available — not disclosed. Orders average <12 months; Strides on long-term supply arrangements
Visibility proxies	Regulated markets 75%+; >half big pharma; 60+ countries; 15–16 of ~50 products = 75%+; top-5 ~55–60%; ≥40 products made each quarter; big-pharma ibuprofen accounts >20 years; "relatively better pricing realizations" (Q1 FY27 deck)
Related-party flow	₹480 Cr Strides RPT approved for FY27 (99.87% for; promoters excluded) — ~35% of FY26 revenue if fully used [Est.]; nature/tenure not seen
Pipeline	~95–96 US DMFs; 4–5 new DMFs/yr from FY27, revenue ~FY29–30; SNAC DMF filed 3-Apr-2026; OneSource product launch FY27; 10 APIs in development; patiromer DMF a 5–8-year option
Order wins	No order-win, contract or capacity-contract announcements in the last 12 months

Expansion plans and drivers

Capacity and capex

FY27 capex ₹55–60 Cr: ~₹40–45 Cr debottlenecking (+20–30% on high-margin lines; payback 2–3 quarters), ₹10–15 Cr maintenance. FY28–29 ₹40–50 Cr/yr. No greenfield.
Base plants at ~70% utilisation → headroom before capex.
Vizag (~700 KL; Phase 2 23 acres) on hold; ~₹250–300 Cr of the ~₹500 Cr invested "usable for CRAMS"; HPAPI/multipurpose conversion would need re-qualification.
Synthix/CRAMS carve-out (target ₹400–500 Cr) on hold; ≥₹200 Cr capex + loss funding was the earlier ask.
Bull sequence per Loggical Investor: ibuprofen resolution → balance sheet → Synthix demerger → Vizag → "Solara 2.0".

New products / markets

New geographies: LatAm (+52% FY26), Korea, Middle East; RoW +148%; North America +18%.
Revived dormant DMFs (~30 of ~95 commercial).
Polymers capacity-constrained — debottlenecking targets them.
Peptides (early); GLP-1 adjacency via SNAC; HPAPI capability.
Management: no five-year outlook — "The world has changed in the last 12 months."

Management guidance numbers

Metric	Guidance	Given
Base revenue growth	≥10% a year; run-rate "slightly higher"; FY27 ~10% "mostly base"	Q4 FY26 / Q1 FY27
Base EBITDA margin	25% ±1%	Q4 FY26 / Q1 FY27
Base gross margin	52–55% (Rao "50% to 55%", aspire ~55%)	Q1 FY27
Ibuprofen EBITDA	Loss ₹10–15 Cr/qtr until resolved	Q1 FY27
Vizag idle cost	₹12–15 Cr/yr	Q1 FY27
Net debt	~₹440 Cr by Mar-27 (~1.7x); net-debt-free FY29	Q1 FY27
Capex	₹55–60 Cr FY27; ₹40–50 Cr FY28–29	Q1 FY27
R&D	~₹25 Cr/yr; 4–5 DMFs/yr	Q4 FY26
Fund-raise	None further	Q4 FY26

Catalysts

Horizon	Catalyst	Direction
16-Oct-2026	Q2 FY27 results: ibuprofen decision (sale/closure/partnering/conversion); impairment size; Vizag/Puducherry/CRAMS roadmap; base >₹300 Cr with GM recovery; third consecutive strong quarter	Binary
~21-Oct-2026	Sep-26 SHP: pledge, TPG residual, forfeiture	Watch
12 months	Strides receivable trajectory (H1 FY27 RPT disclosure)	Watch
12 months	CRISIL A- possible if interest cover >3x (Q1 run-rate ~3.1x) [Est.]	Positive
12 months	Sell-side initiation after ibuprofen resolution (none since Jan-2023)	Positive
FY27	OneSource product launch; debottlenecking payback; net debt path to ~₹440 Cr (FCF sweep = upside)	Positive
Macro	West Asia RM normalisation (stated main profit lever); US tariff scope clarity	Two-way
3–5 years	4–5 DMFs/yr monetising FY29–30; polymer capacity; Vizag reuse; Synthix demerger; ~₹156 Cr unrecognised DTA shields profits; net-debt-free FY29	Positive

Industry tailwinds: global API market 5.95% CAGR 2026–35; merchant API growing faster than captive; China+1; India KSM localisation (Bulk Drug PLI ₹6,940 Cr; Bulk Drug Parks; Dec-2025 ~₹60,000 Cr API programme) — though Solara is not a named PLI beneficiary.

Street coverage

No live sell-side coverage. The last named broker report is ICICI Securities' Buy at ₹518 (27-Jan-2023). The only "consensus" on data terminals (Investing.com, Simply Wall St, Trendlyne) is one unnamed analyst at ₹566, Sell / "Strong Sell" — implying –13% vs ₹650.55, but the S&P-fed estimate dates from ~Jan-2025 and is stale. JM Financial (Neutral ₹700) and Kotak (Neutral ₹650) appear only in an auto-generated Univest blog — unverified. The institutional sell side has effectively orphaned Solara since 2023 after the FY23–24 collapse; no 2024+ broker report on Trendlyne's list.

Analyst / house	Rating	Target ₹	Date	Status
Unnamed (S&P feed: Investing.com, Simply Wall St, Trendlyne)	Sell ("Strong Sell"; 0 Buy / 1 Sell)	566	~Jan-2025; displayed Oct-2026	Stale [Fact that it is displayed]
JM Financial	Neutral	700	"2026", undated	[Unverified] Univest only
Kotak Securities	Neutral	650	"2026", undated	[Unverified] Univest only
ICICI Securities	Buy	518	27-Jan-2023	Last named report ("On the path to gradual recovery"); target met; dormant
ICICI Securities	Buy	520	10-Nov-2022	—
ICICI Securities	Buy	488	05-Aug-2022	—
Axis Direct	Not Rated / "Under Review"	—	02-May-2022	Dropped on weaker ibuprofen demand and cost inflation
Axis Direct	Hold	1,300	12-Nov-2021	Stale (minor rights adjustment applies)
Motilal Oswal	Buy	2,050	04-Aug-2021	—
Axis Direct	Buy → Hold	1,350–1,670	Nov-2020 to Aug-2021	—
Sharekhan	Buy	1,371	30-Oct-2020	—
Macquarie	Outperform (bull case 2,064)	n.a.	Oct-2020	Initiation (search summary)
HDFC Securities	Not Rated (fair value)	650–655	Jun–Sep 2019	—

Consensus math	Value	Tag
Rating split (verifiable)	0 Buy / 0 Hold / 1 Sell	[Fact] Investing.com
Rating split incl. unverified	0 Buy / 2 Neutral / 1 Sell	[Unverified]
Target low / median / high (verifiable)	566 / 566 / 566	[Fact]
Target low / median / high (incl. unverified)	566 / 650 / 700	[Unverified]
Implied move vs ₹650.55	₹566: –13.0%; ₹650: –0.1%; ₹700: +7.6%	[Est.]
Simply Wall St narrative (16-Dec-2025, LLM-generated)	Fair value ₹566; assumes 29% revenue CAGR to ~₹2,610 Cr by 2028, 18.5% net margin, 12.8% discount rate — internally inconsistent [Est.]	[Fact] on content
Univest scenario table (Jun-2026)	Bull ₹700–754 / Base ₹673–675 / Bear ₹422–581	[Unverified]
Zen Nivesh SOTP (3-Oct-2025)	Core API EV ₹3,600–4,000 Cr + Synthix ~₹900 Cr – net debt ~₹500 Cr = equity ₹4,000–4,500 Cr → ~₹825–930/share on ~48.5 mn shares (+27% to +43%)	[Est.] third-party; requires Synthix delivery and clean exit
Trendlyne retail poll	80.5% Buy / 13.5% Sell / 6.0% Hold (185 votes)	[Fact]

Street sentiment and price action

Date	Move	Driver
19-Nov-2025	n/a	USFDA VAI for the Mangalore unit [Fact]
5-Dec-2025	n/a	WTD & COO Mohan Muthunarayanan resigns, effective 31-Dec-2025 [Fact]
6-Feb-2026	Weak	Q3 FY26 consolidated net loss ₹17.4 Cr; board appoints strategic advisors to review ibuprofen and reassess the CRAMS/polymer split [Fact]
28-Apr-2026	Positive	USFDA closes the Puducherry inspection (VAI) [Fact]
15-May-2026	+15 to 18% intraday, to ~₹585–600	Q4 FY26 turnaround: PAT ₹9.6 Cr vs loss ₹2.1 Cr; revenue ₹387 Cr (+42% YoY); best quarter in eight [Fact]
24-Jun-2026	–1%, to ₹573	CRISIL upgrade (dated 22-Jun) to BBB+/Stable/A2 — muted reaction [Fact]
10-Jul-2026	~₹573	TPG Growth IV bulk sale of 3 lakh shares at ₹573.20 [Fact]
23-Jul-2026	+~5%	Q1 FY27: PAT ₹16.3 Cr (+55%, 18-quarter high); revenue ₹382–384 Cr (+20%) [Fact]
18-Aug-2026	+8.05%, to ₹550.20	No company catalyst found [Fact]
20-Aug-2026	+16.35% close (~₹640; Univest's +8.49% was intraday)	No filing. Junomoneta Finsol matched bulk buy/sell (~2.83 lakh at ~₹626) — intraday churn, not conviction [Fact/Est.]
15 to 21-Sep-2026	₹774 intraday high; ₹753 highest close	Momentum on the turnaround narrative; heavy volumes of 5–7 lakh shares a day [Fact]
30-Sep to 9-Oct-2026	–14% (₹753 → ₹644)	De-risking ahead of the ibuprofen decision; –5.3% on 5-Oct and –4.2% on 8-Oct on above-average volume [Fact/Est.]
13-Oct-2026	₹650.55 (–1.83%)	Three days before Q2 FY27 board meeting

Voice	Date	Stance	Thesis
Rajkumar Gupta (Substack, "A Good Business Hiding Behind a Bad Business")	02-Oct-2026	Bull; may hold	Base API ~54% GM and 25–26% EBITDA, ~75% regulated; specialty polymers >50% share in some niches; promoter buying; ~30% spare capacity; net debt target ~₹500 Cr. Risks: ibuprofen decision; ~₹200 Cr R&D with no new filing in four years. Reader comment: IOL expanding ibuprofen to 18,000 t by Dec-2027, which hurts any buyer of the unit
Nivezo / Darshan Patel (Substack)	01-Sep-2026	Bull; "Medium-High" confidence, 12–18 months	"Valuation asymmetry": repurpose Vizag (~30% utilised) into multipurpose HPAPI; trailing EV/EBITDA ~18.5x on FY26 EBITDA ₹191.5 Cr, forward much lower. Risks: ibuprofen delay; Red Sea raw-material and freight inflation
The Loggical Investor with Ameya Deosthali ("How Solara walked into a ₹700 Cr trap")	30-Aug-2026	Bull; may hold	Vizag a cyclical ibuprofen-boom capex "trap" (~9,000 MT capacity vs ~3,000 MT demand); new management (Rao, Sarat Kumar, CBO Vishal Mathur, all Feb-2025) declined IBAP backward integration; first new US DMF (SNAC, Apr-2026); sequence ibuprofen → balance sheet → Synthix → Vizag → "Solara 2.0"; "Heads you win, tails you don't lose much"
Zen Nivesh / Shivam Shah ("The Reset")	03-Oct-2025	Constructive; no holdings	SOTP: core API EV ₹3,600–4,000 Cr + Synthix ~₹900 Cr – ~₹500 Cr net debt = ₹825–930/share
Moneylife ("Core API Business Rebounds as Solara Seeks Solution for Ibuprofen Losses")	11-Jun-2026	Neutral to positive (paywalled)	Core rebound vs ibuprofen overhang
Kalkine	29-Jul-2026	Positive on execution	55% PAT growth shows discipline and mix benefit; ibuprofen a material drag
Univest (auto-blogs)	Jun–Aug 2026	Neutral	Generic content; source of unverified JM/Kotak targets
Saket Mehrotra (Beta to Alpha; ValuePickr)	Mar-2021	Historical bull	"What is up with Solara" (paywalled)
Management: Sandeep Rao, Sarat Kumar	15-May / 23-Jul-2026	"Another quarter of stellar execution"	"Ibuprofen … is a commodity business"; options better operator/sale or multi-product conversion; decision H1 FY27; 4–5 DMFs/yr; net debt ~₹440 Cr Mar-27 (~1.7x); Synthix deferred; no FY27/FY28 numeric P&L guidance; CRAMS ~₹10–12 Cr/yr
Rumour	Undated	n/a	"PE firms consider majority stake in Solara Active Pharma" — could not be traced to a dated, reputable outlet [Unverified]

No named TV anchor or fund-manager public call found in the last 12 months; CEO interviews on CNBC-TV18/ET Now not checked (search budget exhausted).

ValuePickr debate (topic 35661; ~260 posts; last post 18-Jul-2026)	Bull view	Bear / sceptic view
1. Promoter pledge and governance (longest-running)	Promoter rights subscription and open-market buying (Feb-2025 ~₹4 Cr; Jun-2025 ₹99 Cr)	2020: pledge ~51% (Jun-2020), ICDs to SeQuent, deal-making style. Jan-2024 (#199, Dhruv Saraf): Aurore–Hydra Active–Spiracca links; called-off Aurore merger and Spiracca's ~10.5% looked "strategic" [Unverified]
2. Is ibuprofen fixable?	Share fell from ~50% to ~30% of revenue (#252)	Oversupplied commodity; China and IOL cost advantage (#204, #247)
3. Vizag	Idle asset could drive revenue in 1–3 years (#223, #236)	Dedicated ibuprofen plant "can't be fully used for CRAMS" (#237, #250)
4. Valuation	<1.6–1.8x book; ~8x price/OCF; FY29 SOTP ~3x the then ~₹2,300 Cr mcap (#225)	"Fairly priced, not discounted" at ₹480 (#249); only buy below ₹400 (#238)
5. CRAMS/polymer demerger (Synthix)	Value unlocking (#216, #217, #239, #243)	Debt-laden subscale entity: ₹200 Cr debt pushed down, ₹100–150 Cr capex on ~₹120 Cr revenue (#230); CRDMO scale-up slow, cf. PI Industries (#238)
6. Management churn	Rao (ESOPs at ₹375) and ex-Tenshi team	Turnaround CEO Purohit and CFO left Feb-2025; some suspected old team pushed out (#231, #234)
7. Partly-paid arbitrage	Spread between SOLARAPP1 and fully paid shares (#213, #215, #244)
8. Pipeline	Patiromer DMF (filed 2019) a 5–8-year option	Competes with Formosa, Alkem, Vifor (#256); no new DMFs for four years until SNAC (Apr-2026)
Latest state	Jul-2026 (#261): poster asked whether bulls were still invested — no reply; thread quiet through the Aug–Sep rally (forum lags price) [Est.]. Other mentions: Jul-2026 portfolio post lists SOLARA as a margin-transition idea; Jun-2025 holder cites "mean reversion plus insider buying". Reddit: no material threads. X/Twitter not retrieved (coverage gap); StockTwits SOLARA.NSE page exists. Holder count 83,148 (Dec-24) → ~70,490 (Jun-26): retail left even as price recovered

Where views agree

The base API business is good: ~54% GM, 24–26% EBITDA, 75% regulated, ~95 US DMFs; clean USFDA (Mangalore VAI Nov-2025; Puducherry VAI Apr-2026).
Ibuprofen is the problem: ~₹334 Cr revenue, ~₹53 Cr EBITDA loss FY26 (–12% to –22% by quarter); Q1 FY27 still –12%.
Deleveraging is real and recognised by CRISIL: peak gross debt ~₹999 Cr (₹1,012 Cr incl. leases) → net ₹479.5 Cr Jun-26; ~₹440 Cr target Mar-27.
R&D and DMFs contribute nothing before FY29–30.

Where views diverge

Ibuprofen exit value: bulls add back ~₹53 Cr EBITDA; sceptics see few buyers with IOL at 18,000 t → distressed sale, impairment or slow conversion, Vizag stranded, Synthix pushed out.
Valuation: no longer the "<1.6x book, cheap" set-up bulls argued at ₹450–500; SOTP of ₹825–930 needs Synthix delivery and a clean exit.
Smart money vs retail: bullish retail and promoter; exiting TPG, CDPQ, FSSA, Scottish Oriental; non-MF DII ~1.4% → ~2.8% and Mauryan adding; net institutional ownership –1.6 pp; MFs shrinking; rising pledge weakens "skin in the game".
Governance overhang: Spiracca/Hydra/Aurore web and the ₹480 Cr Strides RPT (9th AGM, 18-Sep-2026).

Six-month sentiment arc (Apr–Oct 2026). Apr–May, re-awakening: Puducherry VAI, then the Q4 turnaround (+18% on 15-May). Jun–Jul, validation: CRISIL upgrade; final rights call (~₹100 Cr to debt); Q1 beat (+5%); TPG sold into strength. Aug–Sep, momentum and euphoria: +8% (18-Aug) and +16% (20-Aug) with no filing, run to ₹774 on heavy volume; the Substack bull pieces cluster here (30-Aug, 1-Sep, 2-Oct) — a classic late-narrative signal [Est.]. Oct, de-risking: –14% from highs ahead of the binary 16-Oct print. Net: from "neglected and distrusted" to a crowded retail turnaround idea; the next leg depends on the quality of the ibuprofen outcome, the pledge/TPG data in the Sep-26 SHP, and any broker initiation.

Valuation — current (authoritative basis)

Metric	Current	Basis
Market cap	₹3,156 Cr	Screener (~4.86 Cr shares)
EV	~₹3,657 Cr	[Est.] mcap + net debt ₹479.5 Cr (Jun-26) + leases ₹22 Cr
P/E (TTM)	n.m.	TTM PAT ~–₹1.6 Cr; Screener "739x" (distorted by Q3 FY26 loss) not reproducible
P/E on Q1 FY27 annualised PAT (₹65 Cr)	~48x	[Est.]
EV/EBITDA (TTM company EBITDA ~₹197.5 Cr)	~18.5x	[Est.]; stockanalysis 20.2x
EV/EBITDA (Q1 FY27 annualised, ₹254 Cr)	~14.4x	[Est.]
EV / FY26 base-business EBITDA (₹244.5 Cr)	~14.9x	[Est.]; implies ibuprofen valued at nil or less
P/B (Jun-26 net worth ₹1,406.8 Cr; ~4.82 Cr shares; BVPS ~₹292)	~2.2x	[Est.]; stockanalysis 2.55x on Mar-26 book; Screener BV ₹346 / ~1.9x not reconcilable
P/tangible book (BVPS ex-goodwill ~₹216)	~3.0x	[Est.]
EV/Sales (TTM ₹1,431 Cr)	~2.6x	[Est.]
FCF yield (FY26)	3.2% / 0.25%	Before / after interest [Est.]
Dividend yield	0%	Last dividend Aug-2021; no buybacks ever; accumulated losses ₹319 Cr and covenants make near-term dividend unlikely

Valuation vs history (fiscal year-end, stockanalysis)

	FY22	FY23	FY24	FY25	FY26	3-yr avg (FY24–26)	Current
Year-end price ₹	613.9	301.8	341.9	513.2	425.6	—	650.55
Market cap ₹ Cr	2,398	1,179	1,335	2,466	2,050	1,950	3,156
EV ₹ Cr	3,155	2,151	2,317	3,303	2,695	2,772	~3,657
P/E	n.m.	n.m.	n.m.	n.m. (4,567x)	n.m.	n.m.	n.m.
P/B	1.57	0.79	1.43	2.25	1.63	1.77	~2.2
EV/EBITDA	39.8	16.4	n.m.	16.3	14.8	~15.5 (FY25–26)	~18.5 TTM / 14.4 Q1 ann.
EV/Sales	2.49	1.49	1.80	2.57	1.97	2.11	~2.6
FCF yield	–18.8%	3.8%	5.1%	7.0%	4.9%	5.7%	3.2%

Read-across: on trailing numbers the stock is ~20% above its 3-year EV/EBITDA average and ~25% above its 3-year P/B average (~25–45% using stockanalysis' 2.55x); on the Q1 FY27 run-rate it is roughly in line with history.

Alternative EV/EBITDA bases (clearly labelled)

Basis	EV ₹ Cr	EBITDA ₹ Cr	EV/EBITDA	Source / label
Headline: TTM company EBITDA	3,657	~197.5	~18.5x	financials.md (authoritative)
FY25–26 historical average	—	—	~15.5x	financials.md
Consolidated FY26 (heard basis)	3,635	191.5	~19x	heard.md (EV excl. leases) — alternative
Consolidated FY26, peer-consistent gross-debt basis	3,843	187	20.6x	market.md (Screener) — used only in peer table
Consolidated Q1 FY27 annualised	3,657 / 3,635	254	~14.4x / ~14.3x	financials / heard
Base-business FY26	3,657	244.5	~14.9x	financials.md — base-only alternative
Base-business FY26 (gross-debt EV)	3,843	244.5	~15.7x	market.md — base-only alternative
Base-business Q1 FY27 annualised	3,635–3,843	~288–289	~12.6–13.3x	heard.md 12.6x ("the figure bulls quote"); market.md 13.3x — base-only alternative
Nivezo (Substack)	—	191.5	~18.5x trailing	Third-party; forward "much lower"

EV/EBITDA — Solara on different bases vs peers (x)

HeadlineConsolidated alternativesBase-only alternativesPeer-consistent basisPeers (FY26, gross-debt EV)Divi's ~72x omitted for scale

Illustrative scenario values — Aamara [Analyst View] [Est.]

Scenario	EBITDA assumption	Multiple	EV ₹ Cr	Less net debt + leases	Equity ₹ Cr	Per share ₹ (~4.86 Cr sh.)	vs CMP
Bear	Base flat at FY26 ₹245 Cr; ibuprofen drag continues (–₹50 Cr) → ₹195 Cr	12x	2,340	501.5	1,838.5	~378	–42%
Base	Base FY27E ₹1,041.4 Cr × 1.10 × 25% ≈ ₹286 Cr; ibuprofen exited at nil EBITDA (non-cash impairment)	14x	4,004	501.5	3,502.5	~721	+11%
Bull	Same ₹286 Cr; re-rating toward specialty peers on clean exit + Strides receivable normalised	16x	4,576	501.5	4,074.5	~838	+29%

Mechanical illustration, not a price target: multiples are our choice; excludes any cash proceeds or exit costs from ibuprofen, any Synthix value, the ~₹156 Cr unrecognised DTA and FY27 debt reduction. The bull value sits at the low end of the third-party Zen Nivesh SOTP (₹825–930). Upside to base is modest after the run from ₹422; downside if the exit disappoints is large — the payoff is asymmetric to the downside at today's price.

Final Verdict

Aamara Capital house view as of 13-Oct-2026 (pre-Q2 FY27). [Analyst View]

Business Quality

Medium

Base API franchise is genuinely good (GM ~55%, EBITDA 23–26%, 96 DMFs, clean USFDA). Ibuprofen is structurally broken. Average of the two = Medium.

Management & Governance

Weak

Strides 24% / ~178-day receivable; 37% pledge; 13 of 22 promises missed or re-dated; promoter runs Management Committee; Spiracca, Synthix opacity.

Financial Quality

Weak · improving

PAT –₹654 Cr over 5 yrs; EBIT ≈ interest; FCF after interest ~₹8 Cr; but net debt halved and BBB+.

Valuation

Fair-to-Expensive

18.5x TTM vs 15.5x history; 2.2x book vs 1.8x; cheap only on base-only run-rate (12.6–15x).

Overall View

Neutral

Wait for the 16-Oct ibuprofen decision and Sep-26 SHP before acting.

Bull case

Remove the drag: exiting ibuprofen adds ~₹40–60 Cr EBITDA plus ₹12–15 Cr Vizag idle cost, leaving a ~₹1,150 Cr, 25%-margin specialty API business at ~12.6–15x — cheap vs Neuland, Supriya, Shilpa.
Balance sheet de-risked: net debt ₹999 → ₹480 Cr, BBB+ with A- in reach at >3x cover; ~₹156 Cr unrecognised DTA means near-zero tax for years.
Under-owned and uncovered: no sell-side since 2023; an initiation after a clean exit, plus polymer debottlenecking and 4–5 DMFs/yr, could re-rate toward the ₹825–930 SOTP.

Bear case

Exit disappoints: few buyers in an oversupplied market (IOL to 18,000 MT); impairment of ₹100–300 Cr (8–24% of equity), cash closure costs, Vizag stranded, Synthix pushed out — and the decision slips a fourth time.
Strides is the growth: ex-Strides revenue fell 2.5%; a ₹480 Cr cap and ~178-day receivable mean promoter-group working capital is being financed by minority shareholders.
Priced for success with thin liquidity: 18.5x TTM, 37% pledge rising, 93–95% limit utilisation, going-concern basis note, West Asia margin pressure and a crowded retail base while TPG/FIIs/MFs sell.

Base case (12–18 months)

Solara announces a sale/partnering or phased closure of commodity ibuprofen with a non-cash impairment in Q2/Q3 FY27; reported EBITDA improves toward ₹270–290 Cr as the drag fades; base business grows ~10% at 23–25% margin with GM recovering slowly; net debt reaches ~₹440 Cr by Mar-27. The Strides share stays ~25–30% of revenue. The stock oscillates around ₹600–750 (illustrative base ~₹721) — limited upside from here; the re-rating needs clean governance signals, not just numbers.

Five things to remember

Two businesses: base ₹1,041.4 Cr at 23.5% EBITDA; ibuprofen ₹333.7 Cr at –₹53.0 Cr.
Deleveraging (₹999 → ₹532 Cr gross) was funded by ~₹448 Cr of rights equity and 33% dilution, not by earnings.
Strides = 24% of revenue, all of FY26's growth, ₹160.45 Cr receivable at ~178 days, ₹480 Cr cap for FY27.
The going-concern note is management's, not Deloitte's — opinion unmodified — but liquidity is thin (NCL ₹35.81 Cr; 93–95% utilisation).
Management has missed or re-dated 13 of 22 tracked promises (plus 1 partial); the ibuprofen decision is due 16-Oct-2026 after three slips.

Five questions to ask before investing

What exactly is the ibuprofen outcome — buyer, price, cash in/out, impairment size, Puducherry and Vizag fate, and title-deed clean-up?
Has the Strides receivable come down since Mar-26, and what are the pricing and payment terms under the ₹480 Cr approval?
Who are the pledgees, why did the pledge rise to 37% in H1 2026, and who ultimately owns Devicam and Spiracca?
Why does pre-operational Synthix hold ~₹49.5 Cr of Solara-guaranteed debt in deposits, and were FY26 covenants met?
Can base gross margin return to 54–55% after West Asia normalises, and what is ex-Strides organic growth in FY27?

What would change the view

Trigger	Upgrade to Positive if…	Downgrade to Negative if…
Ibuprofen (16-Oct)	Sale/partnering with cash proceeds; impairment ≤₹150 Cr; no cash closure cost	Further slip, or exit with material cash cost / ₹300 Cr+ write-down
Strides	Receivable back toward ~100 days; ex-Strides growth positive	Receivable rises further; Strides share >30%
Pledge (Sep-26 SHP)	Falls below 26%	Rises above 40% or any invocation
Base business	≥₹310 Cr/qtr at ≥25% EBITDA; GM ≥54%	EBITDA margin <22% two quarters running
Balance sheet	Interest cover >3x; CRISIL A-; FY26 covenants confirmed met	Net debt rises; covenant breach; limit utilisation stays >95%

Final opinion — Neutral. Solara's base API business is better than its consolidated numbers suggest, and the balance sheet is no longer the existential risk it was in 2024. But at ₹650 the market already prices a clean ibuprofen exit, while governance — a promoter flagship absorbing 24% of revenue on ~178-day terms and a rising 37% pledge — argues for a discount, not a premium. Wait for the 16-Oct-2026 decision and the Sep-26 shareholding before committing capital; this report must be refreshed after both.

Sources

Merged and de-duplicated from the six research modules (financials, business, governance, narrative, market, street sentiment) plus the primary-source verification note. All accessed 13-Oct-2026 unless stated. "(search summary)" = seen only via a search-result summary; "(not parsed)" = located but not text-extracted.

Coverage limits disclosed by the modules: the shared web-search budget was exhausted mid-session; BSE/NSE Reg 29/31 PDFs could not be text-extracted; Q2 FY26 and Q4 FY26 calls rest on secondary summaries; AlphaStreet transcripts are auto-generated; some AR tables extracted with misaligned columns. Not verified: JM Financial/Kotak reports, CEO TV interviews, X/Twitter discussion, pledgee names, AIF/FPI category of Mauryan and Turnaround Opportunities, global CDMO market size, full DoP PLI product list, FDA dashboard classifications.

A. Company filings and investor relations (primary)

Source	URL	Accessed
Solara Annual Report FY2025-26 (verified primary text: auditor, going concern, Note 2)	https://www.solara.co.in/uploads/2026/8/Solara_Annual_report_2025-26.pdf	13-Oct-2026
Annual reports page	https://www.solara.co.in/investor-relations/annual-reports	13-Oct-2026
Q4 FY26 financial results	https://www.solara.co.in/uploads/2026/6/Q4_Financial.pdf	13-Oct-2026
Q1 FY27 press release and investor presentation (23-Jul-2026)	https://www.solara.co.in/uploads/2026/7/SE_Press_Release.pdf	13-Oct-2026
Q1 FY27 earnings call transcript (primary)	https://www.solara.co.in/uploads/2026/7/Solara_Transcipt.pdf	13-Oct-2026
Investor updates page	https://www.solara.co.in/investor-relations/investor-update	13-Oct-2026
Rights issue page (incl. "Final reminder and Forfeiture")	https://www.solara.co.in/investor-relations/rights-issue	13-Oct-2026
Rights issue abridged letter of offer (Cameo)	https://rights.cameoindia.com/solara/PDF/Download/Solara%20Active_Abridged.pdf	13-Oct-2026
Board of directors	https://solara.co.in/company/board-of-directors	13-Oct-2026
Leadership	https://solara.co.in/company/leadership	13-Oct-2026
Subsidiary financials	https://solara.co.in/investor-relations/subsidiary-financials	13-Oct-2026
EGM notice (preferential warrants)	https://solara.co.in/uploads/2023/07/Solara-EGM-Notice.pdf	13-Oct-2026
Promoter pledge release, 18-May-2021	https://solara.co.in/uploads/2023/07/Promoters-pledge-release-May-18-2021-1.pdf	13-Oct-2026
Information Memorandum (2018 listing)	https://solara.co.in/uploads/2023/06/Information-Memorandum.pdf	13-Oct-2026
Company home page	https://www.solara.co.in/	13-Oct-2026
Products list	https://www.solara.co.in/products	13-Oct-2026
API capabilities / plants	https://www.solara.co.in/pillars-of-progress/api	13-Oct-2026
CRAMS	https://www.solara.co.in/pillars-of-progress/crams	13-Oct-2026
R&D	https://www.solara.co.in/pillars-of-progress/r-and-d	13-Oct-2026
Contact	https://www.solara.co.in/contact	13-Oct-2026

B. Company product pages (site and filing data)

Product	URL	Accessed
Ibuprofen S250	https://www.solara.co.in/products/ibuprofen-s250-grade	13-Oct-2026
Ibuprofen DC85	https://www.solara.co.in/products/ibuprofen-dc85	13-Oct-2026
Ibuprofen Sodium	https://www.solara.co.in/products/ibuprofen-sodium	13-Oct-2026
Ibuprofen Lysine	https://www.solara.co.in/products/ibuprofen-lysine	13-Oct-2026
S-Ibuprofen	https://www.solara.co.in/products/s-ibuprofen	13-Oct-2026
Naproxen Sodium	https://www.solara.co.in/products/naproxen-sodium	13-Oct-2026
Praziquantel	https://www.solara.co.in/products/praziquantel	13-Oct-2026
Albendazole	https://www.solara.co.in/products/albendazole	13-Oct-2026
Mebendazole	https://www.solara.co.in/products/mebendazole	13-Oct-2026
Artesunate	https://www.solara.co.in/products/artesunate	13-Oct-2026
Cycloserine	https://www.solara.co.in/products/cycloserine	13-Oct-2026
Rifaximin	https://www.solara.co.in/products/rifaximin	13-Oct-2026
Dolutegravir	https://www.solara.co.in/products/dolutegravir	13-Oct-2026
Posaconazole	https://www.solara.co.in/products/posaconazole	13-Oct-2026
Sevelamer Carbonate	https://www.solara.co.in/products/sevelamer-carbonate	13-Oct-2026
Sevelamer HCl	https://www.solara.co.in/products/sevelamer-hcl	13-Oct-2026
Colesevelam HCl	https://www.solara.co.in/products/colesevelam-hcl	13-Oct-2026
Colestipol	https://www.solara.co.in/products/colestipol	13-Oct-2026
Patiromer Sorbitex Calcium	https://www.solara.co.in/products/patiromer-sorbitex-calcium	13-Oct-2026
Lanthanum Carbonate Octahydrate	https://www.solara.co.in/products/lanthanum-carbonate-octahydrate	13-Oct-2026
Sucroferric Oxyhydroxide	https://www.solara.co.in/products/sucroferric-oxyhydroxide	13-Oct-2026
Gabapentin	https://www.solara.co.in/products/gabapentin	13-Oct-2026
Levetiracetam	https://www.solara.co.in/products/levetiracetam	13-Oct-2026
Brivaracetam	https://www.solara.co.in/products/brivaracetam	13-Oct-2026
Lurasidone HCl	https://www.solara.co.in/products/lurasidone-hydrochloride	13-Oct-2026
Mycophenolate Mofetil	https://www.solara.co.in/products/mycophenolate-mofetil	13-Oct-2026
Mesalamine	https://www.solara.co.in/products/mesalamine	13-Oct-2026
Obeticholic Acid	https://www.solara.co.in/products/obeticholic-acid	13-Oct-2026
Mirabegron	https://www.solara.co.in/products/mirabegron	13-Oct-2026
Tranexamic Acid	https://www.solara.co.in/products/tranexamic-acid	13-Oct-2026
Ranitidine HCl	https://www.solara.co.in/products/ranitidine-hcl	13-Oct-2026
Sugammadex	https://www.solara.co.in/products/sugammadex	13-Oct-2026
Succinylcholine Chloride	https://www.solara.co.in/products/succinylcholine-chloride	13-Oct-2026

C. Exchange filings (NSE / BSE)

Source	URL	Accessed
Q4 FY25 investor presentation (NSE)	https://nsearchives.nseindia.com/corporate/SOLARA_15052025165607_SE_file.pdf	13-Oct-2026
Monitoring agency report, Jun-2026 (via search summary)	https://nsearchives.nseindia.com/corporate/SOLARA_23072026172142_SE_MA_Report__June2026_Final_signed.pdf	13-Oct-2026
Puducherry USFDA EIR intimation, 28-Apr-2026	https://nsearchives.nseindia.com/corporate/SOLARA_28042026165601_SE_Intimation_PressReleaseUSFDA.pdf	13-Oct-2026
Q4 FY26 transcript (NSE; not parsed)	https://nsearchives.nseindia.com/corporate/SOLARA_21052026122119_Transcript_SE.pdf	13-Oct-2026
Q1 FY27 transcript (BSE)	https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=26a9553e-e823-47fe-a303-ab79dbb908e8.pdf	13-Oct-2026
TPG SAST disclosure, Jun-2024 (BSE)	https://bseindia.com/xml-data/corpfiling/AttachHis/45E605AA_8C07_4DD6_A864_F88FFAC3FE5A_143208.pdf	13-Oct-2026

D. Credit ratings

Source	URL	Accessed
CRISIL rationale 22-Jun-2026 (upgrade BBB+/Stable/A2)	https://www.crisil.com/mnt/winshare/Ratings/RatingList/RatingDocs/SolaraActivePharmaSciencesLimited_June%2022_%202026_RR_398425.html	13-Oct-2026
CRISIL rationale 30-Apr-2026	https://www.crisil.com/mnt/winshare/Ratings/RatingList/RatingDocs/SolaraActivePharmaSciencesLimited_April%2030_%202026_RR_394414.html	13-Oct-2026
CRISIL rationale 16-Apr-2025	https://www.crisil.com/mnt/winshare/Ratings/RatingList/RatingDocs/SolaraActivePharmaSciencesLimited_April%2016_%202025_RR_367157.html	13-Oct-2026
CRISIL rationale 07-Jun-2024	https://www.crisil.com/mnt/winshare/Ratings/RatingList/RatingDocs/SolaraActivePharmaSciencesLimited_June%2007_%202024_RR_345325.html	13-Oct-2026
CRISIL rationale 22-Feb-2024	https://www.crisil.com/mnt/winshare/Ratings/RatingList/RatingDocs/SolaraActivePharmaSciencesLimited_February%2022,%202024_RR_337662.html	13-Oct-2026
CRISIL rationale 17-Feb-2022	https://www.crisil.com/mnt/winshare/Ratings/RatingList/RatingDocs/SolaraActivePharmaSciencesLimited_February%2017,%202022_RR_288083.html	13-Oct-2026
CRISIL rationale 07-Oct-2021	https://www.crisil.com/mnt/winshare/Ratings/RatingList/RatingDocs/SolaraActivePharmaSciencesLimited_October%2007,%202021_RR_278747.html	13-Oct-2026
JM Financial news — CRISIL upgrade (24-Jun-2026)	https://www.jmfinancialservices.in/market-news-and-insights/1706863	13-Oct-2026

E. Concall transcripts and summaries

Source	URL	Accessed
AlphaStreet Q1 FY27 transcript	https://alphastreet.com/india/solara-active-pharma-sciences-limited-solara-q1-2027-earnings-call-transcript	13-Oct-2026
AlphaStreet Q3 FY26 transcript	https://alphastreet.com/india/solara-active-pharma-sciences-limited-solara-q3-2026-earnings-call-transcript	13-Oct-2026
AlphaStreet Q1 FY26 transcript	https://alphastreet.com/india/solara-active-pharma-sciences-limited-solara-q1-2026-earnings-call-transcript	13-Oct-2026
AlphaStreet Q4 FY25 transcript	https://alphastreet.com/india/solara-active-pharma-sciences-limited-solara-q4-2025-earnings-call-transcript	13-Oct-2026
AlphaStreet Q3 FY25 transcript	https://alphastreet.com/india/solara-active-pharma-sciences-limited-solara-q3-2025-earnings-call-transcript	13-Oct-2026
AlphaStreet Q2 FY25 transcript	https://alphastreet.com/india/solara-active-pharma-sciences-limited-solara-q2-2025-earnings-call-transcript	13-Oct-2026
AlphaStreet Q1 FY26 results note (search summary)	https://alphastreet.com/india/solara-active-pharma-sciences-ltd-q1fy26-12-fall-in-revenue/amp	13-Oct-2026
Arthneeti Q1 FY27 (AI-generated)	https://www.arthneeti.com/insights/solara-active-q1-fy27-earnings	13-Oct-2026
Arthneeti Q4 FY26 (insights)	https://www.arthneeti.com/insights/solara-active-q4-fy26-earnings	13-Oct-2026
Arthneeti Q4 FY26 (concall analysis)	https://www.arthneeti.com/stocks/solara-active/concall/q4-fy26-earnings-call-analysis	13-Oct-2026
Arthneeti Q3 FY26	https://www.arthneeti.com/insights/solara-active-q3-fy26-earnings	13-Oct-2026
Arthneeti Q2 FY26	https://www.arthneeti.com/insights/solara-active-q2-fy26-earnings	13-Oct-2026
Arthneeti Q1 FY26 (insights)	https://www.arthneeti.com/insights/solara-active-q1-fy26-earnings	13-Oct-2026
Arthneeti Q1 FY26 (concall analysis)	https://www.arthneeti.com/stocks/solara-active/concall/q1-fy26-earnings-call-analysis	13-Oct-2026
Arthneeti Q2 FY25	https://www.arthneeti.com/stocks/solara-active/concall/q2-fy25-earnings-call-analysis	13-Oct-2026
Arthneeti Q4 FY24	https://www.arthneeti.com/stocks/solara-active/concall/q4-fy24-earnings-call-analysis	13-Oct-2026
Arthneeti Q4 FY23	https://www.arthneeti.com/stocks/solara-active/concall/q4-fy23-earnings-call-analysis	13-Oct-2026
Yahoo Finance — Q1 FY27 call highlights	https://finance.yahoo.com/markets/stocks/articles/solara-active-pharma-sciences-ltd-010141796.html	13-Oct-2026
Yahoo Finance — Solara article	https://finance.yahoo.com/markets/stocks/articles/solara-active-pharma-sciences-ltd-170032901.html	13-Oct-2026
Multibagg — Q1 FY27 PAT/revenue	https://www.multibagg.ai/market-pulse/articles/solara-q1-fy27-pat-revenue-cmrxawjyo01ef0zp760rfvzrr	13-Oct-2026
Multibagg — Q1 FY27 results	https://www.multibagg.ai/market-pulse/articles/solara-q1fy27-results-pat-cms5rawkn0zdt0znz1eup9crn	13-Oct-2026
Multibagg — Q1 FY27 call (23-Jul)	https://www.multibagg.ai/market-pulse/articles/solara-q1fy27-call-july-23-cmrx8ngzs00z40zp79xghpp1d	13-Oct-2026
Kalkine — Q1 FY27 results	https://www.kalkine.co.in/article/announcements/solara-active-pharma-sciences-nsesolara-what-did-q1-fy27-results-reveal	13-Oct-2026
Kotak Neo — Q1 FY26 results (search summary)	https://www.kotakneo.com/financial-results/solara-active-pharma-sciences-ltd-q1fy2025-26-results/	13-Oct-2026

F. Financial databases and data terminals

Source	URL	Accessed
Screener — Solara consolidated	https://www.screener.in/company/SOLARA/consolidated/	13-Oct-2026
stockanalysis — income statement	https://stockanalysis.com/quote/nse/SOLARA/financials/	13-Oct-2026
stockanalysis — balance sheet	https://stockanalysis.com/quote/nse/SOLARA/financials/balance-sheet/	13-Oct-2026
stockanalysis — cash flow	https://stockanalysis.com/quote/nse/SOLARA/financials/cash-flow-statement/	13-Oct-2026
stockanalysis — ratios	https://stockanalysis.com/quote/nse/SOLARA/financials/ratios/	13-Oct-2026
stockanalysis — statistics	https://stockanalysis.com/quote/nse/SOLARA/statistics/	13-Oct-2026
stockanalysis — dividends	https://stockanalysis.com/quote/nse/SOLARA/dividend/	13-Oct-2026
Arihant Capital — standalone P&L	https://www.arihantcapital.com/company-information/profit-loss/70281	13-Oct-2026
Equitymaster — FY24 AR analysis	https://equitymaster.com/research-it/annual-results-analysis/SOLA/SOLARA-ACTIVE-PHARMA-SCIENCES-2023-24-Annual-Report-Analysis/11605	13-Oct-2026
IIFL — FY25 auditor's report	https://www.indiainfoline.com/company/solara-active-pharma-sciences-ltd/auditors-report/70281	13-Oct-2026
IIFL — FY25 directors' report	https://www.indiainfoline.com/company/solara-active-pharma-sciences-ltd/reports/directors-report	13-Oct-2026
Investing.com — historical data (CMP ₹650.55)	https://in.investing.com/equities/solara-active-pharma-historical-data	13-Oct-2026
Investing.com — consensus estimates	https://in.investing.com/equities/solara-active-pharma-consensus-estimates	13-Oct-2026
Investing.com — quote	https://www.investing.com/equities/solara-active-pharma	13-Oct-2026
MarketScreener — quote	https://in.marketscreener.com/quote/stock/SOLARA-ACTIVE-PHARMA-SCIE-46901468/	13-Oct-2026
MarketScreener — Arun Pillai insider profile	https://www.marketscreener.com/insider/ARUN-PILLAI-A2AA8K/	13-Oct-2026
Simply Wall St — consensus narrative	https://simplywall.st/community/narratives/in/pharmaceuticals-biotech/nse-solara/solara-active-pharma-sciences-shares/sphdlug0-update-for-solara-active-pharma-sciences	13-Oct-2026
Simply Wall St — stock page	https://simplywall.st/stocks/in/pharmaceuticals-biotech/nse-solara/solara-active-pharma-sciences-shares	13-Oct-2026
Trendlyne — equity page (momentum, poll)	https://trendlyne.com/equity/94298/SOLARA/solara-active-pharma-sciences-ltd/	13-Oct-2026
Trendlyne — research reports	https://trendlyne.com/research-reports/stock/94298/SOLARA/solara-active-pharma-sciences-ltd/	13-Oct-2026
MarketsMojo — company CV	https://www.marketsmojo.com/stocks-analysis/companycv/solara-active-pharma-sciences-1003017-0	13-Oct-2026
MarketsMojo (Motilal) — shareholding	https://marketsmojo.motilaloswal.com//stocks-analysis/financial-shareholding/solara-active-pharma-sciences-1003017-0	13-Oct-2026
Choice India — shareholding	https://choiceindia.com/stocks/solara-active-pharma-sciences-ltd-shareholding-pattern	13-Oct-2026
Upstox — shareholding	https://upstox.com/stocks/solara-active-pha-sci-ltd-shareholding/	13-Oct-2026
Infyner — Devicam Capital LLP (MCA data)	https://www.infyner.com/company/devicam-capital-llp/AAB-9882	13-Oct-2026

G. Shareholding patterns and deal logs

Source	URL	Accessed
Trendlyne SHP — latest	https://trendlyne.com/equity/share-holding/94298/SOLARA/latest/solara-active-pharma-sciences-ltd/	13-Oct-2026
Trendlyne SHP — 30-Jun-2026	https://trendlyne.com/equity/share-holding/94298/SOLARA/30-06-2026/solara-active-pharma-sciences-ltd/	13-Oct-2026
Trendlyne SHP — 31-Mar-2026	https://trendlyne.com/equity/share-holding/94298/SOLARA/31-03-2026/solara-active-pharma-sciences-ltd/	13-Oct-2026
Trendlyne SHP — 31-Dec-2025	https://trendlyne.com/equity/share-holding/94298/SOLARA/31-12-2025/solara-active-pharma-sciences-ltd/	13-Oct-2026
Trendlyne SHP — 30-Sep-2025	https://trendlyne.com/equity/share-holding/94298/SOLARA/30-09-2025/solara-active-pharma-sciences-ltd/	13-Oct-2026
Trendlyne SHP — 30-Jun-2025	https://trendlyne.com/equity/share-holding/94298/SOLARA/30-06-2025/solara-active-pharma-sciences-ltd/	13-Oct-2026
Trendlyne SHP — 31-Mar-2025	https://trendlyne.com/equity/share-holding/94298/SOLARA/31-03-2025/solara-active-pharma-sciences-ltd/	13-Oct-2026
Trendlyne SHP — 30-Jun-2024	https://trendlyne.com/equity/share-holding/94298/SOLARA/30-06-2024/solara-active-pharma-sciences-ltd/	13-Oct-2026
Trendlyne SHP — 31-Dec-2023	https://trendlyne.com/equity/share-holding/94298/SOLARA/31-12-2023/solara-active-pharma-sciences-ltd/	13-Oct-2026
Trendlyne SHP — 30-Sep-2023	https://trendlyne.com/equity/share-holding/94298/SOLARA/30-09-2023/solara-active-pharma-sciences-ltd/	13-Oct-2026
Trendlyne — bulk/block deals	https://trendlyne.com/equity/bulk-block-deals/SOLARA/94298/solara-active-pharma-sciences-ltd/	13-Oct-2026

H. News and announcements

Source	URL	Accessed
ScanX — news index	https://scanx.trade/stock-news/solara-active-pharma-sciences-ltd	13-Oct-2026
ScanX — Q1 FY27 call recording	https://scanx.trade/stock-market-news/companies/solara-active-pharma-uploads-q1-fy27-earnings-call-recording/46371671	13-Oct-2026
ScanX — Q1 FY27 call schedule	https://scanx.trade/stock-market-news/companies/solara-active-pharma-sciences-schedules-q1-earnings-call-on-july-23-at-4-pm/45772255	13-Oct-2026
ScanX — Q4 FY26 call schedule	https://scanx.trade/stock-market-news/companies/solara-active-pharma-sciences-schedules-q4fy26-analyst-and-investor-conference-call-for-may-15-2026/40052362	13-Oct-2026
ScanX — FY26 results	https://scanx.trade/stock-market-news/companies/solara-active-pharma-sciences-fy26-results-revenue-up-7-1-375-14/49211724	13-Oct-2026
ScanX — Q3 FY26 loss	https://scanx.trade/stock-market-news/earnings/solara-active-pharma-sciences-reports-q3-consolidated-net-loss-of-174-million-against-previous-year-profit/31911734	13-Oct-2026
ScanX — Q2 FY26 net loss	https://scanx.trade/stock-market-news/earnings/solara-active-pharma-sciences-reports-q2-net-loss-amid-operational-challenges/23934897	13-Oct-2026
ScanX — Q2 FY26 results (a)	https://scanx.trade/stock-market-news/earnings/solara-active-pharma-sciences-reports-q2-fy26-results-operational-challenges-impact-performance/23881072	13-Oct-2026
ScanX — Q2 FY26 results (b)	https://scanx.trade/stock-market-news/earnings/solara-active-pharma-reports-q2-fy26-results-short-term-challenges-impact-performance/23881181	13-Oct-2026
ScanX — AGM approves ₹480 Cr Strides deal	https://scanx.trade/stock-market-news/companies/solara-active-pharma-approves-480-crore-strides-pharma-deal-agm/51277459	13-Oct-2026
ScanX — CIO appointment	https://scanx.trade/stock-market-news/companies/solara-active-pharma-sciences-appoints-ajit-manocha-as-cio/46341101	13-Oct-2026
ScanX — Puducherry EIR VAI	https://scanx.trade/stock-market-news/companies/solara-active-pharma-sciences-receives-us-fda-eir-for-puducherry-facility-with-vai-status/38922073	13-Oct-2026
ScanX — Mangalore passes FDA inspection	https://scanx.trade/stock-market-news/stocks/solara-active-s-mangalore-facility-passes-fda-inspection-retains-cgmp-compliance/25073768	13-Oct-2026
ScanX — board reshuffle / CHRO	https://scanx.trade/stock-market-news/stocks/solara-active-pharma-sciences-announces-board-reshuffle-and-new-chro-appointment/23882587	13-Oct-2026
ScanX — WTD postal ballot	https://scanx.trade/stock-market-news/stocks/solara-active-pharma-sciences-seeks-shareholder-approval-for-whole-time-director-appointment-via-postal-ballot/31771814	13-Oct-2026
ScanX — ₹161.92 Cr tax demand dropped	https://scanx.trade/stock-market-news/companies/solara-active-pharma-gets-tax-demand-161-92-crore-dropped-ay-2019-20/49454408	13-Oct-2026
ScanX — forfeiture notice	https://scanx.trade/stock-market-news/companies/solara-pharma-approves-forfeiture-notice-unpaid-rights-shares/53093623	13-Oct-2026
FilingReader — Mangaluru VAI	https://filingreader.com/news-wire/mumbai/2025-11-19/solara-mangalore-facility-clears-us-fda-inspection-with-vai-classification	13-Oct-2026
FilingReader — Muthunarayanan to lead Synthix	https://filingreader.com/news-wire/mumbai/2025-12-05/solara-active-pharma-sciences-whole-time-director-muthunarayanan-to-lead	13-Oct-2026
Whalesbook — announcements	https://www.whalesbook.com/company/announcements/SOLARAPP	13-Oct-2026
Indian Pharma Post — final call notice	https://www.indianpharmapost.com/news/lite/solara-active-pharma-dispatches-final-rights-share-call-notice-rs-1125-per-share-due-by-may-7-19598	13-Oct-2026
Indian Pharma Post — Cuddalore zero 483s (2023)	https://www.indianpharmapost.com/regulatory/usfda-concludes-inspection-at-solaras-cuddalore-facility-with-zero-483-inspectional-observations-14491	13-Oct-2026
Indian Pharma Post — Puducherry inspection closure	https://www.indianpharmapost.com/regulatory/lite/solara-announces-closure-of-us-fda-inspection-at-puducherry-facility-19986	13-Oct-2026
Business Standard — Q4 FY24 loss ₹255.34 Cr	https://www.business-standard.com/markets/capital-market-news/solara-active-pharma-sciences-reports-consolidated-net-loss-of-rs-255-34-crore-in-the-march-2024-quarter-124052901370_1.html	13-Oct-2026
Business Standard — Q4 FY26 turnaround	https://www.business-standard.com/amp/markets/capital-market-news/solara-active-pharma-spurts-after-reporting-turnaround-q4-perfromance-126051500854_1.html	13-Oct-2026
Business Standard — Q1 FY27 PAT +55% (search summary)	https://www.business-standard.com/amp/markets/capital-market-news/solara-active-pharma-sciences-consolidated-net-profit-rises-55-04-in-the-june-2026-quarter-126072300686_1.html	13-Oct-2026
Business Standard — Rajender Rao resigns (2022)	https://www.business-standard.com/article/markets/solara-active-pharma-slips-15-after-rajender-rao-resigns-as-md-ceo-122050200238_1.html	13-Oct-2026
Business Standard — MD/CEO change (2020)	https://www.business-standard.com/article/news-cm/board-of-solara-active-pharma-sciences-approves-change-in-md-and-ceo-120080301135_1.html	13-Oct-2026
Business Standard — Arun Kumar Baskaran CFO (2024)	https://www.business-standard.com/amp/markets/capital-market-news/solara-active-pharma-appoints-arun-kumar-baskaran-as-cfo-124030800461_1.html	13-Oct-2026
Business Standard — BNP Paribas Arbitrage stake cut (2021)	https://www.business-standard.com/amp/article/news-cm/bnp-paribas-arbitrage-cuts-stake-of-solara-active-pharma-121042000504_1.html	13-Oct-2026
Business Today — shares +18% (15-May-2026)	https://www.businesstoday.in/markets/stocks/story/why-solara-active-pharma-sciences-shares-surged-18-today-531703-2026-05-15	13-Oct-2026
Angel One — rights issue terms	https://www.angelone.in/news/share-market/solara-active-pharma-announces-rights-issue	13-Oct-2026
Angel One — Q1 FY27 +5%	https://www.angelone.in/news/stocks/solara-active-pharma-share-price-rises-5-after-q1-profit-jumps-55-yoy	13-Oct-2026
HDFC Sky — shares fall after Q2 FY26 loss	https://hdfcsky.com/news/solara-active-pharma-shares-fall-after-q2fy26-loss	13-Oct-2026
Pharma Now — FY26 revenue recovery	https://www.pharmanow.live/latest-news/solara-active-pharma-fy26-revenue-recovery-ibuprofen-negative-ebitda	13-Oct-2026
Moneylife — core API rebounds (paywalled)	https://moneylife.in/article/core-api-business-rebounds-as-solara-seeks-solution-for-ibuprofen-losses/80730.html	13-Oct-2026
Sahi — net profit (AI-assisted)	https://sahi.com/news/solara-active-pharma-net-profit-surges-to-96m-with-40-yoy-growth-4590-PE1_COR	13-Oct-2026
Board Stewardship — Synthix leadership transition	https://boardstewardship.com/leadership-transition-at-solara-coo-mohan-muthunarayanan-to-head-synthix-operations/	13-Oct-2026
Board Stewardship — tag page	https://boardstewardship.com/tag/solara-active-pharma/	13-Oct-2026
Medical Dialogues — Sandeep Rao joins	https://medicaldialogues.in/news/industry/pharma/ex-viatris-chief-sandeep-rao-joins-solara-active-pharma-sciences-as-md-ceo-143850	13-Oct-2026
Medical Dialogues — Strides Chemicals ₹131 Cr	https://business.medicaldialogues.in/strides-shasun-to-divest-api-arm-to-solara-for-rs-131-crore/	13-Oct-2026
MarketScreener — Purohit resignation	https://www.marketscreener.com/quote/stock/SOLARA-ACTIVE-PHARMA-SCIE-46901468/news/Solara-Active-Pharma-Sciences-Limited-Announces-Resignation-of-Poorvank-Purohit-as-CEO-49127616/	13-Oct-2026
TradeBrains — Pronomz 4.16% purchase	https://tradebrains.in/pharma-stock-jumps-6-after-promoter-increases-their-stake-by-4-16-in-the-company/	13-Oct-2026
TPG — Growth investment in Solara (2019)	https://www.tpg.com/news-and-insights/tpg-growth-invest-solara-active-pharma-leading-indian-0	13-Oct-2026
YourStory — TPG investment (2019)	https://yourstory.com/2019/02/solara-raise-investment-tpg-growth	13-Oct-2026
Venture Intelligence — TPG sells ₹208 Cr	https://news.ventureintelligence.com/private-equity/tpg-growth-sells-solara-active-pharma-shares-worth-rs208cr-registers-323x-return	13-Oct-2026
CapitalMind — 2018 demerger	https://premium.capitalmind.in/2018/04/strides-and-sequent-scientific-demerger-into-solara-what-is-in-it/	13-Oct-2026
Zerodha TradingQnA — rights issue	https://tradingqna.com/t/everything-you-need-to-know-about-solara-active-pharma-limited-rights-issue/165678	13-Oct-2026
Univest — pros and cons	https://univest.in/blogs/pros-and-cons-of-investing-in-solara-active-pharma-sciences-share	13-Oct-2026
Univest — stock prediction 2026	https://univest.in/blogs/solara-active-stock-prediction-2026	13-Oct-2026
Univest — analyst review 2026 (source of unverified JM/Kotak targets)	https://univest.in/blogs/solara-active-pharma-sciences-share-analyst-review-2026	13-Oct-2026
Univest — TPG stake sale	https://univest.in/blogs/solara-active-pharma-share-price-tpg-growth-stake-sale	13-Oct-2026
Univest — price rise 18-Aug-2026	https://univest.in/blogs/why-solara-active-pharma-sciences-ltd-share-price-rise-2026-08-18	13-Oct-2026
Univest — price rise 20-Aug-2026	https://univest.in/blogs/why-solara-active-pharma-sciences-ltd-share-price-rise-2026-08-20	13-Oct-2026

I. Peers (Screener)

Company	URL	Accessed
Aarti Drugs	https://www.screener.in/company/AARTIDRUGS/consolidated/	13-Oct-2026
Granules India	https://www.screener.in/company/GRANULES/consolidated/	13-Oct-2026
IOL Chemicals & Pharmaceuticals	https://www.screener.in/company/IOLCP/consolidated/	13-Oct-2026
Neuland Laboratories	https://www.screener.in/company/NEULANDLAB/consolidated/	13-Oct-2026
Supriya Lifescience (standalone)	https://www.screener.in/company/SUPRIYA/	13-Oct-2026
Shilpa Medicare	https://www.screener.in/company/SHILPAMED/consolidated/	13-Oct-2026
Divi's Laboratories	https://www.screener.in/company/DIVISLAB/consolidated/	13-Oct-2026
Groww — IOL (search summary)	https://groww.in/stocks/iol-chemicals-pharmaceuticals-ltd	13-Oct-2026
docmadhu — IOL deep dive	https://docmadhu.substack.com/p/deep-dive-iol-chemicals-and-pharmaceuticals	13-Oct-2026
PharmaSource — IOL capacity expansion (search summary)	https://pharmasource.global/content/news/cdmo-news/iol-chemicals-invests-36-8-million-in-ibuprofen-capacity-expansion/	13-Oct-2026

J. Industry, market research and policy

Source	URL	Accessed
Precedence Research — API market	https://www.precedenceresearch.com/active-pharmaceutical-ingredient-market	13-Oct-2026
IBEF — Pharma India	https://www.ibef.org/industry/pharmaceutical-india	13-Oct-2026
HDIN Research — ibuprofen	https://www.hdinresearch.com/news/537	13-Oct-2026
Beroe via PR Newswire — ibuprofen 45,233 MT by 2022 (search summary)	https://www.prnewswire.co.uk/news-releases/global-ibuprofen-market-size-to-reach-45-233-mt-by-2022-says-beroe-inc-850971057.html	13-Oct-2026
Verified Market Research — top ibuprofen companies (search summary)	https://www.verifiedmarketresearch.com/blog/top-ibuprofen-companies/	13-Oct-2026
Intel Market Research — ibuprofen (search summary)	https://www.intelmarketresearch.com/ibuprofen-market-13291	13-Oct-2026
Expert Market Research — ibuprofen price index	https://www.expertmarketresearch.com/price-forecast/ibuprofen-price-trends	13-Oct-2026
ChemAnalyst — ibuprofen pricing (search summary)	https://www.chemanalyst.com/Pricing-data/ibuprofen-1331	13-Oct-2026
Organiser — PLI schemes (28-Sep-2026)	https://organiser.org/2026/09/28/383156/bharat/pli-schemes-boost-indias-pharma-bulk-drugs-and-medical-devices-manufacturing/	13-Oct-2026
DD India — PLI (Sep-2026, search summary)	https://ddindia.co.in/2026/09/pli-schemes-strengthen-indias-pharmaceutical-bulk-drugs-and-medical-devices-manufacturing-ecosystem/	13-Oct-2026
DoP — PLI Bulk Drug applicant list (search summary, not opened)	https://pharma-dept.gov.in/sites/default/files/Revised%20list%20of%20applicant%20-%20PLI%20for%20Bulk%20Drug%20(as%20on%2022.03.2023)_0_0.pdf	13-Oct-2026
PIB — PLI approvals (not accessed, HTTP 403)	https://www.pib.gov.in/PressReleasePage.aspx?PRID=1711482	13-Oct-2026 (failed)

K. Independent analysis, Substack and forums

Source	URL	Accessed
Below Coverage — "a cash machine" (27-Aug-2026; AR page citations)	https://belowcoverage.substack.com/p/solara-active-pharma-a-cash-machine	13-Oct-2026
Rajkumar Gupta — "A Good Business Hiding Behind a Bad Business" (2-Oct-2026)	https://rajkumargupta2.substack.com/p/solara-active-pharma-a-good-business	13-Oct-2026
Nivezo / Darshan Patel — "Pharma API cycle player at inflection" (1-Sep-2026)	https://nivezo.substack.com/p/pharma-api-cycle-player-at-inflection	13-Oct-2026
The Loggical Investor — "How Solara walked into a ₹700 Cr trap" (30-Aug-2026)	https://theloggicalinvestor.substack.com/p/how-solara-active-pharma-walked-into	13-Oct-2026
Zen Nivesh — "The Reset" (3-Oct-2025)	https://zennivesh.substack.com/p/solar-active-pharma-sciences-the	13-Oct-2026
Beta to Alpha — "What is up with Solara" (comments)	https://betatoalpha.substack.com/p/what-is-up-with-solara-active-pharma/comments	13-Oct-2026
Beta to Alpha — "From David to Goliath"	https://betatoalpha.substack.com/p/from-david-to-goliath-saps	13-Oct-2026
Folok Dutta — "Green shoots of turnaround"	https://folokdutta.substack.com/p/solara-active-green-shoots-of-turnaround	13-Oct-2026
ValuePickr — "Solara Active Pharma Sciences – Pure Play API" (topic 35661)	https://forum.valuepickr.com/t/solara-active-pharma-sciences-pure-play-api/35661	13-Oct-2026
ValuePickr — search	https://forum.valuepickr.com/search.json?q=solara	13-Oct-2026
StockTwits — SOLARA.NSE	https://stocktwits.com/symbol/SOLARA.NSE/about	13-Oct-2026

Primary-source precedence: where modules conflicted, the verified AR note (auditor, going concern) and the financial module (debt, valuation) govern. Secondary/unverified items are tagged in-line in each tab.